BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S, Forlani G, Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001;50:1844-1850. [PMID: 11473047 DOI: 10.2337/diabetes.50.8.1844] [Cited by in Crossref: 1698] [Cited by in F6Publishing: 1798] [Article Influence: 77.2] [Reference Citation Analysis]
Number Citing Articles
1 Gruneau L, Ekstedt M, Kechagias S, Henriksson M. Disease Progression Modeling for Economic Evaluation in Nonalcoholic Fatty Liver Disease-A Systematic Review. Clin Gastroenterol Hepatol 2023;21:283-98. [PMID: 34757199 DOI: 10.1016/j.cgh.2021.10.040] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Lee SM, Cho GJ, Wi WY, Norwitz ER, Koo BK, Lee J, Jung YM, Kwak SH, Park C, Jun JK, Joo SK, Oh M, Kim W, Park JS. Metabolic dysfunction-associated fatty liver disease as a risk factor for adverse outcomes in subsequent pregnancy: a nationwide cohort study. Hepatol Int 2022. [DOI: 10.1007/s12072-022-10458-w] [Reference Citation Analysis]
3 Alsaif F, Al-Hamoudi W, Alotaiby M, Alsadoon A, Almayouf M, Almadany H, Abuhaimed J, Ghufran N, Merajuddin A, Ali Khan I. Molecular Screening via Sanger Sequencing of the Genetic Variants in Non-Alcoholic Fatty Liver Disease Subjects in the Saudi Population: A Hospital-Based Study. Metabolites 2022;12. [PMID: 36557278 DOI: 10.3390/metabo12121240] [Reference Citation Analysis]
4 Xie CH, Chen LW, Lin CL, Hu CC, Chien CH. Serum Uric Acid but Not Ferritin Level Is Associated with Hepatic Fibrosis in Lean Subjects with Metabolic Dysfunction-Associated Fatty Liver Disease: A Community-Based Study. J Pers Med 2022;12. [PMID: 36556230 DOI: 10.3390/jpm12122009] [Reference Citation Analysis]
5 Qu B, Liu X, Liang Y, Zheng K, Zhang C, Lu L. Salidroside in the Treatment of NAFLD/NASH. Chem Biodivers 2022;19:e202200401. [PMID: 36210339 DOI: 10.1002/cbdv.202200401] [Reference Citation Analysis]
6 Ha J, Yim SY, Karagozian R. Mortality and Liver-Related Events in Lean Versus Non-Lean Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2022:S1542-3565(22)01099-0. [PMID: 36442727 DOI: 10.1016/j.cgh.2022.11.019] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Songtrai S, Pratchayasakul W, Arunsak B, Chunchai T, Kongkaew A, Chattipakorn N, Chattipakorn SC, Kaewsuwan S. Cyclosorus terminans Extract Ameliorates Insulin Resistance and Non-Alcoholic Fatty Liver Disease (NAFLD) in High-Fat Diet (HFD)-Induced Obese Rats. Nutrients 2022;14. [PMID: 36432581 DOI: 10.3390/nu14224895] [Reference Citation Analysis]
8 Zaghlool SB, Halama A, Stephan N, Gudmundsdottir V, Gudnason V, Jennings LL, Thangam M, Ahlqvist E, Malik RA, Albagha OME, Abou-Samra AB, Suhre K. Metabolic and proteomic signatures of type 2 diabetes subtypes in an Arab population. Nat Commun 2022;13:7121. [PMID: 36402758 DOI: 10.1038/s41467-022-34754-z] [Reference Citation Analysis]
9 Li X, Li Z, Zhang M, Li G, Yu T. Shear wave elastography to evaluate carotid artery elasticity in long‐term drinkers with varying degrees of alcoholic fatty liver disease. J of Clinical Ultrasound 2022. [DOI: 10.1002/jcu.23398] [Reference Citation Analysis]
10 Rojano A, Sena E, Manzano-nuñez R, Pericàs JM, Ciudin A. NAFLD as the metabolic hallmark of obesity. Intern Emerg Med 2022. [DOI: 10.1007/s11739-022-03139-x] [Reference Citation Analysis]
11 Şenol Y, Kaplan O, Varan C, Demirtürk N, Öncül S, Fidan BB, Ercan A, Bilensoy E, Çelebier M. Pharmacometabolomic assessment of vitamin E loaded human serum albumin nanoparticles on HepG2 cancer cell lines. Journal of Drug Delivery Science and Technology 2022. [DOI: 10.1016/j.jddst.2022.104017] [Reference Citation Analysis]
12 Lee SM, Jung YM, Choi ES, Kwak SH, Koo JN, Oh IH, Kim BJ, Kim SM, Kim SY, Kim GM, Joo SK, Koo BK, Shin S, Norwitz ER, Park CW, Jun JK, Kim W, Park JS. Metabolic Dysfunction-Associated Fatty Liver Disease and Subsequent Development of Adverse Pregnancy Outcomes. Clin Gastroenterol Hepatol 2022;20:2542-2550.e8. [PMID: 34798335 DOI: 10.1016/j.cgh.2021.11.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Koo D, Lee W. The crosstalk between insulin resistance and nonalcoholic fatty liver disease/metabolic dysfunction-associated fatty liver disease: a culprit or a consequence? CPP 2022;4:132-141. [DOI: 10.36011/cpp.2022.4.e17] [Reference Citation Analysis]
14 Song H, Yang R, Zhang J, Sun P, Xing X, Wang L, Sairijima T, Hu Y, Liu Y, Cheng H, Zhang Q, Li L. Oleic acid-induced steatosis model establishment in LMH cells and its effect on lipid metabolism. Poult Sci 2023;102:102297. [PMID: 36446267 DOI: 10.1016/j.psj.2022.102297] [Reference Citation Analysis]
15 Cao C, Zhang X, Yuan J, Zan Y, Zhang X, Xue C, Wang Y, Zheng X. Nonlinear relationship between aspartate aminotransferase to alanine aminotransferase ratio and the risk of prediabetes: A retrospective study based on chinese adults. Front Endocrinol 2022;13. [DOI: 10.3389/fendo.2022.1041616] [Reference Citation Analysis]
16 Miyake T, Furukawa S, Matsuura B, Yoshida O, Miyazaki M, Shiomi A, Kanzaki S, Nakaguchi H, Sunago K, Nakamura Y, Imai Y, Watanabe T, Yamamoto Y, Koizumi Y, Tokumoto Y, Hirooka M, Kumagi T, Abe M, Hiasa Y. Plasma Fatty Acid Composition Is Associated with Histological Findings of Nonalcoholic Steatohepatitis. Biomedicines 2022;10:2540. [PMID: 36289802 DOI: 10.3390/biomedicines10102540] [Reference Citation Analysis]
17 Wang Z, Wang Y, Luo F, Zhai Y, Li J, Chen Y, Li Q, Zhu L, Jiao S, Liu P, Zhou Y, Chen Y, Dong J, Sun Y. Impact of advanced liver fibrosis on atrial fibrillation recurrence after ablation in non-alcoholic fatty liver disease patients. Front Cardiovasc Med 2022;9:960259. [PMID: 36277780 DOI: 10.3389/fcvm.2022.960259] [Reference Citation Analysis]
18 An R, Ma S, Zhang N, Lin H, Xiang T, Chen M, Tan H. AST-to-ALT ratio in the first trimester and the risk of gestational diabetes mellitus. Front Endocrinol 2022;13:1017448. [DOI: 10.3389/fendo.2022.1017448] [Reference Citation Analysis]
19 Chrysavgis L, Giannakodimos I, Chatzigeorgiou A, Tziomalos K, Papatheodoridis G, Cholongitas E. The role of fibroblast growth factor 19 in the pathogenesis of nonalcoholic fatty liver disease. Expert Rev Gastroenterol Hepatol 2022;:1-15. [PMID: 36124827 DOI: 10.1080/17474124.2022.2127408] [Reference Citation Analysis]
20 Seo SH, Kim E, Yoon M, Lee S, Park B, Choi K. Metabolic improvement and liver regeneration by inhibiting CXXC5 function for non-alcoholic steatohepatitis treatment. Exp Mol Med. [DOI: 10.1038/s12276-022-00851-8] [Reference Citation Analysis]
21 Meroni M, Longo M, Paolini E, Tria G, Ripolone M, Napoli L, Moggio M, Fracanzani AL, Dongiovanni P. Expanding the phenotypic spectrum of non-alcoholic fatty liver disease and hypertriglyceridemia. Front Nutr 2022;9. [DOI: 10.3389/fnut.2022.967899] [Reference Citation Analysis]
22 Kokabiyan Z, Yaghmaei P, Jameie SB, Hajebrahimi Z. Effect of eugenol on lipid profile, oxidative stress, sex hormone, liver injury, ovarian failure, and expression of COX-2 and PPAR-α genes in a rat model of diabetes.. [DOI: 10.21203/rs.3.rs-2003440/v1] [Reference Citation Analysis]
23 Basu R, Noureddin M, Clark JM. Nonalcoholic Fatty Liver Disease: Review of Management for Primary Care Providers. Mayo Clin Proc 2022;97:1700-16. [PMID: 36058582 DOI: 10.1016/j.mayocp.2022.04.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Pedron FF, de Moura DS, Calcing A, Patias LD, Alvarez GDC, de Assunção Machado AC, de Moraes CMB. Analysis of hepatic markers and lipid profile of patients submitted to gastric by-pass after 2 years – Cohort retrospective. Annals of Medicine and Surgery 2022;81:104211. [DOI: 10.1016/j.amsu.2022.104211] [Reference Citation Analysis]
25 H. Jasim O, M. Mahmood M, Ad’hiah AH. The significance of Liver Function Tests in detecting prediabetes as a prognostic factor. RJPT 2022. [DOI: 10.52711/0974-360x.2022.00620] [Reference Citation Analysis]
26 Power Guerra N, Leyens K, Müller L, Brauer D, Janowitz D, Schlick S, Pilz K, Grabe HJ, Vollmar B, Kuhla A. The effect of different weight loss strategies to treat non-alcoholic fatty liver disease focusing on fibroblast growth factor 21. Front Nutr 2022;9:935805. [PMID: 36034917 DOI: 10.3389/fnut.2022.935805] [Reference Citation Analysis]
27 Li J, Arafa A, Kashima R, Teramoto M, Nakao YM, Honda-Kohmo K, Sakai Y, Watanabe E, Dohi T, Kokubo Y. Liver enzymes, alcohol consumption and the risk of diabetes: the Suita study. Acta Diabetol 2022. [PMID: 35972542 DOI: 10.1007/s00592-022-01949-1] [Reference Citation Analysis]
28 Khasanova AK, Dobrodeeva VS, Shnayder NA, Petrova MM, Pronina EA, Bochanova EN, Lareva NV, Garganeeva NP, Smirnova DA, Nasyrova RF. Blood and Urinary Biomarkers of Antipsychotic-Induced Metabolic Syndrome. Metabolites 2022;12:726. [PMID: 36005598 DOI: 10.3390/metabo12080726] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Calvi P, Terzo S, Amato A. Betalains: colours for human health. Nat Prod Res 2022;:1-20. [PMID: 35921318 DOI: 10.1080/14786419.2022.2106481] [Reference Citation Analysis]
30 Baratta F, D'erasmo L, Bini S, Pastori D, Angelico F, Del Ben M, Arca M, Di Costanzo A. Heterogeneity of non-alcoholic fatty liver disease (NAFLD): Implication for cardiovascular risk stratification. Atherosclerosis 2022. [DOI: 10.1016/j.atherosclerosis.2022.08.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Mare R, Sporea I, Tomescu M, Pop GN, Vitel A, Popescu A, Nistorescu S, Sirli R. Fibrosis Predictive Score in Caucasian Patients with Metabolic Syndrome. Diabetes Metab Syndr Obes 2022;15:1703-13. [PMID: 35698652 DOI: 10.2147/DMSO.S358744] [Reference Citation Analysis]
32 Sun J, Zhang D, Li Y. Extracellular Vesicles in Pathogenesis and Treatment of Metabolic Associated Fatty Liver Disease. Front Physiol 2022;13:909518. [DOI: 10.3389/fphys.2022.909518] [Reference Citation Analysis]
33 Huang Y, Gao Y, Pi X, Zhao S, Liu W. In Vitro Hepatoprotective and Human Gut Microbiota Modulation of Polysaccharide-Peptides in Pleurotus citrinopileatus. Front Cell Infect Microbiol 2022;12:892049. [PMID: 35669115 DOI: 10.3389/fcimb.2022.892049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Rojano-Toimil A, Rivera-Esteban J, Manzano-Nuñez R, Bañares J, Martinez Selva D, Gabriel-Medina P, Ferrer R, Pericàs JM, Ciudin A. When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD. J Clin Med 2022;11:3286. [PMID: 35743358 DOI: 10.3390/jcm11123286] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Atabay Dingil MN, İşgör MM. İn Vitro Hepatik Oksidatif Hasarda Karvakrolün Etkinliğinin Araştırılması. Journal of the Institute of Science and Technology 2022. [DOI: 10.21597/jist.1026055] [Reference Citation Analysis]
36 Wang Y, Chen R, Li J, Zeng G, Yuan J, Su J, Wu C, Lu Z, Zhang F, Ding W. Vanadium(IV)-Chlorodipicolinate Protects against Hepatic Steatosis by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammation. Antioxidants 2022;11:1093. [DOI: 10.3390/antiox11061093] [Reference Citation Analysis]
37 Wijs LA, Doherty DA, Keelan JA, Burton P, Yovich JL, Beilin L, Mori TA, Huang RC, Adams LA, Olynyk JK, Ayonrinde OT, Penova-Veselinovic B, Hart RJ. Comparison of the cardiometabolic profiles of adolescents conceived through ART with those of a non-ART cohort. Hum Reprod 2022:deac122. [PMID: 35640037 DOI: 10.1093/humrep/deac122] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Swislocki ALM. Uric Acid: Is It Time to Come in From the Cold? Metab Syndr Relat Disord 2022. [PMID: 35612466 DOI: 10.1089/met.2022.0037] [Reference Citation Analysis]
39 Todisco S, Santarsiero A, Convertini P, De Stefano G, Gilio M, Iacobazzi V, Infantino V. PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH). Biology (Basel) 2022;11:792. [PMID: 35625520 DOI: 10.3390/biology11050792] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
40 Navik U, Sheth VG, Sharma N, Tikoo K. L-Methionine supplementation attenuates high-fat fructose diet-induced non-alcoholic steatohepatitis by modulating lipid metabolism, fibrosis, and inflammation in rats. Food Funct 2022;13:4941-53. [PMID: 35437549 DOI: 10.1039/d1fo03403k] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
41 Miyake T, Yoshida O, Matsuura B, Furukawa S, Hirooka M, Abe M, Tokumoto Y, Koizumi Y, Watanabe T, Takeshita E, Sunago K, Yukimoto A, Watanabe K, Miyazaki M, Kanzaki S, Nakaguchi H, Koizumu M, Yamamoto Y, Kumagi T, Hiasa Y. Additional Effect of Luseogliflozin on Semaglutide in Nonalcoholic Steatohepatitis Complicated by Type 2 Diabetes Mellitus: An Open-Label, Randomized, Parallel-Group Study. Diabetes Ther 2022;13:1083-96. [PMID: 35312970 DOI: 10.1007/s13300-022-01239-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Ciardullo S, Carbone M, Invernizzi P, Perseghin G. Impact of the new definition of metabolic dysfunction-associated fatty liver disease on detection of significant liver fibrosis in US adolescents. Hepatol Commun 2022. [PMID: 35470984 DOI: 10.1002/hep4.1969] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Paquette M, Bernard S. The Evolving Story of Multifactorial Chylomicronemia Syndrome. Front Cardiovasc Med 2022;9:886266. [DOI: 10.3389/fcvm.2022.886266] [Reference Citation Analysis]
44 Polidori N, Grasso EA, Chiarelli F, Giannini C. Amino Acid-Related Metabolic Signature in Obese Children and Adolescents. Nutrients 2022;14:1454. [PMID: 35406066 DOI: 10.3390/nu14071454] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
45 Koo BK, Lim S. Metabolic Syndrome and Metabolic Dysfunction‐Associated Fatty Liver Disease. Clinical Obesity in Adults and Children 2022. [DOI: 10.1002/9781119695257.ch13] [Reference Citation Analysis]
46 Baars T, Gieseler RK, Patsalis PC, Canbay A. Towards harnessing the value of organokine crosstalk to predict the risk for cardiovascular disease in non-alcoholic fatty liver disease. Metabolism 2022;:155179. [PMID: 35283187 DOI: 10.1016/j.metabol.2022.155179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Tsou M, Chen J. Gender-Based Association of Coronary Artery Calcification and Framingham Risk Score With Non-alcoholic Fatty Liver Disease and Abdominal Obesity in Taiwanese Adults, a Cross-Sectional Study. Front Cardiovasc Med 2022;9:803967. [DOI: 10.3389/fcvm.2022.803967] [Reference Citation Analysis]
48 Visaria A, Pai S, Cheung M, Ahlawat S. Association between aspartate aminotransferase-to-alanine aminotransferase ratio and insulin resistance among US adults. Eur J Gastroenterol Hepatol 2022;34:316-23. [PMID: 34074988 DOI: 10.1097/MEG.0000000000002215] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
49 Xing Y, Chen J, Liu J, Ma H. Associations Between GGT/HDL and MAFLD: A Cross-Sectional Study. Diabetes Metab Syndr Obes 2022;15:383-94. [PMID: 35177915 DOI: 10.2147/DMSO.S342505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
50 Yun CH, Jhuang JR, Tsou MT. Pericardial fat, thoracic peri-aortic adipose tissue, and systemic inflammatory marker in nonalcoholic fatty liver and abdominal obesity phenotype. Sci Rep 2022;12:1958. [PMID: 35121786 DOI: 10.1038/s41598-022-06030-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Sunil B, Ashraf AP. Childhood Hypertriglyceridemia: Is It Time for a New Approach? Curr Atheroscler Rep 2022. [PMID: 35107763 DOI: 10.1007/s11883-022-01000-2] [Reference Citation Analysis]
52 Zaghlool SB, Halama A, Stephan N, Thangam M, Ahlqvist E, Albagha OME, Abou⍰samra AB, Suhre K. Metabolic and proteomic signatures of type 2 diabetes subtypes in an Arab population.. [DOI: 10.1101/2022.01.13.22269204] [Reference Citation Analysis]
53 Hu T, Wei M, Hong G, Qi T, Xiang Y, Yang Y, Yi Y. Xiaoyao San attenuates hepatic steatosis through estrogen receptor α pathway in ovariectomized ApoE-/- mice. J Ethnopharmacol 2022;282:114612. [PMID: 34496266 DOI: 10.1016/j.jep.2021.114612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Mallick B, Anand AC. Gallstone Disease in Cirrhosis-Pathogenesis and Management. J Clin Exp Hepatol 2022;12:551-9. [PMID: 35535063 DOI: 10.1016/j.jceh.2021.09.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Niederau C. Genussmittel und Fettleber. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_33] [Reference Citation Analysis]
56 Bhalla S, Kuchel GA, Pandol S, Bishehsari F. Association of Pancreatic Fatty Infiltration With Age and Metabolic Syndrome Is Sex-Dependent. Gastro Hep Advances 2022;1:344-349. [DOI: 10.1016/j.gastha.2022.01.007] [Reference Citation Analysis]
57 Apostolopoulou M, Roden M. Therapie von Begleiterkrankungen: Diabetes mellitus und Dyslipoproteinämie. Nicht-alkoholische Fettlebererkrankung 2022. [DOI: 10.1007/978-3-662-62484-5_20] [Reference Citation Analysis]
58 Lee YA, Friedman SL. Inflammatory and fibrotic mechanisms in NAFLD-Implications for new treatment strategies. J Intern Med 2022;291:11-31. [PMID: 34564899 DOI: 10.1111/joim.13380] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 17.0] [Reference Citation Analysis]
59 Pelechá M, Villanueva-bádenas E, Timor-lópez E, Donato MT, Tolosa L. Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models. Antioxidants 2022;11:86. [DOI: 10.3390/antiox11010086] [Reference Citation Analysis]
60 Meritsi A, Manesis E, Koussis P, Rapti S, Latsou D, Tsitsopoulos E, Moshoyianni H, Manolakopoulos S, Pektasides D, Thanopoulou A. PNPLA3 rs 738409 and Other Nongenetic Factors Associated with Hepatic Steatosis Estimated by Magnetic Resonance Imaging Proton Density Fat Fraction in Adult Greek Subjects with Type 2 Diabetes Mellitus. Metab Syndr Relat Disord 2021. [PMID: 34962148 DOI: 10.1089/met.2021.0098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Alhinai A, Qayyum-Khan A, Zhang X, Samaha P, Metrakos P, Deschenes M, Wong P, Ghali P, Chen TY, Sebastiani G. Non-alcoholic steatohepatitis in liver transplant recipients diagnosed by serum cytokeratin 18 and transient elastography: A prospective study. World J Hepatol 2021; 13(12): 2179-2191 [DOI: 10.4254/wjh.v13.i12.2179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
62 Wong MYZ, Yap JJL, Sultana R, Cheah M, Goh GBB, Yeo KK. Association between non-alcoholic fatty liver disease and subclinical atherosclerosis in Western and Asian cohorts: an updated meta-analysis. Open Heart 2021;8:e001850. [PMID: 34933963 DOI: 10.1136/openhrt-2021-001850] [Reference Citation Analysis]
63 Kim HS, Cho YK, Kim EH, Lee MJ, Jung CH, Park JY, Kim HK, Lee WJ. Triglyceride Glucose-Waist Circumference Is Superior to the Homeostasis Model Assessment of Insulin Resistance in Identifying Nonalcoholic Fatty Liver Disease in Healthy Subjects. J Clin Med 2021;11:41. [PMID: 35011784 DOI: 10.3390/jcm11010041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
64 Janjua M, Knuiman M, Divitini M, McQuillan B, Olynyk JK, Jeffrey GP, Adams LA. Alcohol Consumption and Cardiovascular Outcomes in Patients With Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Hepatol Commun 2021. [PMID: 34931492 DOI: 10.1002/hep4.1828] [Reference Citation Analysis]
65 Tilg H, Adolph TE, Dudek M, Knolle P. Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity. Nat Metab 2021;3:1596-607. [DOI: 10.1038/s42255-021-00501-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
66 Tang RC, Chen TC, Lin FH. Design Strategy for a Hydroxide-Triggered pH-Responsive Hydrogel as a Mucoadhesive Barrier to Prevent Metabolism Disorders. ACS Appl Mater Interfaces 2021;13:58340-51. [PMID: 34871495 DOI: 10.1021/acsami.1c17706] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
67 Fante T, Simino LAP, Fontana MF, Reginato A, Ramalheira TG, Rodrigues HG, Lisboa PC, de Moura EG, Ignácio-Souza LM, Milanski M, Torsoni MA, Torsoni AS. Maternal high-fat diet consumption programs male offspring to mitigate complications in liver regeneration. J Dev Orig Health Dis 2021;:1-8. [PMID: 34857059 DOI: 10.1017/S2040174421000659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
68 Yamasandhi PG, Dharmalingam M, Balekuduru A. Fetuin-A in newly detected type 2 diabetes mellitus as a marker of non-alcoholic fatty liver disease. Indian J Gastroenterol 2021;40:556-62. [PMID: 34950996 DOI: 10.1007/s12664-021-01176-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
69 Miller BM, Oderberg IM, Goessling W. Hepatic Nervous System in Development, Regeneration, and Disease. Hepatology 2021;74:3513-22. [PMID: 34256416 DOI: 10.1002/hep.32055] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
70 Niu H, Zhou Y. Nonlinear Relationship Between AST-to-ALT Ratio and the Incidence of Type 2 Diabetes Mellitus: A Follow-Up Study. Int J Gen Med 2021;14:8373-82. [PMID: 34819745 DOI: 10.2147/IJGM.S341790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
71 Yang H, Deng Q, Ni T, Liu Y, Lu L, Dai H, Wang H, Yang W. Targeted Inhibition of LPL/FABP4/CPT1 fatty acid metabolic axis can effectively prevent the progression of nonalcoholic steatohepatitis to liver cancer. Int J Biol Sci 2021;17:4207-22. [PMID: 34803493 DOI: 10.7150/ijbs.64714] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
72 Satiya J, Snyder HS, Singh SP, Satapathy SK. Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis. Transl Gastroenterol Hepatol 2021;6:60. [PMID: 34805582 DOI: 10.21037/tgh-20-247] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
73 Zakaria Z, Othman ZA, Bagi Suleiman J, Jalil NAC, Ghazali WSW, Mohamed M. Protective and Therapeutic Effects of Orlistat on Metabolic Syndrome and Oxidative Stress in High-Fat Diet-Induced Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) in Rats: Role on Nrf2 Activation. Vet Sci 2021;8:274. [PMID: 34822647 DOI: 10.3390/vetsci8110274] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
74 Negi CK, Babica P, Bajard L, Bienertova-Vasku J, Tarantino G. Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease. Metabolism 2021;126:154925. [PMID: 34740573 DOI: 10.1016/j.metabol.2021.154925] [Cited by in Crossref: 42] [Cited by in F6Publishing: 56] [Article Influence: 21.0] [Reference Citation Analysis]
75 Wu D, Eeda V, Undi RB, Mann S, Stout M, Lim HY, Wang W. A novel peroxisome proliferator-activated receptor gamma ligand improves insulin sensitivity and promotes browning of white adipose tissue in obese mice. Mol Metab 2021;54:101363. [PMID: 34710641 DOI: 10.1016/j.molmet.2021.101363] [Reference Citation Analysis]
76 Siwatch S, Singh V, Dhaliwal LK, Kumari S, Singh K. Non-alcoholic fatty liver disease in polycystic ovarian syndrome in Indian women. J Obstet Gynaecol 2021;:1-5. [PMID: 34689689 DOI: 10.1080/01443615.2021.1969346] [Reference Citation Analysis]
77 Meroni M, Longo M, Lombardi R, Paolini E, Macchi C, Corsini A, Sirtori CR, Fracanzani AL, Ruscica M, Dongiovanni P. Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun 2021. [PMID: 34677008 DOI: 10.1002/hep4.1830] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
78 Ziolkowska S, Binienda A, Jabłkowski M, Szemraj J, Czarny P. The Interplay between Insulin Resistance, Inflammation, Oxidative Stress, Base Excision Repair and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease. Int J Mol Sci 2021;22:11128. [PMID: 34681787 DOI: 10.3390/ijms222011128] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
79 Chen W, Tumanov S, Fazakerley DJ, Cantley J, James DE, Dunn LL, Shaik T, Suarna C, Stocker R. Bilirubin deficiency renders mice susceptible to hepatic steatosis in the absence of insulin resistance. Redox Biol 2021;47:102152. [PMID: 34610553 DOI: 10.1016/j.redox.2021.102152] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
80 Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology 2021;74:1809-24. [PMID: 33811367 DOI: 10.1002/hep.31843] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 33.0] [Reference Citation Analysis]
81 Koulaouzidis G, Charisopoulou D, Kukla M, Marlicz W, Rydzewska G, Koulaouzidis A, Skonieczna-Żydecka K. Association of non-alcoholic fatty liver disease with coronary artery calcification progression: a systematic review and meta-analysis. Prz Gastroenterol 2021;16:196-206. [PMID: 34584580 DOI: 10.5114/pg.2021.109063] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
82 Li QX, Gao H, Guo YX, Wang BY, Hua RX, Gao L, Shang HW, Lu X, Xu JD. GLP-1 and Underlying Beneficial Actions in Alzheimer's Disease, Hypertension, and NASH. Front Endocrinol (Lausanne) 2021;12:721198. [PMID: 34552561 DOI: 10.3389/fendo.2021.721198] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
83 Brodosi L, Marchignoli F, Marchesini G, Petroni ML. Considerations when prescribing pharmacotherapy for metabolic associated fatty liver disease. Expert Opin Pharmacother 2021;:1-5. [PMID: 34541981 DOI: 10.1080/14656566.2021.1980538] [Reference Citation Analysis]
84 Kudo M, Yamagishi Y, Suguro S, Nishihara M, Yoshitomi H, Hayashi M, Gao M. L-citrulline inhibits body weight gain and hepatic fat accumulation by improving lipid metabolism in a rat nonalcoholic fatty liver disease model. Food Sci Nutr 2021;9:4893-904. [PMID: 34532001 DOI: 10.1002/fsn3.2439] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
85 Kalo E, Read S, Ahlenstiel G. Targeting Gut–Liver Axis for Treatment of Liver Fibrosis and Portal Hypertension. Livers 2021;1:147-79. [DOI: 10.3390/livers1030014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
86 Xiang H, Wu Z, Wang J, Wu T. Research progress, challenges and perspectives on PNPLA3 and its variants in Liver Diseases. J Cancer 2021;12:5929-37. [PMID: 34476007 DOI: 10.7150/jca.57951] [Reference Citation Analysis]
87 Ramírez-Mejía MM, Díaz-Orozco LE, Barranco-Fragoso B, Méndez-Sánchez N. A Review of the Increasing Prevalence of Metabolic-Associated Fatty Liver Disease (MAFLD) in Children and Adolescents Worldwide and in Mexico and the Implications for Public Health. Med Sci Monit 2021;27:e934134. [PMID: 34456329 DOI: 10.12659/MSM.934134] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
88 Tsvetkov VV, Tokin II, Nikitina OE, Lioznov DA. Disorders of lipid metabolism in the liver in patients with chronic viral hepatitis. HERALD of North-Western State Medical University named after I I Mechnikov 2021;13:27-38. [DOI: 10.17816/mechnikov71418] [Reference Citation Analysis]
89 Virostko J, Craddock RC, Williams JM, Triolo TM, Hilmes MA, Kang H, Du L, Wright JJ, Kinney M, Maki JH, Medved M, Waibel M, Kay TWH, Thomas HE, Greeley SAW, Steck AK, Moore DJ, Powers AC. Development of a standardized MRI protocol for pancreas assessment in humans. PLoS One 2021;16:e0256029. [PMID: 34428220 DOI: 10.1371/journal.pone.0256029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
90 Shrestha R, Kc S, Thapa P, Pokharel A, Karki N, Jaishi B. Estimation of Liver Fat by FibroScan in Patients With Nonalcoholic Fatty Liver Disease. Cureus 2021;13:e16414. [PMID: 34422459 DOI: 10.7759/cureus.16414] [Reference Citation Analysis]
91 Lin ZZ, Xu YC, Liu CX, Lu XL, Wen FY. Physical Activity and Liver Cancer Risk: A Systematic Review and Meta-analyses. Clin J Sport Med 2021;31:86-90. [PMID: 30371534 DOI: 10.1097/JSM.0000000000000689] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
92 Nagashimada M, Honda M. Effect of Microbiome on Non-Alcoholic Fatty Liver Disease and the Role of Probiotics, Prebiotics, and Biogenics. Int J Mol Sci 2021;22:8008. [PMID: 34360773 DOI: 10.3390/ijms22158008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
93 Cuthbertson DJ, Koskinen J, Brown E, Magnussen CG, Hutri-Kähönen N, Sabin M, Tossavainen P, Jokinen E, Laitinen T, Viikari J, Raitakari OT, Juonala M. Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Ann Med 2021;53:1256-64. [PMID: 34309471 DOI: 10.1080/07853890.2021.1956685] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
94 Abbate M, Montemayor S, Mascaró CM, Casares M, Gómez C, Ugarriza L, Tejada S, Abete I, Zulet MÁ, Sureda A, Martínez JA, Tur JA. Albuminuria Is Associated with Hepatic Iron Load in Patients with Non-Alcoholic Fatty Liver Disease and Metabolic Syndrome. J Clin Med 2021;10:3187. [PMID: 34300354 DOI: 10.3390/jcm10143187] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
95 Sharma S, Stine JG, Verbeek T, Bezinover D. Management of Patients With Non-alcoholic Steatohepatitis Undergoing Liver Transplantation: Considerations for the Anesthesiologist. J Cardiothorac Vasc Anesth 2021:S1053-0770(21)00601-7. [PMID: 34391652 DOI: 10.1053/j.jvca.2021.07.020] [Reference Citation Analysis]
96 Eswaran S, Babbar A, Drescher HK, Hitch TCA, Clavel T, Muschaweck M, Ritz T, Kroy DC, Trautwein C, Wagner N, Schippers A. Upregulation of Anti-Oxidative Stress Response Improves Metabolic Changes in L-Selectin-Deficient Mice but Does Not Prevent NAFLD Progression or Fecal Microbiota Shifts. Int J Mol Sci 2021;22:7314. [PMID: 34298930 DOI: 10.3390/ijms22147314] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
97 Akkiz H, Taskin E, Karaogullarindan U, Delik A, Kuran S, Kutlu O. The influence of RS738409 I148M polymorphism of patatin-like phospholipase domain containing 3 gene on the susceptibility of non-alcoholic fatty liver disease. Medicine (Baltimore) 2021;100:e25893. [PMID: 34106646 DOI: 10.1097/MD.0000000000025893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
98 Zakaria Z, Othman ZA, Nna VU, Mohamed M. The promising roles of medicinal plants and bioactive compounds on hepatic lipid metabolism in the treatment of non-alcoholic fatty liver disease in animal models: molecular targets. Arch Physiol Biochem 2021;:1-17. [PMID: 34153200 DOI: 10.1080/13813455.2021.1939387] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
99 Niu Z, Wu Q, Sun L, Qi Q, Zheng H, Li H, Zeng R, Lin X, Zong G. Circulating Glycerolipids, Fatty Liver Index, and Incidence of Type 2 Diabetes: A Prospective Study Among Chinese. J Clin Endocrinol Metab 2021;106:2010-20. [PMID: 33711157 DOI: 10.1210/clinem/dgab165] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
100 Stinnett G, Taheri N, Villanova J, Bohloul A, Guo X, Esposito EP, Xiao Z, Stueber D, Avendano C, Decuzzi P, Pautler RG, Colvin VL. 2D Gadolinium Oxide Nanoplates as T1 Magnetic Resonance Imaging Contrast Agents. Adv Healthc Mater 2021;10:e2001780. [PMID: 33882196 DOI: 10.1002/adhm.202001780] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
101 Cao YX, Zhang M, Zhang HW, Jin JL, Liu HH, Zhang Y, Guo YL, Wu NQ, Zhu CG, Xu RX, Gao Y, Dong Q, Sun J, Li JJ. Impact of liver fibrosis score on prognosis in patients with previous myocardial infarction: A prospective cohort study. Liver Int 2021;41:1294-304. [PMID: 33389804 DOI: 10.1111/liv.14780] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
102 Ciardullo S, Bianconi E, Zerbini F, Perseghin G. Current type 2 diabetes, rather than previous gestational diabetes, is associated with liver disease in U.S. Women. Diabetes Res Clin Pract 2021;177:108879. [PMID: 34058299 DOI: 10.1016/j.diabres.2021.108879] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
103 Yoshioka N, Tanaka M, Ochi K, Watanabe A, Ono K, Sawada M, Ogi T, Itoh M, Ito A, Shiraki Y, Enomoto A, Ishigami M, Fujishiro M, Ogawa Y, Suganami T. The sodium-glucose cotransporter-2 inhibitor Tofogliflozin prevents the progression of nonalcoholic steatohepatitis-associated liver tumors in a novel murine model. Biomed Pharmacother 2021;140:111738. [PMID: 34029949 DOI: 10.1016/j.biopha.2021.111738] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
104 Hartl L, Elias J, Prager G, Reiberger T, Unger LW. Individualized treatment options for patients with non-cirrhotic and cirrhotic liver disease. World J Gastroenterol 2021; 27(19): 2281-2298 [PMID: 34040322 DOI: 10.3748/wjg.v27.i19.2281] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
105 Chen LW, Huang MS, Shyu YC, Chien RN. Gamma-glutamyl transpeptidase elevation is associated with metabolic syndrome, hepatic steatosis, and fibrosis in patients with nonalcoholic fatty liver disease: A community-based cross-sectional study. Kaohsiung J Med Sci 2021;37:819-27. [PMID: 34002481 DOI: 10.1002/kjm2.12395] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
106 Juanola O, Martínez-López S, Francés R, Gómez-Hurtado I. Non-Alcoholic Fatty Liver Disease: Metabolic, Genetic, Epigenetic and Environmental Risk Factors. Int J Environ Res Public Health 2021;18:5227. [PMID: 34069012 DOI: 10.3390/ijerph18105227] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 10.5] [Reference Citation Analysis]
107 Miyata S, Kawashima Y, Sakai M, Matsubayashi M, Motoki K, Miyajima Y, Watanabe Y, Chikamatsu N, Taniguchi T, Tokuyama R. Discovery, optimization, and evaluation of non-bile acid FXR/TGR5 dual agonists. Sci Rep 2021;11:9196. [PMID: 33911126 DOI: 10.1038/s41598-021-88493-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
108 Wang W, Zhong X, Guo J. Role of 2‑series prostaglandins in the pathogenesis of type 2 diabetes mellitus and non‑alcoholic fatty liver disease (Review). Int J Mol Med 2021;47:114. [PMID: 33907839 DOI: 10.3892/ijmm.2021.4947] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
109 Kamboj P, Sarkar S, Gupta SK, Bisht N, Kumari D, Alam MJ, Barge S, Kashyap B, Deka B, Bharadwaj S, Rahman S, Dutta PP, Borah JC, Talukdar NC, Banerjee SK, Kumar Y. Methanolic Extract of Lysimachia Candida Lindl. Prevents High-Fat High-Fructose-Induced Fatty Liver in Rats: Understanding the Molecular Mechanism Through Untargeted Metabolomics Study. Front Pharmacol 2021;12:653872. [PMID: 33935766 DOI: 10.3389/fphar.2021.653872] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
110 Miyake T, Miyazaki M, Yoshida O, Kanzaki S, Nakaguchi H, Nakamura Y, Watanabe T, Yamamoto Y, Koizumi Y, Tokumoto Y, Hirooka M, Furukawa S, Takeshita E, Kumagi T, Ikeda Y, Abe M, Toshimitsu K, Matsuura B, Hiasa Y. Relationship between body composition and the histology of non-alcoholic fatty liver disease: a cross-sectional study. BMC Gastroenterol 2021;21:170. [PMID: 33849437 DOI: 10.1186/s12876-021-01748-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
111 Ramadan MS, Russo V, Nigro G, Durante-Mangoni E, Zampino R. Interplay between Heart Disease and Metabolic Steatosis: A Contemporary Perspective. J Clin Med 2021;10:1569. [PMID: 33917867 DOI: 10.3390/jcm10081569] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
112 Colosimo S, Ravaioli F, Petroni ML, Brodosi L, Marchignoli F, Barbanti FA, Sasdelli AS, Marchesini G, Pironi L. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis. Liver Int 2021;41:731-42. [PMID: 33497019 DOI: 10.1111/liv.14799] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
113 Chong PL, Laight D, Aspinall RJ, Higginson A, Cummings MH. A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. BMC Gastroenterol 2021;21:144. [PMID: 33794784 DOI: 10.1186/s12876-021-01660-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
114 Yang Z, Roth K, Agarwal M, Liu W, Petriello MC. The transcription factors CREBH, PPARa, and FOXO1 as critical hepatic mediators of diet-induced metabolic dysregulation. J Nutr Biochem 2021;95:108633. [PMID: 33789150 DOI: 10.1016/j.jnutbio.2021.108633] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
115 Sang C, Wang X, Zhou K, Sun T, Bian H, Gao X, Wang Y, Zhang H, Jia W, Liu P, Xie G, Chen T. Bile Acid Profiles Are Distinct among Patients with Different Etiologies of Chronic Liver Disease. J Proteome Res 2021;20:2340-51. [PMID: 33754726 DOI: 10.1021/acs.jproteome.0c00852] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
116 Dalal DJ, Solanki H. Arbuscular Mycorrhizal Fungi : Diversity and Its Impact with Abiotic Factors in Phoenix dactylifera L. of Kachchh Region, Gujarat, India. IJSRST 2021. [DOI: 10.32628/ijsrst218222] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
117 Trujillo MJ, Chen J, Rubin JM, Gao J. Non-invasive imaging biomarkers to assess nonalcoholic fatty liver disease: A review. Clin Imaging 2021;78:22-34. [PMID: 33721575 DOI: 10.1016/j.clinimag.2021.02.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
118 Russo MF, Lembo E, Mari A, Angelini G, Verrastro O, Nanni G, Pompili M, Raffaelli M, Vecchio FM, Bornstein SR, Mingrone G. Insulin Resistance Is Central to Long-Term Reversal of Histologic Nonalcoholic Steatohepatitis After Metabolic Surgery. J Clin Endocrinol Metab 2021;106:750-61. [PMID: 33248441 DOI: 10.1210/clinem/dgaa892] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
119 Liaqat M, Fatima M, Malik SS, Gillani SA, Manzoor I. Ultrasonographic Features Associated with Diffuse Hepatosteatosis among Diabetic Obese and Normal Body Mass Index Patients. J Med Ultrasound 2020;28:235-8. [PMID: 33659163 DOI: 10.4103/JMU.JMU_94_19] [Reference Citation Analysis]
120 Yao M, Teng H, Lv Q, Gao H, Guo T, Lin Y, Gao S, Ma M, Chen L. Anti-hyperglycemic effects of dihydromyricetin in streptozotocin-induced diabetic rats. Food Science and Human Wellness 2021;10:155-62. [DOI: 10.1016/j.fshw.2021.02.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
121 Ayonrinde OT. Historical narrative from fatty liver in the nineteenth century to contemporary NAFLD - Reconciling the present with the past. JHEP Rep 2021;3:100261. [PMID: 34036255 DOI: 10.1016/j.jhepr.2021.100261] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
122 Panera N, Meroni M, Longo M, Crudele A, Valenti L, Bellacchio E, Miele L, D'Oria V, Paolini E, Maggioni M, Fracanzani AL, Alisi A, Dongiovanni P. The KLB rs17618244 gene variant is associated with fibrosing MAFLD by promoting hepatic stellate cell activation. EBioMedicine 2021;65:103249. [PMID: 33640795 DOI: 10.1016/j.ebiom.2021.103249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
123 Yuan F, Hou L, Wei L, Quan R, Wang J, Liu H, Liu J. Fowl Adenovirus Serotype 4 Induces Hepatic Steatosis via Activation of Liver X Receptor-α. J Virol 2021;95:e01938-20. [PMID: 33361420 DOI: 10.1128/JVI.01938-20] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
124 Shekarchizadeh-Esfahani P, Heydarpour F, Izadi F, Jalili C. The effect of cinnamon supplementation on liver enzymes in adults: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med 2021;58:102699. [PMID: 33639251 DOI: 10.1016/j.ctim.2021.102699] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
125 Jangjo-Borazjani S, Dastgheib M, Kiyamarsi E, Jamshidi R, Rahmati-Ahmadabad S, Helalizadeh M, Iraji R, Cornish SM, Mohammadi-Darestani S, Khojasteh Z, Azarbayjani MA. Effects of resistance training and nigella sativa on type 2 diabetes: implications for metabolic markers, low-grade inflammation and liver enzyme production. Arch Physiol Biochem 2021;:1-9. [PMID: 33612031 DOI: 10.1080/13813455.2021.1886117] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
126 Cervo A, Shengir M, Patel K, Sebastiani G. NASH in HIV. Curr HIV/AIDS Rep 2020;17:601-14. [PMID: 32984925 DOI: 10.1007/s11904-020-00531-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
127 Hydes T, Alam U, Cuthbertson DJ. The Impact of Macronutrient Intake on Non-alcoholic Fatty Liver Disease (NAFLD): Too Much Fat, Too Much Carbohydrate, or Just Too Many Calories? Front Nutr 2021;8:640557. [PMID: 33665203 DOI: 10.3389/fnut.2021.640557] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
128 Sandby K, Geiker NRW, Dalamaga M, Grønbæk H, Magkos F. Efficacy of Dietary Manipulations for Depleting Intrahepatic Triglyceride Content: Implications for the Management of Non-alcoholic Fatty Liver Disease. Curr Obes Rep 2021;10:125-33. [PMID: 33580876 DOI: 10.1007/s13679-021-00430-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
129 Uekita H, Yamamoto H, Niinaga R, Yamane N, Yoshii M, Yamauchi-Takihara K, Kihara S. Reciprocal association of serum Mac-2 binding protein and HDL-cholesterol concentrations. Clin Chim Acta 2021;516:142-8. [PMID: 33571485 DOI: 10.1016/j.cca.2021.02.001] [Reference Citation Analysis]
130 Yang M, Cui Y, Song J, Cui C, Wang L, Liang K, Wang C, Sha S, He Q, Hu H, Guo X, Zang N, Sun L, Chen L. Mesenchymal stem cell-conditioned medium improved mitochondrial function and alleviated inflammation and apoptosis in non-alcoholic fatty liver disease by regulating SIRT1. Biochem Biophys Res Commun 2021;546:74-82. [PMID: 33578292 DOI: 10.1016/j.bbrc.2021.01.098] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
131 Esteve-Luque V, Padró-Miquel A, Fanlo-Maresma M, Corbella E, Corbella X, Pintó X, Candás-Estébanez B. Implication between Genetic Variants from APOA5 and ZPR1 and NAFLD Severity in Patients with Hypertriglyceridemia. Nutrients 2021;13:552. [PMID: 33567543 DOI: 10.3390/nu13020552] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
132 Sah DK, Das AKL, Jana D. A STUDY OF PREVALENCE OF NON ALCOHOLIC FATTY LIVER IN TYPE 2 DIABETES MELLITUS PATIENTS. ijsr. [DOI: 10.36106/ijsr/5434087] [Reference Citation Analysis]
133 Long MT, Zhang X, Xu H, Liu CT, Corey KE, Chung RT, Loomba R, Benjamin EJ. Hepatic Fibrosis Associates With Multiple Cardiometabolic Disease Risk Factors: The Framingham Heart Study. Hepatology 2021;73:548-59. [PMID: 33125745 DOI: 10.1002/hep.31608] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 12.5] [Reference Citation Analysis]
134 Senoymak MC, Ozkan H. Evaluation of the Relationship between Insulin Resistance and HBV DNA Level in Patients with HBeAg-negative Chronic HBV Infection (Natural Course Phase 3). Euroasian J Hepatogastroenterol 2020;10:85-91. [PMID: 33511070 DOI: 10.5005/jp-journals-10018-1329] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
135 Petroni ML, Brodosi L, Bugianesi E, Marchesini G. Management of non-alcoholic fatty liver disease.BMJ. 2021;372:m4747. [PMID: 33461969 DOI: 10.1136/bmj.m4747] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 21.0] [Reference Citation Analysis]
136 Semova I, Biddinger SB. Triglycerides in Nonalcoholic Fatty Liver Disease: Guilty Until Proven Innocent. Trends Pharmacol Sci 2021;42:183-90. [PMID: 33468321 DOI: 10.1016/j.tips.2020.12.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
137 Mishina EE, Mayorov AY, Bogomolov PO, Liusina EO, Bueverov AO. Association of insulin resistance and non-alcoholic fatty liver disease. Diabetes mellitus 2021;23:412-423. [DOI: 10.14341/dm12234] [Reference Citation Analysis]
138 Gantzel RH, Kjær MB, Laursen TL, Kazankov K, George J, Møller HJ, Grønbæk H. Macrophage Activation Markers, Soluble CD163 and Mannose Receptor, in Liver Fibrosis. Front Med (Lausanne) 2020;7:615599. [PMID: 33490096 DOI: 10.3389/fmed.2020.615599] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
139 Bhome R, Peppa N, Karar S, McDonnell D, Mirnezami A, Hamady Z. Metabolic syndrome is a predictor of all site and liver-specific recurrence following primary resection of colorectal cancer: Prospective cohort study of 1006 patients. Eur J Surg Oncol 2021;47:1623-8. [PMID: 33483238 DOI: 10.1016/j.ejso.2020.12.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
140 Ciardullo S, Muraca E, Perra S, Bianconi E, Zerbini F, Oltolini A, Cannistraci R, Parmeggiani P, Manzoni G, Gastaldelli A, Lattuada G, Perseghin G. Screening for non-alcoholic fatty liver disease in type 2 diabetes using non-invasive scores and association with diabetic complications. BMJ Open Diabetes Res Care. 2020;8. [PMID: 32049637 DOI: 10.1136/bmjdrc-2019-000904] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 21.5] [Reference Citation Analysis]
141 Buyco DG, Martin J, Jeon S, Hooks R, Lin C, Carr R. Experimental models of metabolic and alcoholic fatty liver disease. World J Gastroenterol 2021; 27(1): 1-18 [PMID: 33505147 DOI: 10.3748/wjg.v27.i1.1] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
142 Ota T. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH). Adv Exp Med Biol 2021;1261:223-9. [PMID: 33783745 DOI: 10.1007/978-981-15-7360-6_20] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
143 Li C, Kong W, Kang L, Zhang T, Zhang W, Wang W. Study on the correlation between urinary retinol-binding protein and nonalcoholic fatty liver disease. J Med Biochem 2021;40:86-91. [PMID: 33584144 DOI: 10.5937/jomb0-24666] [Reference Citation Analysis]
144 Bin Dahman LS, Humam MA, Barahim OH, Barahman OM, Balfas MA. Association between Liver Enzymes and Dyslipidemia in Yemeni Patients with Type Two Diabetes Mellitus. JDM 2021;11:41-51. [DOI: 10.4236/jdm.2021.112004] [Reference Citation Analysis]
145 Uthayakumar C, Kotalawala S. Impact of Obesity in Non-Alcoholic Fatty Liver Disease. JBiSE 2021;14:21-32. [DOI: 10.4236/jbise.2021.142004] [Reference Citation Analysis]
146 Ajaz S, McPhail MJ, Gnudi L, Trovato FM, Mujib S, Napoli S, Carey I, Agarwal K. Mitochondrial dysfunction as a mechanistic biomarker in patients with non-alcoholic fatty liver disease (NAFLD). Mitochondrion 2021;57:119-30. [PMID: 33387664 DOI: 10.1016/j.mito.2020.12.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
147 Atanasova I, Sojoodi M, Leitão HS, Shuvaev S, Geraldes CFGC, Masia R, Guimaraes AS, Tanabe KK, Fuchs BC, Caravan P. Molecular Magnetic Resonance Imaging of Fibrin Deposition in the Liver as an Indicator of Tissue Injury and Inflammation. Invest Radiol 2020;55:209-16. [PMID: 31895219 DOI: 10.1097/RLI.0000000000000631] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
148 Yacoub B, Spandorfer A, Schoepf UJ, Litwin SE. Assessment of Intramyocardial Fat Content Using Computed Tomography: Is There a Relationship With Obesity? J Thorac Imaging 2021;36:162-5. [PMID: 33875630 DOI: 10.1097/RTI.0000000000000571] [Reference Citation Analysis]
149 Yuan Y, Naito H, Kitamori K, Hashimoto S, Asano T, Nakajima T. The antihypertensive agent hydralazine reduced extracellular matrix synthesis and liver fibrosis in nonalcoholic steatohepatitis exacerbated by hypertension. PLoS One 2020;15:e0243846. [PMID: 33315911 DOI: 10.1371/journal.pone.0243846] [Reference Citation Analysis]
150 Power Guerra N, Müller L, Pilz K, Glatzel A, Jenderny D, Janowitz D, Vollmar B, Kuhla A. Dietary-Induced Low-Grade Inflammation in the Liver. Biomedicines 2020;8:E587. [PMID: 33317065 DOI: 10.3390/biomedicines8120587] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
151 Kumar R, Rahman MA, Nazarko TY. Nitrogen Starvation and Stationary Phase Lipophagy Have Distinct Molecular Mechanisms. Int J Mol Sci 2020;21:E9094. [PMID: 33260464 DOI: 10.3390/ijms21239094] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
152 Koushki M, Zare M, Shabani M, Teimouri M, Hosseini H, Babaei Khorzoughi R, Meshkani R. Resveratrol Reduces Lipid Accumulation through Upregulating the Expression of MicroRNAs Regulating Fatty Acid Bet Oxidation in Liver Cells: Evidence from In-vivo and In-vitro Studies. Iran J Pharm Res 2020;19:333-40. [PMID: 33224240 DOI: 10.22037/ijpr.2019.111745.13332] [Reference Citation Analysis]
153 Wang X, Xie J, Pang J, Zhang H, Chen X, Lin J, Li Q, Chen Q, Ma J, Xu X, Yang Y, Ling W, Chen Y. Serum SHBG Is Associated With the Development and Regression of Nonalcoholic Fatty Liver Disease: A Prospective Study. J Clin Endocrinol Metab 2020;105:dgz244. [PMID: 31793624 DOI: 10.1210/clinem/dgz244] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
154 Sirinawasatien A, Techasirioangkun T. The Prevalence and Determinants of Hepatic Steatosis Assessed by Controlled Attenuation Parameter in Thai Chronic Hepatitis C Patients. Gastroenterol Res Pract 2020;2020:8814135. [PMID: 33204256 DOI: 10.1155/2020/8814135] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
155 Singh A, Amin H, Garg R, Gupta M, Lopez R, Alkhouri N, MCCullough A. Increased Prevalence of Obesity and Metabolic Syndrome in Patients with Alcoholic Fatty Liver Disease. Dig Dis Sci 2020;65:3341-9. [PMID: 31981110 DOI: 10.1007/s10620-020-06056-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
156 Geltinger F, Schartel L, Wiederstein M, Tevini J, Aigner E, Felder TK, Rinnerthaler M. Friend or Foe: Lipid Droplets as Organelles for Protein and Lipid Storage in Cellular Stress Response, Aging and Disease. Molecules 2020;25:E5053. [PMID: 33143278 DOI: 10.3390/molecules25215053] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
157 Hanafy AS, Basha MAK, Wadea FM. Novel markers of endothelial dysfunction in hepatitis C virus-related cirrhosis: More than a mere prediction of esophageal varices. World J Hepatol 2020; 12(10): 850-862 [PMID: 33200022 DOI: 10.4254/wjh.v12.i10.850] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
158 Lisboa QC, Nardelli MJ, Pereira PA, Miranda DM, Ribeiro SN, Costa RSN, Versiani CA, Vidigal PVT, Ferrari TCA, Couto CA. PNPLA3 and TM6SF2 polymorphisms in Brazilian patients with nonalcoholic fatty liver disease. World J Hepatol 2020; 12(10): 792-806 [PMID: 33200017 DOI: 10.4254/wjh.v12.i10.792] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
159 Abdalgwad R, Rafey MF, Murphy C, Ioana I, O'Shea PM, Slattery E, Davenport C, O'Keeffe DT, Finucane FM. Changes in alanine aminotransferase in adults with severe and complicated obesity during a milk-based meal replacement programme. Nutr Metab (Lond) 2020;17:87. [PMID: 33072167 DOI: 10.1186/s12986-020-00512-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
160 Diehl KL, Vorac J, Hofmann K, Meiser P, Unterweger I, Kuerschner L, Weighardt H, Förster I, Thiele C. Kupffer Cells Sense Free Fatty Acids and Regulate Hepatic Lipid Metabolism in High-Fat Diet and Inflammation. Cells 2020;9:E2258. [PMID: 33050035 DOI: 10.3390/cells9102258] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
161 Schwertheim S, Kälsch J, Jastrow H, Schaefer CM, Theurer S, Ting S, Canbay A, Wedemeyer H, Schmid KW, Baba HA. Characterization of two types of intranuclear hepatocellular inclusions in NAFLD. Sci Rep 2020;10:16533. [PMID: 33024131 DOI: 10.1038/s41598-020-71646-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
162 Ji G, Sun R, Hu H, Xu F, Yu X, Priya Veeraraghavan V, Krishna Mohan S, Chi X. Vannilic acid ameliorates hyperglycemia-induced oxidative stress and inflammation in streptozotocin-induced diabetic rats. Journal of King Saud University - Science 2020;32:2905-11. [DOI: 10.1016/j.jksus.2020.04.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
163 Jung YM, Lee SM, Hong S, Koo JN, Oh IH, Kim BJ, Kim SM, Kim SY, Kim GM, Kyung Joo S, Shin S, Norwitz ER, Park CW, Jun JK, Kim W, Park JS. The risk of pregnancy-associated hypertension in women with nonalcoholic fatty liver disease. Liver Int 2020;40:2417-26. [PMID: 32558189 DOI: 10.1111/liv.14563] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
164 T SK, B LK, T SS. WOMEN IN THE AGE GROUP OF 20 TO 50 YEARS ARE LESS PRONE TO DEVELOP NAFLD IN KERALA, SOUTH INDIA: A POPULATION BASED STUDY. IJAR 2020. [DOI: 10.36106/ijar/6000585] [Reference Citation Analysis]
165 Abbasi-Ghahramanloo A, Moshiri E, Afrashteh S, Gholami A, Safiri S, Mohammadbeigi A, Ansari H. Comorbidity of metabolic syndrome components in a population-based screening program: A latent class analysis. Med J Islam Repub Iran 2020;34:69. [PMID: 32974235 DOI: 10.34171/mjiri.34.69] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
166 Valenzuela R, Ortiz M, Hernández-Rodas MC, Echeverría F, Videla LA. Targeting n-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease. Curr Med Chem 2020;27:5250-72. [PMID: 30968772 DOI: 10.2174/0929867326666190410121716] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
167 Kjær MB, George J, Kazankov K, Grønbæk H. Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy? Expert Rev Gastroenterol Hepatol 2021;15:51-64. [PMID: 32878486 DOI: 10.1080/17474124.2020.1817740] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
168 Amin NB, Carvajal-Gonzalez S, Purkal J, Zhu T, Crowley C, Perez S, Chidsey K, Kim AM, Goodwin B. Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis. Sci Transl Med. 2019;11. [PMID: 31776293 DOI: 10.1126/scitranslmed.aav9701] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 9.3] [Reference Citation Analysis]
169 Lee CH, Fu Y, Yang SJ, Chi CC. Effects of Omega-3 Polyunsaturated Fatty Acid Supplementation on Non-Alcoholic Fatty Liver: A Systematic Review and Meta-Analysis. Nutrients 2020;12:E2769. [PMID: 32932796 DOI: 10.3390/nu12092769] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
170 Acierno C, Caturano A, Pafundi PC, Nevola R, Adinolfi LE, Sasso FC. Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin. Exploration of Medicine 2020;1. [DOI: 10.37349/emed.2020.00019] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
171 Li C, Liu H, Yang J, Mu J, Wang R, Zhao X. Effect of soybean milk fermented with Lactobacillus plantarum HFY01 isolated from yak yogurt on weight loss and lipid reduction in mice with obesity induced by a high-fat diet. RSC Adv 2020;10:34276-89. [PMID: 35519026 DOI: 10.1039/d0ra06977a] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
172 Zhao J, Zhu XY, Ren Y, Li JY. Analysis of the correlation between periodontal disease and metabolic syndrome among coal mine workers: A clinical study. Medicine (Baltimore) 2020;99:e21566. [PMID: 32872008 DOI: 10.1097/MD.0000000000021566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
173 Tou J, Oldaker C, Yuan YV. Novel Marine Sources of Nutraceuticals and Functional Foods. Encyclopedia of Marine Biotechnology 2020. [DOI: 10.1002/9781119143802.ch119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
174 Meroni M, Longo M, Dongiovanni P. Genetic and metabolic factors: the perfect combination to treat metabolic associated fatty liver disease. Exploration of Medicine 2020;1:218-43. [DOI: 10.37349/emed.2020.00015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
175 Chiang C, Huang H, Huang T, Shih Y, Hsieh T, Lin H. Nonalcoholic Fatty Liver Disease Associated With Bladder Cancer. The American Journal of the Medical Sciences 2020;360:161-5. [DOI: 10.1016/j.amjms.2020.04.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
176 Kim MJ. Non-alcoholic Fatty Liver Disease, Cardio-metabolic Syndrome and Hypertension: One Concept Fits Multi-systemic Presentations. Korean Circ J 2020;50:706-8. [PMID: 32725977 DOI: 10.4070/kcj.2020.0217] [Reference Citation Analysis]
177 Baykal AP, Parks EJ, Shamburek R, Syed-Abdul MM, Chacko S, Cochran E, Startzell M, Gharib AM, Ouwerkerk R, Abd-Elmoniem KZ, Walter PJ, Walter M, Muniyappa R, Chung ST, Brown RJ. Leptin decreases de novo lipogenesis in patients with lipodystrophy. JCI Insight 2020;5:137180. [PMID: 32573497 DOI: 10.1172/jci.insight.137180] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
178 Savic D, Hodson L, Neubauer S, Pavlides M. The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients 2020;12:E2178. [PMID: 32708036 DOI: 10.3390/nu12082178] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
179 Zhang L, Ren Q, Chen Q. Transcriptome Analysis on the Effect of Tartary Buckwheat Polysaccharide on the Liver of NAFLD-Model Mice. Proceedings of the Fourth International Conference on Biological Information and Biomedical Engineering 2020. [DOI: 10.1145/3403782.3403818] [Reference Citation Analysis]
180 Park J, Lee Y, Jung EH, Kim SM, Cho H, Han IO. Glucosamine regulates hepatic lipid accumulation by sensing glucose levels or feeding states of normal and excess. Biochim Biophys Acta Mol Cell Biol Lipids 2020;1865:158764. [PMID: 32663610 DOI: 10.1016/j.bbalip.2020.158764] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
181 Dongiovanni P, Meroni M, Petta S, Longo M, Alisi A, Soardo G, Valenti L, Miele L, Grimaudo S, Pennisi G, Antonio G, Consonni D, Fargion S, Fracanzani AL. Neurotensin up-regulation is associated with advanced fibrosis and hepatocellular carcinoma in patients with MAFLD. Biochim Biophys Acta Mol Cell Biol Lipids 2020;1865:158765. [PMID: 32663609 DOI: 10.1016/j.bbalip.2020.158765] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
182 Zhang M, Hu ML, Huang JJ, Xia SS, Yang Y, Dong K. Association of leukocyte telomere length with non-alcoholic fatty liver disease in patients with type 2 diabetes. Chin Med J (Engl) 2019;132:2927-33. [PMID: 31809318 DOI: 10.1097/CM9.0000000000000559] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
183 Ott-Fontes PR, Diedrich Neto JA, Goldoni MB. Comparison of the severity of non-alcoholic fatty liver disease in diabetic and non-diabetic obese patients. Rev Col Bras Cir 2020;47:e20202485. [PMID: 32638913 DOI: 10.1590/0100-6991e-20202485] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
184 Kim NH, Jung YS, Park JH, Park DI, Sohn CI. Impact of nonalcoholic fatty liver disease on the risk of metachronous colorectal neoplasia after polypectomy. Korean J Intern Med 2021;36:557-67. [PMID: 32630984 DOI: 10.3904/kjim.2019.360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
185 Meroni M, Longo M, Fracanzani AL, Dongiovanni P. MBOAT7 down-regulation by genetic and environmental factors predisposes to MAFLD. EBioMedicine 2020;57:102866. [PMID: 32629394 DOI: 10.1016/j.ebiom.2020.102866] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
186 Tilg H, Effenberger M. From NAFLD to MAFLD: when pathophysiology succeeds. Nat Rev Gastroenterol Hepatol 2020;17:387-8. [PMID: 32461575 DOI: 10.1038/s41575-020-0316-6] [Cited by in Crossref: 103] [Cited by in F6Publishing: 98] [Article Influence: 34.3] [Reference Citation Analysis]
187 Bertol FS, Araujo B, Jorge BB, Rinaldi N, De Carli LA, Tovo CV. Role of micronutrients in staging of nonalcoholic fatty liver disease: A retrospective cross-sectional study. World J Gastrointest Surg 2020; 12(6): 269-276 [PMID: 32774765 DOI: 10.4240/wjgs.v12.i6.269] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
188 Lv X, Dong Y, Hu L, Lu F, Zhou C, Qin S. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review. Endocrinol Diabetes Metab 2020;3:e00163. [PMID: 32704576 DOI: 10.1002/edm2.163] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
189 Chung GE, Yim JY, Kim D, Kwak MS, Yang JI, Park B, An SJ, Kim JS. Nonalcoholic Fatty Liver Disease Is Associated with Benign Prostate Hyperplasia. J Korean Med Sci 2020;35:e164. [PMID: 32508064 DOI: 10.3346/jkms.2020.35.e164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
190 Pirola CJ, Sookoian S. Epigenetics factors in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology. [DOI: 10.1080/17474124.2020.1765772] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
191 Liu TT, Liu XT, Chen QX, Shi Y. Lipase Inhibitors for Obesity: A Review. Biomed Pharmacother 2020;128:110314. [PMID: 32485574 DOI: 10.1016/j.biopha.2020.110314] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 22.7] [Reference Citation Analysis]
192 Al-Mrabeh A. Pathogenesis and remission of type 2 diabetes: what has the twin cycle hypothesis taught us? Cardiovasc Endocrinol Metab 2020;9:132-42. [PMID: 33225228 DOI: 10.1097/XCE.0000000000000201] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
193 Rametta R, Meroni M, Dongiovanni P. From Environment to Genome and Back: A Lesson from HFE Mutations. Int J Mol Sci 2020;21:E3505. [PMID: 32429125 DOI: 10.3390/ijms21103505] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
194 Rhee EJ. Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective. Endocrinol Metab (Seoul) 2019;34:226-33. [PMID: 31565874 DOI: 10.3803/EnM.2019.34.3.226] [Cited by in Crossref: 38] [Cited by in F6Publishing: 40] [Article Influence: 12.7] [Reference Citation Analysis]
195 Wang HH, Lee DK, Liu M, Portincasa P, Wang DQ. Novel Insights into the Pathogenesis and Management of the Metabolic Syndrome. Pediatr Gastroenterol Hepatol Nutr 2020;23:189-230. [PMID: 32483543 DOI: 10.5223/pghn.2020.23.3.189] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 21.7] [Reference Citation Analysis]
196 Zhou IY, Clavijo Jordan V, Rotile NJ, Akam E, Krishnan S, Arora G, Krishnan H, Slattery H, Warner N, Mercaldo N, Farrar CT, Wellen J, Martinez R, Schlerman F, Tanabe KK, Fuchs BC, Caravan P. Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis. Radiology 2020;296:67-75. [PMID: 32343209 DOI: 10.1148/radiol.2020192118] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
197 Ioannou GN, Nagana Gowda GA, Djukovic D, Raftery D. Distinguishing NASH Histological Severity Using a Multiplatform Metabolomics Approach. Metabolites 2020;10:E168. [PMID: 32344559 DOI: 10.3390/metabo10040168] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
198 Rampally V, Biri SK, Nair IK, Vadlakonda A. Determination of association between nonalcoholic fatty liver disease and carotid artery atherosclerosis among nondiabetic individuals. J Family Med Prim Care 2020;9:1182-6. [PMID: 32318489 DOI: 10.4103/jfmpc.jfmpc_957_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
199 Meroni M, Longo M, Rustichelli A, Dongiovanni P. Nutrition and Genetics in NAFLD: The Perfect Binomium. Int J Mol Sci 2020;21:E2986. [PMID: 32340286 DOI: 10.3390/ijms21082986] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 10.0] [Reference Citation Analysis]
200 Alferink LJM, Erler NS, de Knegt RJ, Janssen HLA, Metselaar HJ, Darwish Murad S, Kiefte-de Jong JC. Adherence to a plant-based, high-fibre dietary pattern is related to regression of non-alcoholic fatty liver disease in an elderly population. Eur J Epidemiol 2020;35:1069-85. [PMID: 32323115 DOI: 10.1007/s10654-020-00627-2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
201 Watt MJ, Miotto PM, De Nardo W, Montgomery MK. The Liver as an Endocrine Organ-Linking NAFLD and Insulin Resistance. Endocr Rev. 2019;40:1367-1393. [PMID: 31098621 DOI: 10.1210/er.2019-00034] [Cited by in Crossref: 185] [Cited by in F6Publishing: 202] [Article Influence: 61.7] [Reference Citation Analysis]
202 Akahane T, Namisaki T, Kaji K, Moriya K, Kawaratani H, Takaya H, Sawada Y, Shimozato N, Fujinaga Y, Furukawa M, Kitagawa K, Ozutsumi T, Tsuji Y, Kaya D, Ogawa H, Takagi H, Ishida K, Yoshiji H. Chronic Alcohol Consumption is Inversely Associated with Insulin Resistance and Fatty Liver in Japanese Males. Nutrients 2020;12:E1036. [PMID: 32283773 DOI: 10.3390/nu12041036] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
203 Jung SJ, Hwang JH, Park SH, Choi EK, Ha KC, Baek HI, Shin DG, Seo JH, Chae SW. A 12-week, randomized, double-blind study to evaluate the efficacy and safety of liver function after using fermented ginseng powder (GBCK25). Food Nutr Res 2020;64. [PMID: 32425736 DOI: 10.29219/fnr.v64.3517] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
204 Fuller KNZ, McCoin CS, Allen J, Bell-Glenn S, Koestler DC, Dorn GW, Thyfault JP. Sex and BNIP3 genotype, rather than acute lipid injection, modulate hepatic mitochondrial function and steatosis risk in mice. J Appl Physiol (1985) 2020;128:1251-61. [PMID: 32240015 DOI: 10.1152/japplphysiol.00035.2020] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
205 Singh A, Dhaliwal AS, Singh S, Kumar A, Lopez R, Gupta M, Noureddin M, Carey W, McCullough A, Alkhouri N. Awareness of Nonalcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort. Dig Dis Sci 2020;65:978-86. [PMID: 31187324 DOI: 10.1007/s10620-019-05700-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 7.3] [Reference Citation Analysis]
206 Belhadj S, Dal S, Khaskhoussi F, Maillard-Pedracini E, Hentati O, Sigrist S. Anorexic and metabolic effect of jojoba: potential treatment against metabolic syndrome and hepatic complications. Nutr Metab (Lond) 2020;17:24. [PMID: 32256672 DOI: 10.1186/s12986-020-00441-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
207 Pu S, Liu Y, Liang S, Liu P, Qian H, Wu Q, Wang Y. The Metabolic Changes of Artesunate and Ursolic Acid on Syrian Golden Hamsters Fed with the High-Fat Diet. Molecules 2020;25:E1392. [PMID: 32197531 DOI: 10.3390/molecules25061392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
208 Kumar R, Rahman MA, Nazarko TY. Nitrogen starvation and stationary phase lipophagy have distinct molecular mechanisms.. [DOI: 10.1101/2020.03.17.996082] [Reference Citation Analysis]
209 Konishi K, Miyake T, Furukawa S, Senba H, Kanzaki S, Nakaguchi H, Yukimoto A, Nakamura Y, Watanabe T, Koizumi Y, Yoshida O, Tokumoto Y, Hirooka M, Kumagi T, Abe M, Matsuura B, Hiasa Y. Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor. Atherosclerosis 2020;299:32-7. [PMID: 32203743 DOI: 10.1016/j.atherosclerosis.2020.02.026] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
210 Pirmoazen AM, Khurana A, El Kaffas A, Kamaya A. Quantitative ultrasound approaches for diagnosis and monitoring hepatic steatosis in nonalcoholic fatty liver disease. Theranostics 2020;10:4277-89. [PMID: 32226553 DOI: 10.7150/thno.40249] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 12.0] [Reference Citation Analysis]
211 Xu Z, Wu Y, Wang F, Li X, Wang P, Li Y, Wu J, Li Y, Jiang T, Pan X, Zhang X, Xie L, Xiao J, Liu Y. Fibroblast Growth Factor 1 Ameliorates Diabetes-Induced Liver Injury by Reducing Cellular Stress and Restoring Autophagy. Front Pharmacol 2020;11:52. [PMID: 32194395 DOI: 10.3389/fphar.2020.00052] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
212 Latorre J, Ortega FJ, Liñares-Pose L, Moreno-Navarrete JM, Lluch A, Comas F, Oliveras-Cañellas N, Ricart W, Höring M, Zhou Y, Liebisch G, Nidhina Haridas PA, Olkkonen VM, López M, Fernández-Real JM. Compounds that modulate AMPK activity and hepatic steatosis impact the biosynthesis of microRNAs required to maintain lipid homeostasis in hepatocytes. EBioMedicine 2020;53:102697. [PMID: 32143184 DOI: 10.1016/j.ebiom.2020.102697] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
213 Lee KY, Agriproduct Processing Experiment Station, Gangwon-do Agricultural Research and Experiment Services, Korea, Kim TH, Kim JE, Bae SW, Park A, Lee HY, Choi SJ, Park JY, Kwon SB, Kim HY. Inhibitory Effect of Purple Corn ‘Seakso 1’ Husk and Cob Extracts on Lipid Accumulation in Oleic Acid- Induced Non-Alcoholic Fatty Liver Disease HepG2 Model. J Fd Hyg Safety 2020;35:93-101. [DOI: 10.13103/jfhs.2020.35.1.93] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
214 Wang P, Wang J, Li D, Ke W, Chen F, Hu X. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis. J Nutr Biochem 2020;81:108363. [PMID: 32388250 DOI: 10.1016/j.jnutbio.2020.108363] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 13.3] [Reference Citation Analysis]
215 Tahir F, Majid Z, Majid B, Ahmed J, Zaman A, Tariq M, Imtiaz F, Tahir SA. Anthropometric Measurements and Lifestyle Characteristics of Individuals with Non-alcoholic Fatty Liver Disease. Cureus 2020;12:e7016. [PMID: 32211252 DOI: 10.7759/cureus.7016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
216 Kechagias S, Nasr P, Blomdahl J, Ekstedt M. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism 2020;111S:154183. [PMID: 32061907 DOI: 10.1016/j.metabol.2020.154183] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
217 Meroni M, Dongiovanni P, Longo M, Carli F, Baselli G, Rametta R, Pelusi S, Badiali S, Maggioni M, Gaggini M, Fracanzani AL, Romeo S, Gatti S, Davidson NO, Gastaldelli A, Valenti L. Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes. EBioMedicine 2020;52:102658. [PMID: 32058943 DOI: 10.1016/j.ebiom.2020.102658] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 13.7] [Reference Citation Analysis]
218 Cebola I. Liver gene regulatory networks: Contributing factors to nonalcoholic fatty liver disease. Wiley Interdiscip Rev Syst Biol Med 2020;12:e1480. [PMID: 32020788 DOI: 10.1002/wsbm.1480] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
219 Avramovski P, Avramovska M, Nikleski Z, Ilkovska B, Sotiroski K, Sikole E. The predictive value of the hepatorenal index for detection of impaired glucose metabolism in patients with non-alcoholic fatty liver disease. Indian J Gastroenterol 2020;39:50-9. [PMID: 32185691 DOI: 10.1007/s12664-019-01009-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
220 Kumar R, Porwal YC, Dev N, Kumar P, Chakravarthy S, Kumawat A. Association of high-sensitivity C-reactive protein (hs-CRP) with non-alcoholic fatty liver disease (NAFLD) in Asian Indians: A cross-sectional study. J Family Med Prim Care 2020;9:390-4. [PMID: 32110624 DOI: 10.4103/jfmpc.jfmpc_887_19] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
221 Petersen MC, Samuel VT, Petersen KF, Shulman GI. Non‐alcoholic Fatty Liver Disease and Insulin Resistance. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 455-71. [DOI: 10.1002/9781119436812.ch37] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
222 Kwon H, Pessin JE. Insulin‐Mediated PI3K and AKT Signaling. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 485-95. [DOI: 10.1002/9781119436812.ch39] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
223 Zhang B, Zhang C, Zhang X, Li N, Dong Z, Sun G, Sun X. Atorvastatin promotes AMPK signaling to protect against high fat diet-induced non-alcoholic fatty liver in golden hamsters. Exp Ther Med 2020;19:2133-42. [PMID: 32104276 DOI: 10.3892/etm.2020.8465] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
224 Azzaroli F, Mazzella G, Marchesini G, Brodosi L, Petroni ML. Fatty liver in pregnancy: a narrative review of two distinct conditions. Expert Rev Gastroenterol Hepatol 2020;14:127-35. [PMID: 31928239 DOI: 10.1080/17474124.2020.1715210] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
225 Paquette M, Gauthier D, Chamberland A, Prat A, De Lucia Rolfe E, Rasmussen JJ, Kaduka L, Seidah NG, Bernard S, Christensen DL, Baass A. Circulating PCSK9 is associated with liver biomarkers and hepatic steatosis. Clin Biochem 2020;77:20-5. [PMID: 31972148 DOI: 10.1016/j.clinbiochem.2020.01.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
226 Tahara A, Takasu T. Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice. Endocr Res 2020;45:147-61. [PMID: 31955626 DOI: 10.1080/07435800.2020.1713802] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
227 Softic S, Stanhope KL, Boucher J, Divanovic S, Lanaspa MA, Johnson RJ, Kahn CR. Fructose and hepatic insulin resistance. Crit Rev Clin Lab Sci. 2020;57:308-322. [PMID: 31935149 DOI: 10.1080/10408363.2019.1711360] [Cited by in Crossref: 53] [Cited by in F6Publishing: 42] [Article Influence: 17.7] [Reference Citation Analysis]
228 Umano GR, Caprio S. Ectopic Fat and Insulin Resistance in Youth. Contemporary Endocrinology 2020. [DOI: 10.1007/978-3-030-25057-7_10] [Reference Citation Analysis]
229 Khneizer G, Rizvi S, Gawrieh S. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus. Adv Exp Med Biol 2021;1307:417-40. [PMID: 32424494 DOI: 10.1007/5584_2020_532] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
230 Iqbal J, Jahangir Z, Al-qarni AA. Microsomal Triglyceride Transfer Protein: From Lipid Metabolism to Metabolic Diseases. Advances in Experimental Medicine and Biology 2020. [DOI: 10.1007/978-981-15-6082-8_4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
231 Li Y, Chen H, Ke Z, Huang J, Huang L, Yang B, Fan S, Huang C. Identification of isotschimgine as a novel farnesoid X receptor agonist with potency for the treatment of obesity in mice. Biochemical and Biophysical Research Communications 2020;521:639-45. [DOI: 10.1016/j.bbrc.2019.10.169] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
232 Wan X, Ai C, Chen Y, Gao X, Zhong R, Liu B, Chen X, Zhao C. Physicochemical Characterization of a Polysaccharide from Green Microalga Chlorella pyrenoidosa and Its Hypolipidemic Activity via Gut Microbiota Regulation in Rats. J Agric Food Chem 2020;68:1186-97. [DOI: 10.1021/acs.jafc.9b06282] [Cited by in Crossref: 32] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
233 Pereira RM, Rodrigues KCDC, Anaruma CP, Sant'Ana MR, de Campos TDP, Gaspar RS, Canciglieri RDS, de Melo DG, Mekary RA, da Silva ASR, Cintra DE, Ropelle ER, Pauli JR, de Moura LP. Short-term strength training reduces gluconeogenesis and NAFLD in obese mice. J Endocrinol 2019;241:59-70. [PMID: 30878016 DOI: 10.1530/JOE-18-0567] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
234 Gan M, Shen L, Fan Y, Tan Y, Zheng T, Tang G, Niu L, Zhao Y, Chen L, Jiang D, Li X, Zhang S, Zhu L. MicroRNA-451 and Genistein Ameliorate Nonalcoholic Steatohepatitis in Mice. Int J Mol Sci 2019;20:E6084. [PMID: 31816816 DOI: 10.3390/ijms20236084] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
235 King SE, Nilsson E, Beck D, Skinner MK. Adipocyte epigenetic alterations and potential therapeutic targets in transgenerationally inherited lean and obese phenotypes following ancestral exposures. Adipocyte 2019;8:362-78. [PMID: 31755359 DOI: 10.1080/21623945.2019.1693747] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
236 Makhlouf M, Saleh S, Rushdy M, Abdelhakam S, Abd-elghani E. Pentraxin-3 in non-alcoholic fatty liver disease and its affection by concomitant chronic hepatitis C infection. Egypt Liver Journal 2019;9:7. [DOI: 10.1186/s43066-019-0009-4] [Reference Citation Analysis]
237 Ting YW, Wong SW, Anuar Zaini A, Mohamed R, Jalaludin MY. Metabolic Syndrome Is Associated With Advanced Liver Fibrosis Among Pediatric Patients With Non-alcoholic Fatty Liver Disease. Front Pediatr 2019;7:491. [PMID: 31850288 DOI: 10.3389/fped.2019.00491] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
238 Wardani HA, Rahmadi M, Ardianto C, Balan SS, Kamaruddin NS, Khotib J. Development of nonalcoholic fatty liver disease model by high-fat diet in rats. J Basic Clin Physiol Pharmacol. 2019;30. [PMID: 31760381 DOI: 10.1515/jbcpp-2019-0258] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
239 Mary Varghese S, Thomas J. The Effect ofM. latifoliaLeaf Extract on High-Fructose Corn Syrup (HFCS)-Induced Non-alcoholic Fatty Liver Disease in Rat Models. Nonalcoholic Fatty Liver Disease - An Update 2019. [DOI: 10.5772/intechopen.82200] [Reference Citation Analysis]
240 Kim WK, Bae KH, Lee SC, Oh KJ. The Latest Insights into Adipokines in Diabetes. J Clin Med 2019;8:E1874. [PMID: 31694224 DOI: 10.3390/jcm8111874] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
241 Xu Y, Zhao Z, Liu S, Xiao Y, Miao M, Dong Q, Xin Y. Association of Nonalcoholic Fatty Liver Disease and Coronary Artery Disease with FADS2 rs3834458 Gene Polymorphism in the Chinese Han Population. Gastroenterol Res Pract 2019;2019:6069870. [PMID: 31781193 DOI: 10.1155/2019/6069870] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
242 Goltz FR, Thackray AE, Varela-Mato V, King JA, Dorling JL, Dowejko M, Mastana S, Thompson J, Atkinson G, Stensel DJ. Exploration of associations between the FTO rs9939609 genotype, fasting and postprandial appetite-related hormones and perceived appetite in healthy men and women. Appetite 2019;142:104368. [PMID: 31310836 DOI: 10.1016/j.appet.2019.104368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
243 Esquivel CM, Garcia M, Armando L, Ortiz G, Lascano FM, Foscarini JM. Laparoscopic Sleeve Gastrectomy Resolves NAFLD: Another Formal Indication for Bariatric Surgery? Obes Surg 2018;28:4022-33. [PMID: 30121855 DOI: 10.1007/s11695-018-3466-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
244 Reis-Júnior P, Tanigawa R, de Mesquita GHA, Basan N, Alves V, D'Albuquerque LAC, Andraus W. Steatosis and steatohepatitis found in adults after death due to non-burn trauma. Clinics (Sao Paulo) 2019;74:e1070. [PMID: 31618320 DOI: 10.6061/clinics/2019/e1070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
245 Mu J, Wang X, Wang Q, Cheng F, Zhu W, Li C, Ma C, Zhai C, Lian Y, Du X. Molecular mechanism of non-alcoholic fatty liver disease induced and aggravated by chronic stress through HSL/ATGL-FFA which promotes fat mobilization. Journal of Traditional Chinese Medical Sciences 2019;6:315-324. [DOI: 10.1016/j.jtcms.2019.08.001] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
246 Rinella ME, Tacke F, Sanyal AJ, Anstee QM; participants of the AASLD/EASL Workshop. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. J Hepatol 2019;71:823-33. [PMID: 31300231 DOI: 10.1016/j.jhep.2019.04.019] [Cited by in Crossref: 83] [Cited by in F6Publishing: 77] [Article Influence: 20.8] [Reference Citation Analysis]
247 Hörbelt T, Knebel B, Fahlbusch P, Barbosa D, de Wiza DH, Van de Velde F, Van Nieuwenhove Y, Lapauw B, Thoresen GH, Al-hasani H, Müller-wieland D, Ouwens DM, Kotzka J. The adipokine sFRP4 induces insulin resistance and lipogenesis in the liver. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 2019;1865:2671-84. [DOI: 10.1016/j.bbadis.2019.07.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
248 Lavrentaki A, Thomas T, Subramanian A, Valsamakis G, Thomas N, Toulis KA, Wang J, Daly B, Saravanan P, Sumilo D, Mastorakos G, Tahrani AA, Nirantharakumar K. Increased risk of non-alcoholic fatty liver disease in women with gestational diabetes mellitus: A population-based cohort study, systematic review and meta-analysis. Journal of Diabetes and its Complications 2019;33:107401. [DOI: 10.1016/j.jdiacomp.2019.06.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
249 Zhao P, Han SN, Arumugam S, Yousaf MN, Qin Y, Jiang JX, Torok NJ, Chen Y, Mankash MS, Liu J, Li J, Iwakiri Y, Ouyang X. Digoxin improves steatohepatitis with differential involvement of liver cell subsets in mice through inhibition of PKM2 transactivation. Am J Physiol Gastrointest Liver Physiol 2019;317:G387-97. [PMID: 31411894 DOI: 10.1152/ajpgi.00054.2019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
250 Rinella ME, Tacke F, Sanyal AJ, Anstee QM; participants of the AASLD/EASL Workshop. Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD. Hepatology 2019;70:1424-36. [PMID: 31287572 DOI: 10.1002/hep.30782] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 13.8] [Reference Citation Analysis]
251 Kiapidou S, Liava C, Kalogirou M, Akriviadis E, Sinakos E. Chronic kidney disease in patients with non-alcoholic fatty liver disease: What the Hepatologist should know? Ann Hepatol 2020;19:134-44. [PMID: 31606352 DOI: 10.1016/j.aohep.2019.07.013] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
252 Hara T, Seko Y, Iwai N, Inada Y, Tsuji T, Okuda T, Komaki T, Itoh Y, Kagawa K. Comparison of the effect of light alcohol consumption on Japanese men with and without fatty liver. biom rep 2019. [DOI: 10.3892/br.2019.1242] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
253 Ebrahimi R, Shanaki M, Mohassel Azadi S, Bahiraee A, Radmard AR, Poustchi H, Emamgholipour S. Low level of adiponectin predicts the development of Nonalcoholic fatty liver disease: Is it irrespective to visceral adiposity index, visceral adipose tissue thickness and other obesity indices? Arch Physiol Biochem 2019;:1-8. [PMID: 31482741 DOI: 10.1080/13813455.2019.1661496] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
254 Yue W, Sun X, Du T. Cholecystectomy versus central obesity or insulin resistance in relation to the risk of nonalcoholic fatty liver disease: the third US National Health and Nutrition Examination Survey. BMC Endocr Disord 2019;19:95. [PMID: 31477078 DOI: 10.1186/s12902-019-0423-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
255 Niederau C. Welchen Einfluss haben Ernährung und Genussmittel auf die Fettleber? Gastro-News 2019;6:38-43. [DOI: 10.1007/s15036-019-0660-y] [Reference Citation Analysis]
256 Koopman N, Molinaro A, Nieuwdorp M, Holleboom AG. Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2019;50:628-39. [PMID: 31373710 DOI: 10.1111/apt.15416] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 5.5] [Reference Citation Analysis]
257 Kim S, Yoon YY, Park YW, Whang W, Park S, Hwang KW. Cynandione A from Cynanchum wilfordii inhibits hepatic de novo lipogenesis by activating the LKB1/AMPK pathway in HepG2 cells. J Nat Med 2020;74:142-52. [DOI: 10.1007/s11418-019-01356-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
258 El Saeed KM, Ahmed OA, Khalifa MO, Fahmy EM. Detection of patatin-like phospholipase domain-containing protein 3 in nonalcoholic fatty liver disease among egyptian patients. Egypt J Intern Med 2019;31:273-80. [DOI: 10.4103/ejim.ejim_43_18] [Reference Citation Analysis]
259 Thompson DS, Tennant IA, Soares DP, Osmond C, Byrne CD, Forrester TE, Boyne MS. Nonalcoholic Fatty Liver Disease in Nonobese Subjects of African Origin Has Atypical Metabolic Characteristics. J Endocr Soc 2019;3:2051-63. [PMID: 31637346 DOI: 10.1210/js.2019-00138] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
260 Corbit KC, Wilson CG, Lowe D, Tran JL, Vera NB, Clasquin M, Mattis AN, Weiss EJ. Adipocyte JAK2 mediates spontaneous metabolic liver disease and hepatocellular carcinoma. JCI Insight 2019;5:131310. [PMID: 31393852 DOI: 10.1172/jci.insight.131310] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
261 Wang G, Huang W, Xia Y, Xiong Z, Ai L. Cholesterol-lowering potentials of Lactobacillus strain overexpression of bile salt hydrolase on high cholesterol diet-induced hypercholesterolemic mice. Food Funct 2019;10:1684-95. [PMID: 30839966 DOI: 10.1039/c8fo02181c] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 11.8] [Reference Citation Analysis]
262 Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA; Nonalcoholic Steatohepatitis Clinical Research Network. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Hepatology 2019;70:522-31. [PMID: 30549292 DOI: 10.1002/hep.30418] [Cited by in Crossref: 30] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
263 Le Stunff H, Véret J, Kassis N, Denom J, Meneyrol K, Paul JL, Cruciani-Guglielmacci C, Magnan C, Janel N. Deciphering the Link Between Hyperhomocysteinemia and Ceramide Metabolism in Alzheimer-Type Neurodegeneration. Front Neurol 2019;10:807. [PMID: 31417486 DOI: 10.3389/fneur.2019.00807] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
264 Gabbia D, Roverso M, Guido M, Sacchi D, Scaffidi M, Carrara M, Orso G, Russo FP, Floreani A, Bogialli S, De Martin S. Western Diet-Induced Metabolic Alterations Affect Circulating Markers of Liver Function before the Development of Steatosis. Nutrients 2019;11:E1602. [PMID: 31311123 DOI: 10.3390/nu11071602] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
265 Newsome P, Francque S, Harrison S, Ratziu V, Van Gaal L, Calanna S, Hansen M, Linder M, Sanyal A. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. Aliment Pharmacol Ther 2019;50:193-203. [PMID: 31246368 DOI: 10.1111/apt.15316] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 18.8] [Reference Citation Analysis]
266 Hamilton S, de Cabo R, Bernier M. Maternally expressed gene 3 in metabolic programming. Biochim Biophys Acta Gene Regul Mech 2020;1863:194396. [PMID: 31271897 DOI: 10.1016/j.bbagrm.2019.06.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
267 Adiga U, P K, P.b N. Association of Insulin Based Insulin Resistance with Liver Biomarkers in Type 2 Diabetes mellitus. J Pure Appl Microbiol 2019;13:1199-1205. [DOI: 10.22207/jpam.13.2.60] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
268 Zhu F, Li YM, Feng TT, Wu Y, Zhang HX, Jin GY, Liu JP. Freeze-dried Si-Ni-San powder can ameliorate high fat diet-induced non-alcoholic fatty liver disease. World J Gastroenterol 2019; 25(24): 3056-3068 [PMID: 31293341 DOI: 10.3748/wjg.v25.i24.3056] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
269 Corbit KC, Wilson CG, Lowe D, Tran JL, Vera NB, Clasquin M, Mattis AN, Weiss EJ. Adipocyte JAK2 mediates aging-associated metabolic liver disease and progression to hepatocellular carcinoma.. [DOI: 10.1101/681809] [Reference Citation Analysis]
270 Sundelin EIO, Gormsen LC, Heebøll S, Vendelbo MH, Jakobsen S, Munk OL, Feddersen S, Brøsen K, Hamilton-Dutoit SJ, Pedersen SB, Grønbaek H, Jessen N. Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease. Br J Clin Pharmacol 2019;85:1761-70. [PMID: 30973968 DOI: 10.1111/bcp.13962] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
271 Abbasalizad Farhangi M, Vajdi M, Nikniaz L, Nikniaz Z. The interaction between dietary inflammatory index and 6 P21 rs2010963 gene variants in metabolic syndrome. Eat Weight Disord 2020;25:1049-60. [PMID: 31197703 DOI: 10.1007/s40519-019-00729-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
272 Cree-Green M, Ravi S, Carreau AM, Sewell R, Baumgartner A, Coe G, Bergman BC, Scherzinger A, Jensen T, Pyle L, Nadeau KJ. Nonalcoholic fatty liver disease in obese adolescent females is associated with multi-tissue insulin resistance and visceral adiposity markers. Metabol Open 2019;2:100011. [PMID: 32812939 DOI: 10.1016/j.metop.2019.100011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
273 Takeuchi H, Aoyagi T. Clinical characteristics in urolithiasis formation according to body mass index. Biomed Rep 2019;11:38-42. [PMID: 31281643 DOI: 10.3892/br.2019.1220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
274 Kharazmi-Khorassani S, Kharazmi-Khorassani J, Rastegar-Moghadam A, Samadi S, Ghazizadeh H, Tayefi M, Ferns GA, Ghayour-Mobarhan M, Avan A, Esmaily H. Association of a genetic variant in the angiopoietin-like protein 4 gene with metabolic syndrome. BMC Med Genet 2019;20:97. [PMID: 31164103 DOI: 10.1186/s12881-019-0825-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
275 Ouyang X, Han SN, Zhang JY, Dioletis E, Nemeth BT, Pacher P, Feng D, Bataller R, Cabezas J, Stärkel P, Caballeria J, Pongratz RL, Cai SY, Schnabl B, Hoque R, Chen Y, Yang WH, Garcia-Martinez I, Wang FS, Gao B, Torok NJ, Kibbey RG, Mehal WZ. Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis. Cell Metab 2018;27:339-350.e3. [PMID: 29414684 DOI: 10.1016/j.cmet.2018.01.007] [Cited by in Crossref: 37] [Cited by in F6Publishing: 42] [Article Influence: 9.3] [Reference Citation Analysis]
276 Iida A, Kuranuki S, Yamamoto R, Uchida M, Ohta M, Ichimura M, Tsuneyama K, Masaki T, Seike M, Nakamura T. Analysis of amino acid profiles of blood over time and biomarkers associated with non-alcoholic steatohepatitis in STAM mice. Exp Anim 2019;68:417-28. [PMID: 31155606 DOI: 10.1538/expanim.18-0152] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
277 Cuthbertson DJ, Brown E, Koskinen J, Magnussen CG, Hutri-Kähönen N, Sabin M, Tossavainen P, Jokinen E, Laitinen T, Viikari J, Raitakari OT, Juonala M. Longitudinal analysis of risk of non-alcoholic fatty liver disease in adulthood. Liver Int 2019;39:1147-54. [PMID: 30347485 DOI: 10.1111/liv.13993] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
278 Gawlik A, Shmoish M, Hartmann MF, Wudy SA, Olczak Z, Gruszczynska K, Hochberg Z. Steroid metabolomic signature of liver disease in nonsyndromic childhood obesity. Endocr Connect 2019;8:764-71. [PMID: 31071683 DOI: 10.1530/EC-18-0536] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
279 King SE, McBirney M, Beck D, Sadler-Riggleman I, Nilsson E, Skinner MK. Sperm epimutation biomarkers of obesity and pathologies following DDT induced epigenetic transgenerational inheritance of disease. Environ Epigenet 2019;5:dvz008. [PMID: 31186947 DOI: 10.1093/eep/dvz008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 9.0] [Reference Citation Analysis]
280 Li H, Yoo W, Park HM, Lim SY, Shin DH, Kim S, Park HY, Jeong TS. Arazyme Suppresses Hepatic Steatosis and Steatohepatitis in Diet-Induced Non-Alcoholic Fatty Liver Disease-Like Mouse Model. Int J Mol Sci 2019;20:E2325. [PMID: 31083413 DOI: 10.3390/ijms20092325] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
281 Agyemang-Yeboah F, Eghan BAJ, Annani-Akollor ME, Togbe E, Donkor S, Oppong Afranie B. Evaluation of Metabolic Syndrome and Its Associated Risk Factors in Type 2 Diabetes: A Descriptive Cross-Sectional Study at the Komfo Anokye Teaching Hospital, Kumasi, Ghana. Biomed Res Int 2019;2019:4562904. [PMID: 31187045 DOI: 10.1155/2019/4562904] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
282 Wang W, Li C, Xu J, Li X. Bridging Fatty Liver Disease and Traditional Chinese Medicine: A Complex Network Approach. 2019 IEEE International Symposium on Circuits and Systems (ISCAS) 2019. [DOI: 10.1109/iscas.2019.8702097] [Reference Citation Analysis]
283 Kim JW, Lee YJ, You YH, Moon MK, Yoon KH, Ahn YB, Ko SH. Effect of sodium-glucose cotransporter 2 inhibitor, empagliflozin, and α-glucosidase inhibitor, voglibose, on hepatic steatosis in an animal model of type 2 diabetes. J Cell Biochem 2019;120:8534-46. [PMID: 30474134 DOI: 10.1002/jcb.28141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 6.5] [Reference Citation Analysis]
284 Lee WG, Wells CI, Mccall JL, Murphy R, Plank LD. Prevalence of diabetes in liver cirrhosis: A systematic review and meta‐analysis. Diabetes Metab Res Rev 2019;35. [DOI: 10.1002/dmrr.3157] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
285 Esler WP, Bence KK. Metabolic Targets in Nonalcoholic Fatty Liver Disease. Cell Mol Gastroenterol Hepatol 2019;8:247-67. [PMID: 31004828 DOI: 10.1016/j.jcmgh.2019.04.007] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 17.3] [Reference Citation Analysis]
286 Paruk IM, Pirie FJ, Motala AA. Non-alcoholic fatty liver disease in Africa: A hidden danger. Glob Health Epidemiol Genom. 2019;4:e3. [PMID: 31019719 DOI: 10.1017/gheg.2019.2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
287 Lattuada G, Radaelli MG, De Cobelli F, Esposito A, Manzoni G, Perra S, Del Maschio A, Castoldi G, Perseghin G. Fasting Whole-Body Energy Homeostasis and Hepatic Energy Metabolism in Nondiabetic Humans with Fatty Liver. Oxid Med Cell Longev 2019;2019:9796175. [PMID: 31097978 DOI: 10.1155/2019/9796175] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
288 Mika A, Sledzinski T, Stepnowski P. Current Progress of Lipid Analysis in Metabolic Diseases by Mass Spectrometry Methods. Curr Med Chem 2019;26:60-103. [PMID: 28971757 DOI: 10.2174/0929867324666171003121127] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
289 Badi RM, Mostafa DG, Khaleel EF, Satti HH. Resveratrol protects against hepatic insulin resistance in a rat's model of non-alcoholic fatty liver disease by down-regulation of GPAT-1 and DGAT2 expression and inhibition of PKC membranous translocation. Clin Exp Pharmacol Physiol 2019;46:545-55. [PMID: 30773673 DOI: 10.1111/1440-1681.13074] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
290 Li D, Ikaga R, Yamazaki T. Soya protein β-conglycinin ameliorates fatty liver and obesity in diet-induced obese mice through the down-regulation of PPARγ. Br J Nutr 2018;119:1220-32. [PMID: 29770757 DOI: 10.1017/S0007114518000739] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
291 Shin KA. Comparison of the Serum Gamma-Glutamyl Transferase and Serum Uric Acid Levels according to the Obesity Types Based upon on the Body Mass Index in Korean Men. Korean J Clin Lab Sci 2019;51:50-56. [DOI: 10.15324/kjcls.2019.51.1.50] [Reference Citation Analysis]
292 Vahid F, Shivappa N, Hekmatdoost A, R Hebert J, Poustchi H, Shamsipour A, Eslamparast T, Meibodi M, Rahmani D. Association of Pro-inflammatory Dietary Intake and Non-Alcoholic Fatty Liver Disease: Findings from Iranian case-control study. Int J Vitam Nutr Res 2018;88:144-50. [PMID: 30887902 DOI: 10.1024/0300-9831/a000571] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
293 Boemeke L, Raimundo FV, Bopp M, Leonhardt LR, Fernandes SA, Marroni CA. The correlation of neck circumference and insulin resistance in NAFLD patients. Arq Gastroenterol. 2019;56:28-33. [PMID: 31141077 DOI: 10.1590/s0004-2803.201900000-06] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
294 Kim MC, Park JG, Jang BI, Lee HJ, Lee WK. Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease. Medicine (Baltimore) 2019;98:e14139. [PMID: 30732129 DOI: 10.1097/MD.0000000000014139] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
295 Sakasai-Sakai A, Takata T, Takino JI, Takeuchi M. The Relevance of Toxic AGEs (TAGE) Cytotoxicity to NASH Pathogenesis: A Mini-Review. Nutrients. 2019;11. [PMID: 30813302 DOI: 10.3390/nu11020462] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
296 Lim DW, Kim H, Lee SJ, Yu GR, Kim JE, Park WH. Jwa Kum Whan Attenuates Nonalcoholic Fatty Liver Disease by Modulating Glucose Metabolism and the Insulin Signaling Pathway. Evid Based Complement Alternat Med 2019;2019:4589810. [PMID: 30881473 DOI: 10.1155/2019/4589810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
297 Abdelmoemen G, Khodeir SA, Zaki AN, Kassab M, Abou-saif S, Abd-elsalam S. Overexpression of Hepassocin in Diabetic Patients with Nonalcoholic Fatty Liver Disease May Facilitate Increased Hepatic Lipid Accumulation. EMIDDT 2019;19:185-8. [DOI: 10.2174/1871530318666180716100543] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
298 Kim SH, Hong SH, Park YJ, Sung JH, Suh W, Lee KW, Jung K, Lim C, Kim JH, Kim H, Park KS, Park SG. MD001, a Novel Peroxisome Proliferator-activated Receptor α/γ Agonist, Improves Glucose and Lipid Metabolism. Sci Rep 2019;9:1656. [PMID: 30733541 DOI: 10.1038/s41598-018-38281-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
299 Hou C, Zhang W, Li J, Du L, Lv O, Zhao S, Li J. Beneficial Effects of Pomegranate on Lipid Metabolism in Metabolic Disorders. Mol Nutr Food Res 2019;63:1800773. [DOI: 10.1002/mnfr.201800773] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 8.8] [Reference Citation Analysis]
300 Yang JS, Qi W, Farias-Pereira R, Choi S, Clark JM, Kim D, Park Y. Permethrin and ivermectin modulate lipid metabolism in steatosis-induced HepG2 hepatocyte. Food Chem Toxicol 2019;125:595-604. [PMID: 30738135 DOI: 10.1016/j.fct.2019.02.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
301 Chen P, Hou X, Wei L, Feng L, Zhong L, Jiao L, Wang H, Bao Y, Jia W. Free triiodothyronine is associated with the occurrence and remission of nonalcoholic fatty liver disease in euthyroid women. Eur J Clin Invest 2019;49:e13070. [PMID: 30636282 DOI: 10.1111/eci.13070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
302 Fakhoury-sayegh N, Trak-smayra V, Sayegh R, Haidar F, Obeid O, Asmar S, Khazzaka A. Fructose threshold for inducing organ damage in a rat model of nonalcoholic fatty liver disease. Nutrition Research 2019;62:101-12. [DOI: 10.1016/j.nutres.2018.11.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
303 Ortega-Pacheco D, Jiménez-Pérez MM, Serafín-López J, Juárez-Rojas JG, Ruiz-García A, Pacheco-García U. Vanadyl Sulfate Effects on Systemic Profiles of Metabolic Syndrome in Old Rats with Fructose-Induced Obesity. Int J Endocrinol 2018;2018:5257216. [PMID: 30675160 DOI: 10.1155/2018/5257216] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
304 Watanabe S, Kumazaki S, Yamamoto S, Sato I, Kitamori K, Mori M, Yamori Y, Hirohata S. Non-alcoholic steatohepatitis aggravates nitric oxide synthase inhibition-induced arteriosclerosis in SHRSP5/Dmcr rat model. Int J Exp Pathol 2018;99:282-94. [PMID: 30680827 DOI: 10.1111/iep.12301] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
305 Di Costanzo A, Pacifico L, Chiesa C, Perla FM, Ceci F, Angeloni A, D'Erasmo L, Di Martino M, Arca M. Genetic and metabolic predictors of hepatic fat content in a cohort of Italian children with obesity. Pediatr Res 2019;85:671-7. [PMID: 30710115 DOI: 10.1038/s41390-019-0303-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 6.0] [Reference Citation Analysis]
306 Jasbi P, Baker O, Shi X, Gonzalez LA, Wang S, Anderson S, Xi B, Gu H, Johnston CS. Daily red wine vinegar ingestion for eight weeks improves glucose homeostasis and affects the metabolome but does not reduce adiposity in adults. Food Funct 2019;10:7343-55. [DOI: 10.1039/c9fo01082c] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
307 Suksangrat T, Phannasil P, Jitrapakdee S. miRNA Regulation of Glucose and Lipid Metabolism in Relation to Diabetes and Non-alcoholic Fatty Liver Disease. Reviews on Biomarker Studies of Metabolic and Metabolism-Related Disorders 2019. [DOI: 10.1007/978-3-030-12668-1_7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
308 Arora S, Katyal A. Protein Modifications and Lifestyle Disorders. Protein Modificomics 2019. [DOI: 10.1016/b978-0-12-811913-6.00004-7] [Reference Citation Analysis]
309 Almanza D, Gharaee-Kermani M, Zhilin-Roth A, Rodriguez-Nieves JA, Colaneri C, Riley T, Macoska JA. Nonalcoholic Fatty Liver Disease Demonstrates a Pre-fibrotic and Premalignant Molecular Signature. Dig Dis Sci 2019;64:1257-69. [PMID: 30519850 DOI: 10.1007/s10620-018-5398-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
310 Al-sayed HM, Soliman WI. Potential Toxic Effects of Olanzapine on Metabolic Parameters in <i>de Novo</i> Paranoid Schizophrenic Patients. The Role of Adjunctive Aripeprazole: Clinical and Experimental Study. ODEM 2019;07:91-113. [DOI: 10.4236/odem.2019.73008] [Reference Citation Analysis]
311 Paniagua González JA, Vidal-puig A. Obesity in the Pathophysiology of Diabetes. The Diabetes Textbook 2019. [DOI: 10.1007/978-3-030-11815-0_13] [Reference Citation Analysis]
312 Lim S, Taskinen MR, Borén J. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome. Obes Rev 2019;20:599-611. [PMID: 30589487 DOI: 10.1111/obr.12820] [Cited by in Crossref: 43] [Cited by in F6Publishing: 45] [Article Influence: 8.6] [Reference Citation Analysis]
313 Tsuma Y, Mori J, Ota T, Kawabe Y, Morimoto H, Fukuhara S, Kodo K, Umemura A, Nakajima H, Hosoi H. Erythropoietin and long-acting erythropoiesis stimulating agent ameliorate non-alcoholic fatty liver disease by increasing lipolysis and decreasing lipogenesis via EPOR/STAT pathway. Biochem Biophys Res Commun 2019;509:306-13. [PMID: 30583863 DOI: 10.1016/j.bbrc.2018.12.131] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
314 Real-Hohn A, Navegantes C, Ramos K, Ramos-Filho D, Cahuê F, Galina A, Salerno VP. The synergism of high-intensity intermittent exercise and every-other-day intermittent fasting regimen on energy metabolism adaptations includes hexokinase activity and mitochondrial efficiency. PLoS One 2018;13:e0202784. [PMID: 30576325 DOI: 10.1371/journal.pone.0202784] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
315 Yamazaki T, Li D, Ikaga R. Effective Food Ingredients for Fatty Liver: Soy Protein β-Conglycinin and Fish Oil. Int J Mol Sci 2018;19:E4107. [PMID: 30567368 DOI: 10.3390/ijms19124107] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
316 Barrea L, Annunziata G, Muscogiuri G, Di Somma C, Laudisio D, Maisto M, de Alteriis G, Tenore GC, Colao A, Savastano S. Trimethylamine-N-oxide (TMAO) as Novel Potential Biomarker of Early Predictors of Metabolic Syndrome. Nutrients. 2018;10. [PMID: 30551613 DOI: 10.3390/nu10121971] [Cited by in Crossref: 117] [Cited by in F6Publishing: 122] [Article Influence: 23.4] [Reference Citation Analysis]
317 Khanal UP, Paudel B, Gurung G, Hu YS, Kuo CW. Correlational Study of Nonalcoholic Fatty Liver Disease Diagnosed by Ultrasonography with Lipid Profile and Body Mass Index in Adult Nepalese Population. J Med Ultrasound 2019;27:19-25. [PMID: 31031531 DOI: 10.4103/JMU.JMU_53_18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
318 Kim SH, Lee ES, Yoo J, Kim Y. Predicting risk of type 2 diabetes mellitus in Korean adults aged 40-69 by integrating clinical and genetic factors. Prim Care Diabetes. 2019;13:3-10. [PMID: 30477970 DOI: 10.1016/j.pcd.2018.07.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
319 Lee SM, Kwak SH, Koo JN, Oh IH, Kwon JE, Kim BJ, Kim SM, Kim SY, Kim GM, Joo SK, Koo BK, Shin S, Vixay C, Norwitz ER, Park C, Jun JK, Kim W, Park JS. Non-alcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes mellitus. Diabetologia 2019;62:238-48. [DOI: 10.1007/s00125-018-4779-8] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 8.6] [Reference Citation Analysis]
320 Suceveanu A, Mazilu L, Gheorghe A, Pantea Stoian A, Voinea F, Suceveanu A. Metabolic Risk Factors in Hepatocellular Carcinoma. Liver Cancer 2018. [DOI: 10.5772/intechopen.80527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
321 Moh Moh MA, Jung C, Lee B, Choi D, Kim B, Kim C, Kang S, Mok J. Association of glucagon-to-insulin ratio and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Diabetes and Vascular Disease Research 2019;16:186-95. [DOI: 10.1177/1479164118810691] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
322 Kim K, Kim DS, Kim KN. Serum Alanine Aminotransferase Level as a Risk Factor for Coronary Heart Disease Prediction in Koreans: Analysis of the Korea National Health and Nutrition Examination Survey (V-1, 2010 and V-2, 2011). Korean J Fam Med 2019;40:124-8. [PMID: 30419632 DOI: 10.4082/kjfm.17.0068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
323 Nejabat M, Leisser A, Karanikas G, Wadsak W, Mitterhauser M, Mayerhöfer M, Kienbacher C, Trauner M, Hacker M, Haug AR. [11C]acetate PET as a tool for diagnosis of liver steatosis. Abdom Radiol (NY) 2018;43:2963-9. [PMID: 29644441 DOI: 10.1007/s00261-018-1558-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
324 Bifari F, Manfrini R, Dei Cas M, Berra C, Siano M, Zuin M, Paroni R, Folli F. Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Pharmacol Res 2018;137:219-29. [PMID: 30359962 DOI: 10.1016/j.phrs.2018.09.025] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 8.0] [Reference Citation Analysis]
325 Yamamoto K, Kogiso T, Taniai M, Hashimoto E, Tokushige K. Differences in the genetic backgrounds of patients with alcoholic liver disease and non-alcoholic fatty liver disease. JGH Open 2019;3:17-24. [PMID: 30834336 DOI: 10.1002/jgh3.12097] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
326 Feldman A, Eder SK, Felder TK, Paulweber B, Zandanell S, Stechemesser L, Schranz M, Strebinger G, Huber-Schönauer U, Niederseer D, Patsch W, Weghuber D, Tevini J, Datz C, Aigner E. Clinical and metabolic characterization of obese subjects without non-alcoholic fatty liver: A targeted metabolomics approach. Diabetes Metab 2019;45:132-9. [PMID: 30266576 DOI: 10.1016/j.diabet.2018.09.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
327 Zhang J, Zhu W, Qiu L, Huang L, Fang L. Sex- and Age-Specific Optimal Anthropometric Indices as Screening Tools for Metabolic Syndrome in Chinese Adults. Int J Endocrinol 2018;2018:1067603. [PMID: 30310390 DOI: 10.1155/2018/1067603] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
328 Miyake T, Yoshida S, Furukawa S, Sakai T, Tada F, Senba H, Yamamoto S, Koizumi Y, Yoshida O, Hirooka M, Kumagi T, Niiya T, Miyaoka H, Masanori A, Matsuura B, Hiasa Y. Ipragliflozin Ameliorates Liver Damage in Non-alcoholic Fatty Liver Disease. Open Med (Wars). 2018;13:402-409. [PMID: 30234161 DOI: 10.1515/med-2018-0059] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
329 Watanabe T, Takeuchi T, Kubota N, Wainai T, Kataoka K, Nakaya T, Sugimoto A, Sato T, Ohira H, Tsujino I, Kumagai K, Kubota T, Hasegawa C, Tokuyama K, Ueki K, Yamauchi T, Mishina M, Kadowaki T. A transgenic mutant mouse line accompanied by the complete deletion of interleukin-33 showed insulin and leptin resistances.. [DOI: 10.1101/416529] [Reference Citation Analysis]
330 Casagrande D, Waib PH, Jordão Júnior AA. Mechanisms of action and effects of the administration of Coenzyme Q10 on metabolic syndrome. Journal of Nutrition & Intermediary Metabolism 2018;13:26-32. [DOI: 10.1016/j.jnim.2018.08.002] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
331 He C, Cheng D, Wang H, Wu K, Zhu Y, Lu N. Helicobacter pylori infection aggravates diet-induced nonalcoholic fatty liver in mice. Clinics and Research in Hepatology and Gastroenterology 2018;42:360-7. [DOI: 10.1016/j.clinre.2017.12.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
332 Janovsky CCPS, Cesena FH, Valente VAT, Conceição RDO, Santos RD, Bittencourt MS. Association between Thyroid-Stimulating Hormone Levels and Non-Alcoholic Fatty Liver Disease Is Not Independent from Metabolic Syndrome Criteria. Eur Thyroid J 2018;7:302-7. [PMID: 30574460 DOI: 10.1159/000492324] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
333 Kim KH, Lee MS. Pathogenesis of Nonalcoholic Steatohepatitis and Hormone-Based Therapeutic Approaches. Front Endocrinol (Lausanne). 2018;9:485. [PMID: 30197624 DOI: 10.3389/fendo.2018.00485] [Cited by in Crossref: 35] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
334 Jiang W, Huang S, Teng H, Wang P, Wu M, Zhou X, Ran H. Diagnostic accuracy of point shear wave elastography and transient elastography for staging hepatic fibrosis in patients with non-alcoholic fatty liver disease: a meta-analysis. BMJ Open 2018;8:e021787. [PMID: 30139901 DOI: 10.1136/bmjopen-2018-021787] [Cited by in Crossref: 63] [Cited by in F6Publishing: 67] [Article Influence: 12.6] [Reference Citation Analysis]
335 Shin SK, Cho HW, Song SE, Song DK. Catalase and nonalcoholic fatty liver disease. Pflugers Arch 2018;470:1721-37. [PMID: 30120555 DOI: 10.1007/s00424-018-2195-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
336 Cho YK, Kang YM, Yoo JH, Lee J, Lee SE, Yang DH, Kang JW, Park JY, Jung CH, Kim HK, Lee WJ. The impact of non-alcoholic fatty liver disease and metabolic syndrome on the progression of coronary artery calcification. Sci Rep 2018;8:12004. [PMID: 30104707 DOI: 10.1038/s41598-018-30465-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.4] [Reference Citation Analysis]
337 Real-hohn A, Navegantes C, Ramos K, Ramos-filho D, Cahuê F, Galina A, Salerno VP. Hexokinase: A central player in the synergism of high-intensity intermittent exercise and every-other-day intermittent fasting regimen on energy metabolism adaptations.. [DOI: 10.1101/389668] [Reference Citation Analysis]
338 Yuan Y, Naito H, Nakajima T. The Role of Cholesterol in the Pathogenesis of Hypertension- Associated Nonalcoholic Steatohepatitis. Cholesterol - Good, Bad and the Heart 2018. [DOI: 10.5772/intechopen.76199] [Reference Citation Analysis]
339 Danford CJ, Yao ZM, Jiang ZG. Non-alcoholic fatty liver disease: a narrative review of genetics. J Biomed Res 2018;32:389-400. [PMID: 30355853 DOI: 10.7555/JBR.32.20180045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 17] [Article Influence: 0.4] [Reference Citation Analysis]
340 Mora SI, García-Román J, Gómez-Ñañez I, García-Román R. Chronic liver diseases and the potential use of S-adenosyl-L-methionine as a hepatoprotector. Eur J Gastroenterol Hepatol 2018;30:893-900. [PMID: 29683981 DOI: 10.1097/MEG.0000000000001141] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
341 Régnier M, Polizzi A, Guillou H, Loiseau N. Sphingolipid metabolism in non-alcoholic fatty liver diseases. Biochimie 2019;159:9-22. [PMID: 30071259 DOI: 10.1016/j.biochi.2018.07.021] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 6.4] [Reference Citation Analysis]
342 Liu S, Yuan J, Yue W, Bi Y, Shen X, Gao J, Xu X, Lu Z. GCN2 deficiency protects against high fat diet induced hepatic steatosis and insulin resistance in mice. Biochim Biophys Acta Mol Basis Dis 2018;1864:3257-67. [PMID: 30006154 DOI: 10.1016/j.bbadis.2018.07.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
343 Howell GE 3rd, McDevitt E, Henein L, Mulligan C, Young D. Alterations in cellular lipid metabolism produce neutral lipid accumulation following exposure to the organochlorine compound trans-nonachlor in rat primary hepatocytes. Environ Toxicol 2018;33:962-71. [PMID: 29964320 DOI: 10.1002/tox.22583] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
344 Zaki M, Yousef W, Kamal S, Mohamed R, Saleh O, Ezzat W. Association Between Metabolic Abnormalities and Non-Alcoholic Fatty Liver in Obese Premenopausal Women. Biomed Pharmacol J 2018;11:1161-1166. [DOI: 10.13005/bpj/1477] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
345 Vernekar M, Singhal R, Joshi K, Amarapurkar D. Variation in the Plasma Levels of Polyunsaturated Fatty Acids in Control vis-à-vis Nonalcoholic Fatty Liver Disease Subjects and Its Possible Association with Gut Microbiome. Metab Syndr Relat Disord 2018;16:329-35. [PMID: 29873593 DOI: 10.1089/met.2018.0008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
346 Marmur J, Beshara S, Eggertsen G, Onelöv L, Albiin N, Danielsson O, Hultcrantz R, Stål P. Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease. BMC Gastroenterol 2018;18:78. [PMID: 29871592 DOI: 10.1186/s12876-018-0804-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
347 Rix I, Steen Pedersen J, Storgaard H, Gluud LL. Cardiometabolic effects of antidiabetic drugs in non-alcoholic fatty liver disease. Clin Physiol Funct Imaging 2019;39:122-7. [PMID: 29808958 DOI: 10.1111/cpf.12526] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
348 Xu J, Cao X. Long noncoding RNAs in the metabolic control of inflammation and immune disorders. Cell Mol Immunol 2019;16:1-5. [PMID: 29795339 DOI: 10.1038/s41423-018-0042-y] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
349 Miyake T, Yoshida S, Yamamoto S, Furukawa S, Yoshida O, Kanzaki S, Senba H, Ishihara T, Koizumi M, Tokumoto Y, Hirooka M, Kumagi T, Abe M, Kitai K, Matsuura B, Hiasa Y. Low Urine pH Is Associated with Non-alcoholic Fatty Liver Disease: A Community-based Cross-sectional Study. Intern Med 2018;57:2799-805. [PMID: 29780107 DOI: 10.2169/internalmedicine.0167-17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
350 Wu J, Yao XY, Shi RX, Liu SF, Wang XY. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis. Reprod Health. 2018;15:77. [PMID: 29747678 DOI: 10.1186/s12978-018-0519-2] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 11.6] [Reference Citation Analysis]
351 Mokhayeri Y, Riahi SM, Rahimzadeh S, Pourhoseingholi MA, Hashemi-nazari SS. Metabolic syndrome prevalence in the Iranian adult’s general population and its trend: A systematic review and meta-analysis of observational studies. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2018;12:441-53. [DOI: 10.1016/j.dsx.2017.12.023] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
352 Matsuba I, Matsuba R, Ishibashi S, Yamashita S, Arai H, Yokote K, Suganami H, Araki E. Effects of a novel selective peroxisome proliferator-activated receptor-α modulator, pemafibrate, on hepatic and peripheral glucose uptake in patients with hypertriglyceridemia and insulin resistance. J Diabetes Investig 2018;9:1323-32. [PMID: 29603684 DOI: 10.1111/jdi.12845] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
353 Farhangi MA, Jahangiry L. Dietary diversity score is associated with cardiovascular risk factors and serum adiponectin concentrations in patients with metabolic syndrome. BMC Cardiovasc Disord 2018;18:68. [PMID: 29665770 DOI: 10.1186/s12872-018-0807-3] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
354 Kim JY, Cho J, Yang HR. Biochemical Predictors of Early Onset Non-Alcoholic Fatty Liver Disease in Young Children with Obesity. J Korean Med Sci 2018;33:e122. [PMID: 29651819 DOI: 10.3346/jkms.2018.33.e122] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
355 Preuss HG, Kaats GR, Mrvichin N, Swaroop A, Bagchi D, Clouatre D, Preuss JM. Examining the Relationship Between Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome in Nondiabetic Subjects. J Am Coll Nutr 2018;37:457-65. [PMID: 29652564 DOI: 10.1080/07315724.2018.1443292] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
356 Howell GE 3rd, McDevitt E, Henein L, Mulligan C, Young D. "Trans-nonachlor increases extracellular free fatty acid accumulation and de novo lipogenesis to produce hepatic steatosis in McArdle-RH7777 cells". Toxicol In Vitro 2018;50:285-92. [PMID: 29654899 DOI: 10.1016/j.tiv.2018.04.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
357 Li W, Zhu X, Song Y, Fan L, Wu L, Kabagambe EK, Hou L, Shrubsole MJ, Liu J, Dai Q. Intakes of magnesium, calcium and risk of fatty liver disease and prediabetes. Public Health Nutr 2018;21:2088-95. [PMID: 29607802 DOI: 10.1017/S1368980018000642] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
358 Trembling PM, Apostolidou S, Gentry-Maharaj A, Parkes J, Ryan A, Tanwar S, Burnell M, Menon U, Rosenberg WM. Association between skirt size and chronic liver disease in post-menopausal women: a prospective cohort study within the United Kingdom Trial of Ovarian Cancer Screening (UKCTOCS). BMC Public Health 2018;18:409. [PMID: 29587697 DOI: 10.1186/s12889-018-5308-x] [Reference Citation Analysis]
359 Lee YJ, Kim JW. Monoacylglycerol O-acyltransferase 1 (MGAT1) localizes to the ER and lipid droplets promoting triacylglycerol synthesis. BMB Rep 2017;50:367-72. [PMID: 28347400 DOI: 10.5483/bmbrep.2017.50.7.036] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
360 Bouhajja H, Abdelhedi R, Amouri A, Hadj Kacem F, Marrakchi R, Safi W, Mrabet H, Chtourou L, Charfi N, Fourati M, Bensassi S, Jamoussi K, Abid M, Ayadi H, Mnif-Feki M, Bougacha-Elleuch N. Potential role of liver enzyme levels as predictive markers of glucose metabolism disorders in a Tunisian population. Can J Physiol Pharmacol 2018;96:1171-80. [PMID: 29527933 DOI: 10.1139/cjpp-2017-0579] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
361 Jung TW, Kang C, Goh J, Chae SI, Kim H, Lee TJ, Abd El‐aty A, Jeong JH. WISP1 promotes non‐alcoholic fatty liver disease and skeletal muscle insulin resistance via TLR4/JNK signaling. J Cell Physiol 2018;233:6077-87. [DOI: 10.1002/jcp.26449] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
362 Kim G, Jang SY, Nam CM, Kang ES. Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study. J Hepatol 2018;68:476-84. [PMID: 29107150 DOI: 10.1016/j.jhep.2017.10.018] [Cited by in Crossref: 74] [Cited by in F6Publishing: 76] [Article Influence: 14.8] [Reference Citation Analysis]
363 Singh A, Le P, Peerzada MM, Lopez R, Alkhouri N. The Utility of Noninvasive Scores in Assessing the Prevalence of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Type 2 Diabetic Patients. J Clin Gastroenterol 2018;52:268-72. [PMID: 28787358 DOI: 10.1097/MCG.0000000000000905] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
364 Di Costanzo A, Belardinilli F, Bailetti D, Sponziello M, D'Erasmo L, Polimeni L, Baratta F, Pastori D, Ceci F, Montali A, Girelli G, De Masi B, Angeloni A, Giannini G, Del Ben M, Angelico F, Arca M. Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy. Sci Rep 2018;8:3702. [PMID: 29487372 DOI: 10.1038/s41598-018-21939-0] [Cited by in Crossref: 47] [Cited by in F6Publishing: 49] [Article Influence: 9.4] [Reference Citation Analysis]
365 Savastano S, Barrea L, Savanelli MC, Nappi F, Di Somma C, Orio F, Colao A. Low vitamin D status and obesity: Role of nutritionist. Rev Endocr Metab Disord 2017;18:215-25. [PMID: 28229265 DOI: 10.1007/s11154-017-9410-7] [Cited by in Crossref: 82] [Cited by in F6Publishing: 78] [Article Influence: 16.4] [Reference Citation Analysis]
366 Perseghin G, Manzoni G, Grassi G. Hypertension and hepatic triglycerides content: a two (multi)-faceted clinical challenge? J Hypertens 2017;35:715-7. [PMID: 28248900 DOI: 10.1097/HJH.0000000000001290] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
367 Wang D, Cong H, Wang X, Cao Y, Ikuyama S, Fan B, Gu J. Pycnogenol protects against diet-induced hepatic steatosis in apolipoprotein-E-deficient mice. Am J Physiol Endocrinol Metab 2018;315:E218-28. [PMID: 29462565 DOI: 10.1152/ajpendo.00009.2017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
368 Yuk T, Kim Y, Yang J, Sung J, Jeong HS, Lee J. Nobiletin Inhibits Hepatic Lipogenesis via Activation of AMP-Activated Protein Kinase. Evid Based Complement Alternat Med 2018;2018:7420265. [PMID: 29552085 DOI: 10.1155/2018/7420265] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 3.4] [Reference Citation Analysis]
369 Palma-Duran SA, Kontogianni MD, Vlassopoulos A, Zhao S, Margariti A, Georgoulis M, Papatheodoridis G, Combet E. Serum levels of advanced glycation end-products (AGEs) and the decoy soluble receptor for AGEs (sRAGE) can identify non-alcoholic fatty liver disease in age-, sex- and BMI-matched normo-glycemic adults. Metabolism. 2018;83:120-127. [PMID: 29409822 DOI: 10.1016/j.metabol.2018.01.023] [Cited by in Crossref: 41] [Cited by in F6Publishing: 42] [Article Influence: 8.2] [Reference Citation Analysis]
370 Petrova M. Vitamin D and Related Deficiencies, Sarcopenia and Visceral Obesity in Obese People with NAFLD. GHOA 2018;9. [DOI: 10.15406/ghoa.2018.09.00284] [Reference Citation Analysis]
371 Chandrashekar C, Patil A, Hasabi IS, Ganteppanavar CK, Baligar BD. A STUDY OF SPECTRUM OF LIVER DYSFUNCTION IN TYPE 2 DIABETES MELLITUS. jebmh 2018;5:1-3. [DOI: 10.18410/jebmh/2018/1] [Reference Citation Analysis]
372 K.n. L, Channarayappa, Venkataranganna M, Gowtham Raj G, Patil H, Dave H. Augmentation of antioxidant and iron(III) chelation properties of tertiary mixture of bioactive ligands. Journal of Trace Elements in Medicine and Biology 2018;45:114-24. [DOI: 10.1016/j.jtemb.2017.10.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
373 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver 2018. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
374 Fernández-quintela A, González M, Aguirre L, Milton-laskibar I, Léniz A, Portillo MP. Resveratrol and Protection in Hepatic Steatosis: Antioxidant Effects. The Liver 2018. [DOI: 10.1016/b978-0-12-803951-9.00017-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
375 Ota T. Diabetes and Liver Disorders. Diabetes and Aging-related Complications 2018. [DOI: 10.1007/978-981-10-4376-5_7] [Reference Citation Analysis]
376 Mulaikal TA, Emond JC. Physiology and Anatomy of the Liver. Liver Anesthesiology and Critical Care Medicine 2018. [DOI: 10.1007/978-3-319-64298-7_1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
377 Jorge ASB, Andrade JMO, Paraíso AF, Jorge GCB, Silveira CM, de Souza LR, Santos EP, Guimaraes ALS, Santos SHS, De-paula AMB. Body mass index and the visceral adipose tissue expression of IL-6 and TNF-alpha are associated with the morphological severity of non-alcoholic fatty liver disease in individuals with class III obesity. Obesity Research & Clinical Practice 2018;12:1-8. [DOI: 10.1016/j.orcp.2016.03.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 34] [Article Influence: 5.8] [Reference Citation Analysis]
378 Ediriweera MK, Tennekoon KH, Samarakoon SR. A Review on Ethnopharmacological Applications, Pharmacological Activities, and Bioactive Compounds of Mangifera indica (Mango). Evid Based Complement Alternat Med 2017;2017:6949835. [PMID: 29456572 DOI: 10.1155/2017/6949835] [Cited by in Crossref: 66] [Cited by in F6Publishing: 72] [Article Influence: 11.0] [Reference Citation Analysis]
379 Nasr P, Ignatova S, Kechagias S, Ekstedt M. Natural history of nonalcoholic fatty liver disease: A prospective follow-up study with serial biopsies. Hepatol Commun. 2018;2:199-210. [PMID: 29404527 DOI: 10.1002/hep4.1134] [Cited by in Crossref: 70] [Cited by in F6Publishing: 74] [Article Influence: 11.7] [Reference Citation Analysis]
380 Bagherniya M, Nobili V, Blesso CN, Sahebkar A. Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: A clinical review. Pharmacol Res 2018;130:213-40. [PMID: 29287685 DOI: 10.1016/j.phrs.2017.12.020] [Cited by in Crossref: 128] [Cited by in F6Publishing: 95] [Article Influence: 21.3] [Reference Citation Analysis]
381 Wu L, Zhu X, Fan L, Kabagambe EK, Song Y, Tao M, Zhong X, Hou L, Shrubsole MJ, Liu J, Dai Q. Magnesium intake and mortality due to liver diseases: Results from the Third National Health and Nutrition Examination Survey Cohort. Sci Rep 2017;7:17913. [PMID: 29263344 DOI: 10.1038/s41598-017-18076-5] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
382 Alves-Bezerra M, Cohen DE. Triglyceride Metabolism in the Liver. Compr Physiol 2017;8:1-8. [PMID: 29357123 DOI: 10.1002/cphy.c170012] [Cited by in Crossref: 138] [Cited by in F6Publishing: 214] [Article Influence: 23.0] [Reference Citation Analysis]
383 Zhang J, Liu Z, Zhang X, Zhang L, Jin X. Association between urine retinol-binding protein levels and nonalcoholic fatty liver disease: A cross-sectional study in Chinese population. J Clin Lab Anal 2018;32:e22359. [PMID: 29194759 DOI: 10.1002/jcla.22359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
384 Asfari MM, Niyazi F, Lopez R, Dasarathy S, McCullough AJ. The association of nonalcoholic steatohepatitis and obstructive sleep apnea. Eur J Gastroenterol Hepatol 2017;29:1380-4. [PMID: 28914694 DOI: 10.1097/MEG.0000000000000973] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
385 Radaelli MG, Martucci F, Perra S, Accornero S, Castoldi G, Lattuada G, Manzoni G, Perseghin G. NAFLD/NASH in patients with type 2 diabetes and related treatment options. J Endocrinol Invest 2018;41:509-21. [DOI: 10.1007/s40618-017-0799-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]
386 Watanabe S, Kumazaki S, Kusunoki K, Inoue T, Maeda Y, Usui S, Shinohata R, Ohtsuki T, Hirohata S, Kusachi S, Kitamori K, Mori M, Yamori Y, Oka H. A High-Fat and High-Cholesterol Diet Induces Cardiac Fibrosis, Vascular Endothelial, and Left Ventricular Diastolic Dysfunction in SHRSP5/Dmcr Rats. J Atheroscler Thromb 2018;25:439-53. [PMID: 29162773 DOI: 10.5551/jat.40956] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
387 Sasaki H, Hirai K, Martins CM, Furusho H, Battaglino R, Hashimoto K. Interrelationship Between Periapical Lesion and Systemic Metabolic Disorders. Curr Pharm Des 2016;22:2204-15. [PMID: 26881444 DOI: 10.2174/1381612822666160216145107] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 7.8] [Reference Citation Analysis]
388 Fakhoury-Sayegh N, Younes H, Heraoui GNHA, Sayegh R. Nutritional Profile and Dietary Patterns of Lebanese Non-Alcoholic Fatty Liver Disease Patients: A Case-Control Study. Nutrients 2017;9:E1245. [PMID: 29135945 DOI: 10.3390/nu9111245] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
389 Xu JL, Li LY, Wang YQ, Li YQ, Shan M, Sun SZ, Yu Y, Wang B. Hepatocyte-specific deletion of BAP31 promotes SREBP1C activation, promotes hepatic lipid accumulation, and worsens IR in mice. J Lipid Res 2018;59:35-47. [PMID: 29113994 DOI: 10.1194/jlr.M077016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
390 Hua X, Li M, Pan F, Xiao Y, Cui W, Hu Y. Non-alcoholic fatty liver disease is an influencing factor for the association of SHBG with metabolic syndrome in diabetes patients. Sci Rep. 2017;7:14532. [PMID: 29109457 DOI: 10.1038/s41598-017-15232-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
391 Xiong J, Zhang H, Wang Y, Wang A, Bian J, Huang H, Zheng Y, Sang X, Xu Y, Lu X, Zhao H. Hepatitis B virus infection and the risk of nonalcoholic fatty liver disease: a meta-analysis. Oncotarget 2017;8:107295-302. [PMID: 29291029 DOI: 10.18632/oncotarget.22364] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
392 Kim S, Chang Y, Sung E, Kim CH, Yun KE, Jung HS, Shin H, Ryu S. Non-alcoholic fatty liver disease and the development of nephrolithiasis: A cohort study. PLoS One 2017;12:e0184506. [PMID: 29073130 DOI: 10.1371/journal.pone.0184506] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
393 Argo CK, Henry ZH, Caldwell SH. Nonalcoholic Fatty Liver Disease. Schiff's Diseases of the Liver 2017. [DOI: 10.1002/9781119251316.ch32] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
394 Yadav D, Lee MY, Kim JY, Ryu H, Huh JH, Bae KS, Ahn SV, Chung CH, Park JT, Koh SB. Combined Effect of Initial and Longitudinal Increases in γ-Glutamyltransferase on Incident Metabolic Syndrome: ARIRANG Study. Yonsei Med J 2017;58:763-9. [PMID: 28540989 DOI: 10.3349/ymj.2017.58.4.763] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
395 Gouda W, Ashour E, Shaker Y, Ezzat W. MTP genetic variants associated with non-alcoholic fatty liver in metabolic syndrome patients. Genes Dis 2017;4:222-8. [PMID: 30258926 DOI: 10.1016/j.gendis.2017.09.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
396 Yu XL, Shu L, Shen XM, Zhang XY, Zheng PF. Gender difference on the relationship between hyperuricemia and nonalcoholic fatty liver disease among Chinese: An observational study. Medicine (Baltimore) 2017;96:e8164. [PMID: 28953666 DOI: 10.1097/MD.0000000000008164] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
397 Papandreou D, Karavetian M, Karabouta Z, Andreou E. Obese Children with Metabolic Syndrome Have 3 Times Higher Risk to Have Nonalcoholic Fatty Liver Disease Compared with Those without Metabolic Syndrome. Int J Endocrinol 2017;2017:2671692. [PMID: 29118811 DOI: 10.1155/2017/2671692] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
398 Pasarín M, Abraldes JG, Liguori E, Kok B, La Mura V. Intrahepatic vascular changes in non-alcoholic fatty liver disease: Potential role of insulin-resistance and endothelial dysfunction. World J Gastroenterol 2017; 23(37): 6777-6787 [PMID: 29085222 DOI: 10.3748/wjg.v23.i37.6777] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
399 Dai W, Ye L, Liu A, Wen SW, Deng J, Wu X, Lai Z. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: A meta-analysis. Medicine (Baltimore). 2017;96:e8179. [PMID: 28953675 DOI: 10.1097/md.0000000000008179] [Cited by in Crossref: 144] [Cited by in F6Publishing: 153] [Article Influence: 24.0] [Reference Citation Analysis]
400 Saokaew S, Kanchanasuwan S, Apisarnthanarak P, Charoensak A, Charatcharoenwitthaya P, Phisalprapa P, Chaiyakunapruk N. Clinical risk scoring for predicting non-alcoholic fatty liver disease in metabolic syndrome patients (NAFLD-MS score). Liver Int 2017;37:1535-43. [PMID: 28294515 DOI: 10.1111/liv.13413] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
401 Sharma DL, Lakhani HV, Klug RL, Snoad B, El-Hamdani R, Shapiro JI, Sodhi K. Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis. J Clin Cell Immunol 2017;8:523. [PMID: 29177105 DOI: 10.4172/2155-9899.1000523] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
402 Li N, Chang G, Xu Y, Ding Y, Li G, Yu T, Yao R, Li J, Shen Y, Wang X, Wang J. Biallelic mutations in GPD1 gene in a Chinese boy mainly presented with obesity, insulin resistance, fatty liver, and short stature. Am J Med Genet 2017;173:3189-94. [DOI: 10.1002/ajmg.a.38473] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
403 Franzini M, Scataglini I, Ricchiuti A, Fierabracci V, Paolicchi A, Pompella A, Dell'Omo G, Pedrinelli R, Corti A. Association between plasma gamma-glutamyltransferase fractions and metabolic syndrome among hypertensive patients. Sci Rep 2017;7:12003. [PMID: 28931896 DOI: 10.1038/s41598-017-12356-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
404 Yuan Y, Naito H, Jia X, Kitamori K, Nakajima T. Combination of Hypertension Along with a High Fat and Cholesterol Diet Induces Severe Hepatic Inflammation in Rats via a Signaling Network Comprising NF-κB, MAPK, and Nrf2 Pathways. Nutrients 2017;9:E1018. [PMID: 28906458 DOI: 10.3390/nu9091018] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
405 Atanasovska B, Rensen SS, van der Sijde MR, Marsman G, Kumar V, Jonkers I, Withoff S, Shiri-Sverdlov R, Greve JWM, Faber KN, Moshage H, Wijmenga C, van de Sluis B, Hofker MH, Fu J. A liver-specific long noncoding RNA with a role in cell viability is elevated in human nonalcoholic steatohepatitis. Hepatology 2017;66:794-808. [PMID: 28073183 DOI: 10.1002/hep.29034] [Cited by in Crossref: 65] [Cited by in F6Publishing: 67] [Article Influence: 10.8] [Reference Citation Analysis]
406 Petta S, Eslam M, Valenti L, Bugianesi E, Barbara M, Cammà C, Porzio M, Rosso C, Fargion S, George J, Craxì A. Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study. Liver Int 2017;37:1389-96. [PMID: 28235154 DOI: 10.1111/liv.13397] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
407 Bae CR, Hino J, Hosoda H, Arai Y, Son C, Makino H, Tokudome T, Tomita T, Kimura T, Nojiri T, Hosoda K, Miyazato M, Kangawa K. Overexpression of C-type Natriuretic Peptide in Endothelial Cells Protects against Insulin Resistance and Inflammation during Diet-induced Obesity. Sci Rep 2017;7:9807. [PMID: 28852070 DOI: 10.1038/s41598-017-10240-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
408 Tang L, Wu Y, Tian M, Sjöström CD, Johansson U, Peng XR, Smith DM, Huang Y. Dapagliflozin slows the progression of the renal and liver fibrosis associated with type 2 diabetes. Am J Physiol Endocrinol Metab 2017;313:E563-76. [PMID: 28811292 DOI: 10.1152/ajpendo.00086.2017] [Cited by in Crossref: 78] [Cited by in F6Publishing: 80] [Article Influence: 13.0] [Reference Citation Analysis]
409 Manco M. Insulin Resistance and NAFLD: A Dangerous Liaison beyond the Genetics. Children (Basel) 2017;4:E74. [PMID: 28805745 DOI: 10.3390/children4080074] [Cited by in Crossref: 26] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
410 Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E. Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice. European Journal of Pharmacology 2017;809:163-71. [DOI: 10.1016/j.ejphar.2017.05.019] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
411 Shouhed D, Steggerda J, Burch M, Noureddin M. The role of bariatric surgery in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Expert Rev Gastroenterol Hepatol. 2017;11:797-811. [PMID: 28712339 DOI: 10.1080/17474124.2017.1355731] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
412 Moon J, Kim OY, Jo G, Shin MJ. Alterations in Circulating Amino Acid Metabolite Ratio Associated with Arginase Activity Are Potential Indicators of Metabolic Syndrome: The Korean Genome and Epidemiology Study. Nutrients 2017;9:E740. [PMID: 28704931 DOI: 10.3390/nu9070740] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
413 Kumar R, Mohan S. Non-alcoholic Fatty Liver Disease in Lean Subjects: Characteristics and Implications. J Clin Transl Hepatol. 2017;5:216-223. [PMID: 28936403 DOI: 10.14218/jcth.2016.00068] [Cited by in Crossref: 22] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
414 Moon CM, Yun KE, Ryu S, Chang Y, Park DI. High serum alanine aminotransferase is associated with the risk of colorectal adenoma in Korean men. J Gastroenterol Hepatol 2017;32:1310-7. [PMID: 28002874 DOI: 10.1111/jgh.13684] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
415 Wu L, He Y, Jiang B, Liu M, Yang S, Wang Y, Zeng J, Yao Y, Wang J. Gender difference in the association between aminotransferase levels and hypertension in a Chinese elderly population. Medicine (Baltimore) 2017;96:e6996. [PMID: 28538411 DOI: 10.1097/MD.0000000000006996] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
416 Isokuortti E, Zhou Y, Peltonen M, Bugianesi E, Clement K, Bonnefont-Rousselot D, Lacorte JM, Gastaldelli A, Schuppan D, Schattenberg JM, Hakkarainen A, Lundbom N, Jousilahti P, Männistö S, Keinänen-Kiukaanniemi S, Saltevo J, Anstee QM, Yki-Järvinen H. Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study. Diabetologia 2017;60:1873-82. [PMID: 28660493 DOI: 10.1007/s00125-017-4340-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 63] [Article Influence: 10.5] [Reference Citation Analysis]
417 Borai IH, Shaker Y, Kamal MM, Ezzat WM, Ashour E, Afify M, Gouda W, Elbrashy MM. Evaluation of Biomarkers in Egyptian Patients with Different Grades of Nonalcoholic Fatty Liver Disease. J Clin Transl Hepatol 2017;5:109-18. [PMID: 28660148 DOI: 10.14218/JCTH.2017.00004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
418 Trembling PM, Apostolidou S, Gentry-Maharaj A, Parkes J, Ryan A, Tanwar S, Burnell M, Jacobs I, Menon U, Rosenberg WM. Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMC Public Health 2017;17:603. [PMID: 28659136 DOI: 10.1186/s12889-017-4518-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
419 Afolabi BI, Ibitoye BO, Ikem RT, Omisore AD, Idowu BM, Soyoye DO. The Relationship Between Glycaemic Control and Non-Alcoholic Fatty Liver Disease in Nigerian Type 2 Diabetic Patients. J Natl Med Assoc. 2018;110:256-264. [PMID: 29778128 DOI: 10.1016/j.jnma.2017.06.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
420 A-Kader HH. Lysosomal acid lipase deficiency: a form of non-obese fatty liver disease (NOFLD). Expert Rev Gastroenterol Hepatol 2017;11:911-24. [PMID: 28612634 DOI: 10.1080/17474124.2017.1343144] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
421 Ouelaa W, Jegatheesan P, M’bouyou-boungou J, Vicente C, Nakib S, Nubret E, De Bandt J. Citrulline decreases hepatic endotoxin-induced injury in fructose-induced non-alcoholic liver disease: an ex vivo study in the isolated perfused rat liver. Br J Nutr 2017;117:1487-94. [DOI: 10.1017/s0007114517001453] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
422 Takeuchi M, Takino JI, Sakasai-Sakai A, Takata T, Tsutsumi M. Toxic AGE (TAGE) Theory for the Pathophysiology of the Onset/Progression of NAFLD and ALD. Nutrients 2017;9:E634. [PMID: 28632197 DOI: 10.3390/nu9060634] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
423 Abdel-Hamed AR, Ghattas MH, Mesbah NM, Saleh SM, Abo-Elmatty DM. Association of interleukin-1A insertion/deletion gene polymorphism and possible high risk factors with non-alcoholic fatty liver disease in Egyptian patients. Arch Physiol Biochem 2017;123:330-3. [PMID: 28627263 DOI: 10.1080/13813455.2017.1339717] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
424 Gill C, Vatcheva KP, Pan JJ, Smulevitz B, McPherson DD, Fallon M, McCormick JB, Fisher-Hoch SP, Laing ST. Frequency of Nonalcoholic Fatty Liver Disease and Subclinical Atherosclerosis Among Young Mexican Americans. Am J Cardiol 2017;119:1717-22. [PMID: 28395890 DOI: 10.1016/j.amjcard.2017.03.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
425 Kwak MS, Kim D, Chung GE, Kim W, Kim JS. The preventive effect of sustained physical activity on incident nonalcoholic fatty liver disease. Liver Int 2017;37:919-26. [PMID: 27917585 DOI: 10.1111/liv.13332] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
426 Li M, Chen D, Huang H, Wang J, Wan X, Xu C, Li C, Ma H, Yu C, Li Y. Caveolin1 protects against diet induced hepatic lipid accumulation in mice. PLoS One 2017;12:e0178748. [PMID: 28570612 DOI: 10.1371/journal.pone.0178748] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
427 Martin-Rodriguez JL, Gonzalez-Cantero J, Gonzalez-Cantero A, Arrebola JP, Gonzalez-Calvin JL. Diagnostic accuracy of serum alanine aminotransferase as biomarker for nonalcoholic fatty liver disease and insulin resistance in healthy subjects, using 3T MR spectroscopy. Medicine (Baltimore). 2017;96:e6770. [PMID: 28445310 DOI: 10.1097/md.0000000000006770] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.8] [Reference Citation Analysis]
428 Su H, Huang J, Shin J, Chao C, Ho S. Clinical characteristics of nonB nonC hepatocellular carcinoma compared to HBV- and HCV-related hepatocellular carcinoma. Advances in Digestive Medicine 2017;4:43-49. [DOI: 10.1002/aid2.12043] [Reference Citation Analysis]
429 Martínez BB, Pereira AC, Muzetti JH, Telles FP, Mundim FG, Teixeira MA. Experimental model of glucocorticoid-induced insulin resistance. Acta Cir Bras 2016;31:645-9. [PMID: 27828596 DOI: 10.1590/S0102-865020160100000001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
430 Sid V, Siow YL, O K. Role of folate in nonalcoholic fatty liver disease. Can J Physiol Pharmacol. 2017;95:1141-1148. [PMID: 28460180 DOI: 10.1139/cjpp-2016-0681] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 6.2] [Reference Citation Analysis]
431 Kim GW, Jo HK, Chung SH. Ginseng seed oil ameliorates hepatic lipid accumulation in vitro and in vivo. J Ginseng Res 2018;42:419-28. [PMID: 30344430 DOI: 10.1016/j.jgr.2017.04.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
432 Zhang S, Du T, Li M, Lu H, Lin X, Yu X. Combined effect of obesity and uric acid on nonalcoholic fatty liver disease and hypertriglyceridemia. Medicine (Baltimore) 2017;96:e6381. [PMID: 28328829 DOI: 10.1097/MD.0000000000006381] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
433 Li T, Feng R, Zhao C, Wang Y, Wang J, Liu S, Cao J, Wang H, Wang T, Guo Y, Lu Z. Dimethylarginine Dimethylaminohydrolase 1 Protects Against High-Fat Diet-Induced Hepatic Steatosis and Insulin Resistance in Mice. Antioxidants & Redox Signaling 2017;26:598-609. [DOI: 10.1089/ars.2016.6742] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 4.2] [Reference Citation Analysis]
434 Mokhtari Z, Poustchi H, Eslamparast T, Hekmatdoost A. Egg consumption and risk of non-alcoholic fatty liver disease. World J Hepatol 2017; 9(10): 503-509 [PMID: 28443155 DOI: 10.4254/wjh.v9.i10.503] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
435 Cheng F, Ma C, Wang X, Zhai C, Wang G, Xu X, Mu J, Li C, Wang Z, Zhang X, Yue W, Du X, Lian Y, Zhu W, Yin X, Wei Z, Song W, Wang Q. Effect of traditional Chinese medicine formula Sinisan on chronic restraint stress-induced nonalcoholic fatty liver disease: a rat study. BMC Complement Altern Med 2017;17:203. [PMID: 28388904 DOI: 10.1186/s12906-017-1707-2] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
436 Tokita Y, Maejima Y, Shimomura K, Takenoshita S, Ishiyama N, Akuzawa M, Shimomura Y, Nakajima K. Non-alcoholic Fatty Liver Disease Is a Risk Factor for Type 2 Diabetes in Middle-aged Japanese Men and Women. Intern Med 2017;56:763-71. [PMID: 28381741 DOI: 10.2169/internalmedicine.56.7115] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
437 Kim W, Kim BG, Lee JS, Lee CK, Yeon JE, Chang MS, Kim JH, Kim H, Yi S, Lee J, Cho JY, Kim SG, Lee JH, Kim YJ. Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha-inhibitory dithiolethione in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;45:1073-83. [PMID: 28225186 DOI: 10.1111/apt.13981] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 7.7] [Reference Citation Analysis]
438 Yoon CY, Lee M, Kim SU, Lim H, Chang TI, Kee YK, Han SG, Han IM, Kwon YE, Park KS, Lee MJ, Park JT, Han SH, Ahn SH, Kang SW, Yoo TH. Fatty liver associated with metabolic derangement in patients with chronic kidney disease: A controlled attenuation parameter study. Kidney Res Clin Pract 2017;36:48-57. [PMID: 28392997 DOI: 10.23876/j.krcp.2017.36.1.48] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
439 Chen X, Shen T, Li Q, Chen X, Li Y, Li D, Chen G, Ling W, Chen YM. Retinol Binding Protein-4 Levels and Non-alcoholic Fatty Liver Disease: A community-based cross-sectional study. Sci Rep 2017;7:45100. [PMID: 28332619 DOI: 10.1038/srep45100] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
440 Qin L, Zhang W, Yang Z, Niu Y, Li X, Lu S, Xing Y, Lin N, Zhang H, Ning G, Fan J, Su Q. Impaired lung function is associated with non-alcoholic fatty liver disease independently of metabolic syndrome features in middle-aged and elderly Chinese. BMC Endocr Disord 2017;17:18. [PMID: 28330472 DOI: 10.1186/s12902-017-0168-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
441 Kan YC, Chen KH, Lin HC. Developing a ubiquitous health management system with healthy diet control for metabolic syndrome healthcare in Taiwan. Comput Methods Programs Biomed 2017;144:37-48. [PMID: 28495005 DOI: 10.1016/j.cmpb.2017.02.027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
442 Kim SJ, Park SH, Sin HS, Jang SH, Lee SW, Kim SY, Kwon B, Yu KY, Kim SY, Yang DK. Hypocholesterolemic Effects of Probiotic Mixture on Diet-Induced Hypercholesterolemic Rats. Nutrients. 2017;9:pii: E293. [PMID: 28300786 DOI: 10.3390/nu9030293] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 7.7] [Reference Citation Analysis]
443 Miyaaki H, Nakao K. Significance of genetic polymorphisms in patients with nonalcoholic fatty liver disease. Clin J Gastroenterol. 2017;10:201-207. [PMID: 28290069 DOI: 10.1007/s12328-017-0732-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
444 Barros F, Setúbal S, Martinho JM, Ferraz L, Gaudêncio A. CORRELATION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND FEATURES OF METABOLIC SYNDROME IN MORBIDLY OBESE PATIENTS IN THE PREOPERATIVE ASSESSMENT FOR BARIATRIC SURGERY. Arq Bras Cir Dig 2016;29:260-3. [PMID: 28076482 DOI: 10.1590/0102-6720201600040011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
445 Zhang Y, Takemori H, Wang C, Fu J, Xu M, Xiong L, Li N, Wen X. Role of salt inducible kinase 1 in high glucose-induced lipid accumulation in HepG2 cells and metformin intervention. Life Sciences 2017;173:107-15. [DOI: 10.1016/j.lfs.2017.02.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
446 Unger LW, Herac M, Staufer K, Salat A, Silberhumer G, Hofmann M, Trauner M, Rasoul-Rockenschaub S, Soliman T, Reiberger T, Berlakovich GA. The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study. Eur J Gastroenterol Hepatol 2017;29:309-16. [PMID: 27922486 DOI: 10.1097/MEG.0000000000000794] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
447 Khodadoostan M, Zamanidoost M, Shavakhi A, Sanei H, Shahbazi M, Ahmadian M. Effects of Phlebotomy on Liver Enzymes and Histology of Patients with Nonalcoholic Fatty Liver Disease. Adv Biomed Res 2017;6:12. [PMID: 28299304 DOI: 10.4103/2277-9175.200787] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
448 Qian LY, Tu JF, Ding YH, Pang J, Che XD, Zou H, Huang DS. Association of blood pressure level with nonalcoholic fatty liver disease in nonhypertensive population: Normal is not the new normal. Medicine (Baltimore) 2016;95:e4293. [PMID: 27442673 DOI: 10.1097/MD.0000000000004293] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
449 Nam HY, Jun S, Pak K, Kim IJ. Concurrent Low Brain and High Liver Uptake on FDG PET Are Associated with Cardiovascular Risk Factors. Korean J Radiol 2017;18:392-401. [PMID: 28246520 DOI: 10.3348/kjr.2017.18.2.392] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
450 Delvecchio M, Muggeo P, Monteduro M, Lassandro G, Novielli C, Valente F, Salinaro E, Zito A, Ciccone MM, Miniello VL, Santoro N, Giordano P, Faienza MF. Non-alcoholic fatty liver disease is associated with early left ventricular dysfunction in childhood acute lymphoblastic leukaemia survivors. European Journal of Endocrinology 2017;176:111-21. [DOI: 10.1530/eje-16-0608] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
451 Herta T, Fischer J, Berg T. Genetik metabolischer und viraler Lebererkrankungen. Gastroenterologe 2017;12:16-31. [DOI: 10.1007/s11377-016-0128-y] [Reference Citation Analysis]
452 Erukainure OL, Hafizur RM, Choudhary MI, Adhikari A, Mesaik AM, Atolani O, Banerjee P, Preissner R, Muhammad A, Islam MS. Anti-diabetic effect of the ethyl acetate fraction of Clerodendrum volubile: protocatechuic acid suppresses phagocytic oxidative burst and modulates inflammatory cytokines. Biomedicine & Pharmacotherapy 2017;86:307-15. [DOI: 10.1016/j.biopha.2016.12.035] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
453 Mahmoudi T, Nobakht H, Dabiri R, Maleki I, Dehghan P, Mansour-ghanaei F, Derakhshan F, Zali MR. Association between insulin receptor gene exon 17 rs1799817 variant and risk of nonalcoholic fatty liver disease. Meta Gene 2017;11:205-208. [DOI: 10.1016/j.mgene.2016.10.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
454 Park CC, Nguyen P, Hernandez C, Bettencourt R, Ramirez K, Fortney L, Hooker J, Sy E, Savides MT, Alquiraish MH, Valasek MA, Rizo E, Richards L, Brenner D, Sirlin CB, Loomba R. Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease. Gastroenterology 2017;152:598-607.e2. [PMID: 27911262 DOI: 10.1053/j.gastro.2016.10.026] [Cited by in Crossref: 363] [Cited by in F6Publishing: 384] [Article Influence: 60.5] [Reference Citation Analysis]
455 Jeong HS, Kim KH, Lee IS, Park JY, Kim Y, Kim KS, Jang HJ. Ginkgolide A ameliorates non-alcoholic fatty liver diseases on high fat diet mice. Biomed Pharmacother. 2017;88:625-634. [PMID: 28142119 DOI: 10.1016/j.biopha.2017.01.114] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
456 Moon YA. The SCAP/SREBP Pathway: A Mediator of Hepatic Steatosis. Endocrinol Metab (Seoul) 2017;32:6-10. [PMID: 28116873 DOI: 10.3803/EnM.2017.32.1.6] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 9.8] [Reference Citation Analysis]
457 Neuman MG, French SW, Zakhari S, Malnick S, Seitz HK, Cohen LB, Salaspuro M, Voinea-Griffin A, Barasch A, Kirpich IA, Thomes PG, Schrum LW, Donohue TM Jr, Kharbanda KK, Cruz M, Opris M. Alcohol, microbiome, life style influence alcohol and non-alcoholic organ damage. Exp Mol Pathol 2017;102:162-80. [PMID: 28077318 DOI: 10.1016/j.yexmp.2017.01.003] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.7] [Reference Citation Analysis]
458 Dong Y, Lv Q, Li S, Wu Y, Li L, Li J, Zhang F, Sun X, Tong N. Efficacy and safety of glucagon-like peptide-1 receptor agonists in non-alcoholic fatty liver disease: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol. 2017;41:284-295. [PMID: 28065744 DOI: 10.1016/j.clinre.2016.11.009] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 8.0] [Reference Citation Analysis]
459 Feldman A, Eder SK, Felder TK, Kedenko L, Paulweber B, Stadlmayr A, Huber-Schönauer U, Niederseer D, Stickel F, Auer S, Haschke-Becher E, Patsch W, Datz C, Aigner E. Clinical and Metabolic Characterization of Lean Caucasian Subjects With Non-alcoholic Fatty Liver. Am J Gastroenterol 2017;112:102-10. [PMID: 27527746 DOI: 10.1038/ajg.2016.318] [Cited by in Crossref: 142] [Cited by in F6Publishing: 141] [Article Influence: 23.7] [Reference Citation Analysis]
460 Takino J, Nagamine K, Suzuki M, Sakasai-sakai A, Takeuchi M, Hori T. Gene Expression Changes Associated with the Loss of Heterogeneous Nuclear Ribonucleoprotein M Function. AJMB 2017;07:87-98. [DOI: 10.4236/ajmb.2017.72007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
461 Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol 2017;14:32-42. [PMID: 27729660 DOI: 10.1038/nrgastro.2016.147] [Cited by in Crossref: 505] [Cited by in F6Publishing: 483] [Article Influence: 84.2] [Reference Citation Analysis]
462 Hirten R, Bodenheimer HC, Meyer DF, Bernstein D. Diabetes and Liver Disease. Principles of Diabetes Mellitus 2017. [DOI: 10.1007/978-3-319-20797-1_35-2] [Reference Citation Analysis]
463 Hirten R, Bodenheimer HC, Bernstein D. Diabetes and Liver Disease. Principles of Diabetes Mellitus 2017. [DOI: 10.1007/978-3-319-18741-9_35] [Reference Citation Analysis]
464 Manoria P, Inamdar S, Kumar R. Hepatobiliary dysfunction in Type-2 diabetes mellitus. J Family Med Prim Care 2017;6:563-7. [PMID: 29417009 DOI: 10.4103/2249-4863.222018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
465 Gawrieh S. Nonalcoholic Fatty Liver Disease. Liver Disorders 2017. [DOI: 10.1007/978-3-319-30103-7_14] [Reference Citation Analysis]
466 Derosa G, Maffioli P. Traditional Markers in Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2017. [DOI: 10.1007/978-94-007-7675-3_13] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
467 Ahn JS, Sinn DH, Min YW, Hong SN, Kim HS, Jung SH, Gu S, Rhee PL, Paik SW, Son HJ, Gwak GY. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment Pharmacol Ther 2017;45:345-53. [PMID: 27859470 DOI: 10.1111/apt.13866] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
468 Derosa G, Maffioli P. Histological Biomarkers of Nonalcoholic Fatty Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2017. [DOI: 10.1007/978-94-007-7675-3_23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
469 Brunt EM, Carpenter DH. Cirrhosis and portal hypertension. Blumgart's Surgery of the Liver, Biliary Tract and Pancreas, 2-Volume Set 2017. [DOI: 10.1016/b978-0-323-34062-5.00076-5] [Reference Citation Analysis]
470 Chung GE, Yim JY, Kim D, Kwak MS, Yang JI, Chung SJ, Yang SY, Kim JS. Associations between hemoglobin concentrations and the development of incidental metabolic syndrome or nonalcoholic fatty liver disease. Dig Liver Dis 2017;49:57-62. [PMID: 27810399 DOI: 10.1016/j.dld.2016.10.004] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
471 Yin Y, Gao L, Lin H, Wu Y, Han X, Zhu Y, Li J. Luteolin improves non-alcoholic fatty liver disease in db/db mice by inhibition of liver X receptor activation to down-regulate expression of sterol regulatory element binding protein 1c. Biochemical and Biophysical Research Communications 2017;482:720-6. [DOI: 10.1016/j.bbrc.2016.11.101] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 5.7] [Reference Citation Analysis]
472 Cázarez-garcía D, Ramírez Loustalot-laclette M, Ann Markow T, Winkler R. Lipidomic profiles of Drosophila melanogaster and cactophilic fly species: models of human metabolic diseases. Integr Biol 2017;9:885-91. [DOI: 10.1039/c7ib00155j] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
473 El-din M Omar H. Review of Pathophysiological Aspects and Risk Factors for Liver Dysfunction. Arch Clin Gastroenterol 2016. [DOI: 10.17352/2455-2283.000025] [Reference Citation Analysis]
474 Roden M, Petersen K, Shulman G. Insulin Resistance in Type 2 Diabetes. Textbook of Diabetes 2016. [DOI: 10.1002/9781118924853.ch13] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
475 Alawad AS, Levy C. FXR Agonists: From Bench to Bedside, a Guide for Clinicians. Dig Dis Sci 2016;61:3395-404. [PMID: 27734248 DOI: 10.1007/s10620-016-4334-8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
476 Messiah SE, Vidot DC, Baeker Bispo J, Arheart KL, Khorgami Z, De La Cruz-muñoz N. Ethnic and Gender Differences in the Prevalence of Nonalcoholic Steatohepatitis Among Bariatric Surgery Patients. Bariatric Surgical Practice and Patient Care 2016;11:153-7. [DOI: 10.1089/bari.2016.0018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
477 Díaz-Rúa R, Palou A, Oliver P. Cpt1a gene expression in peripheral blood mononuclear cells as an early biomarker of diet-related metabolic alterations. Food Nutr Res 2016;60:33554. [PMID: 27885970 DOI: 10.3402/fnr.v60.33554] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
478 Katsagoni CN, Georgoulis M, Papatheodoridis GV, Fragopoulou E, Ioannidou P, Papageorgiou M, Alexopoulou A, Papadopoulos N, Deutsch M, Kontogianni MD. Associations Between Lifestyle Characteristics and the Presence of Nonalcoholic Fatty Liver Disease: A Case-Control Study. Metab Syndr Relat Disord 2017;15:72-9. [PMID: 27869531 DOI: 10.1089/met.2016.0105] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
479 Paniagua JA. Nutrition, insulin resistance and dysfunctional adipose tissue determine the different components of metabolic syndrome. World J Diabetes 2016; 7(19): 483-514 [PMID: 27895819 DOI: 10.4239/wjd.v7.i19.483] [Cited by in CrossRef: 83] [Cited by in F6Publishing: 87] [Article Influence: 11.9] [Reference Citation Analysis]
480 Kanwar P, Nelson JE, Yates K, Kleiner DE, Unalp-Arida A, Kowdley KV. Association between metabolic syndrome and liver histology among NAFLD patients without diabetes. BMJ Open Gastroenterol 2016;3:e000114. [PMID: 27933201 DOI: 10.1136/bmjgast-2016-000114] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
481 Katsagoni CN, Papatheodoridis GV, Papageorgiou MV, Ioannidou P, Deutsch M, Alexopoulou A, Papadopoulos N, Fragopoulou E, Kontogianni MD. A "healthy diet-optimal sleep" lifestyle pattern is inversely associated with liver stiffness and insulin resistance in patients with nonalcoholic fatty liver disease. Appl Physiol Nutr Metab 2017;42:250-6. [PMID: 28133993 DOI: 10.1139/apnm-2016-0492] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
482 Lin TY, Chen YJ, Chen WL, Peng TC. The Relationship between Nonalcoholic Fatty Liver Disease and Retinopathy in NHANES III. PLoS One. 2016;11:e0165970. [PMID: 27802330 DOI: 10.1371/journal.pone.0165970] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
483 Hagström H, Nasr P, Bottai M, Ekstedt M, Kechagias S, Hultcrantz R, Stål P. Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up. Liver Int 2016;36:1688-95. [PMID: 27064133 DOI: 10.1111/liv.13144] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 5.1] [Reference Citation Analysis]
484 Ohki T, Isogawa A, Toda N, Tagawa K. Effectiveness of Ipragliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor, as a Second-line Treatment for Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Who Do Not Respond to Incretin-Based Therapies Including Glucagon-like Peptide-1 Analogs and Dipeptidyl Peptidase-4 Inhibitors. Clin Drug Investig. 2016;36:313-319. [PMID: 26914659 DOI: 10.1007/s40261-016-0383-1] [Cited by in Crossref: 55] [Cited by in F6Publishing: 59] [Article Influence: 7.9] [Reference Citation Analysis]
485 Bekaert M, Ouwens DM, Hörbelt T, Van de Velde F, Fahlbusch P, Herzfeld de Wiza D, Van Nieuwenhove Y, Calders P, Praet M, Hoorens A, Geerts A, Verhelst X, Kaufman J, Lapauw B. Reduced expression of chemerin in visceral adipose tissue associates with hepatic steatosis in patients with obesity: Chemerin Expression in Patients with NAFLD. Obesity 2016;24:2544-52. [DOI: 10.1002/oby.21674] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
486 Chen G, Yu D, Nian X, Liu J, Koenig RJ, Xu B, Sheng L. LncRNA SRA promotes hepatic steatosis through repressing the expression of adipose triglyceride lipase (ATGL). Sci Rep 2016;6:35531. [PMID: 27759039 DOI: 10.1038/srep35531] [Cited by in Crossref: 62] [Cited by in F6Publishing: 69] [Article Influence: 8.9] [Reference Citation Analysis]
487 Angeles TS, Hudkins RL. Recent advances in targeting the fatty acid biosynthetic pathway using fatty acid synthase inhibitors. Expert Opin Drug Discov 2016;11:1187-99. [PMID: 27701891 DOI: 10.1080/17460441.2016.1245286] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 9.3] [Reference Citation Analysis]
488 Zhang L, Shen L, Xu D, Wang L, Guo Y, Liu Z, Liu Y, Liu L, Magdalou J, Chen L, Wang H. Increased susceptibility of prenatal food restricted offspring to high-fat diet-induced nonalcoholic fatty liver disease is intrauterine programmed. Reproductive Toxicology 2016;65:236-47. [DOI: 10.1016/j.reprotox.2016.08.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
489 Kang Y, Zhang X, Cai Y, Su J, Kong X. Gut microbiota and metabolic disease: from pathogenesis to new therapeutic strategies. Reviews in Medical Microbiology 2016;27:141-52. [DOI: 10.1097/mrm.0000000000000085] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
490 Li XD, Qiu BH, Su FC, Sun SX. Gender impacts on the correlations between nonalcoholic fatty liver disease and hypertension in a Chinese population aged 45-60 y. Clin Exp Hypertens 2016;38:639-43. [PMID: 27680771 DOI: 10.1080/10641963.2016.1182181] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
491 Tan HL, Mohamed R, Mohamed Z, Zain SM. Phosphatidylethanolamine N-methyltransferase gene rs7946 polymorphism plays a role in risk of nonalcoholic fatty liver disease: evidence from meta-analysis. Pharmacogenet Genomics. 2016;26:88-95. [PMID: 26636496 DOI: 10.1097/fpc.0000000000000193] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
492 Pelusi S, Petta S, Rosso C, Borroni V, Fracanzani AL, Dongiovanni P, Craxi A, Bugianesi E, Fargion S, Valenti L. Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression: An Observational Study in Patients with Nonalcoholic Fatty Liver Disease. PLoS One. 2016;11:e0163069. [PMID: 27649410 DOI: 10.1371/journal.pone.0163069] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
493 Brede S, Serfling G, Klement J, Schmid SM, Lehnert H. Clinical Scenario of the Metabolic Syndrome. Visc Med 2016;32:336-41. [PMID: 27921045 DOI: 10.1159/000449028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
494 Shen H, Peng JL, Tayarachakul S, Liangpunsakul S. Association between serum cotinine level and prevalence of non-alcoholic fatty liver disease: a cross-sectional study from the Third National Health and Nutrition Examination Survey. J Investig Med 2017;65:43-8. [PMID: 27634642 DOI: 10.1136/jim-2016-000213] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
495 Ahangarpour A, Ali-akbari FR, Mohaghegh SM, Asadinia E. Effects of Arctium lappa aqueous extract on lipid profile and hepatic enzyme levels of sucrose-induced metabolic syndrome in female rats. Braz J Pharm Sci 2016;52:425-31. [DOI: 10.1590/s1984-82502016000300008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
496 Matsubara F, Nagai Y, Tsukiyama H, Shimizu H, Yamanouchi E, Iwamoto T, Sada Y, Kato H, Ohta A, Tanaka Y. Proposed cut-off value of the intrahepatic lipid content for metabolically normal persons assessed by proton magnetic resonance spectroscopy in a Japanese population. Diabetes Research and Clinical Practice 2016;119:75-82. [DOI: 10.1016/j.diabres.2016.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
497 Miguel NA, Andrade SF, Nai G, Laposy CB, Nascimento FF, Dinallo HR, Melchert A. EFFECTS OF RESVERATROL ON LIVER FUNCTION OF OBESE FEMALE WISTAR RATS. Ciênc anim bras 2016;17:402-10. [DOI: 10.1590/1089-6891v17i332990] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
498 Peng XE, Chen FL, Liu W, Hu Z, Lin X. Lack of association between SREBF-1c gene polymorphisms and risk of non-alcoholic fatty liver disease in a Chinese Han population. Sci Rep 2016;6:32110. [PMID: 27572914 DOI: 10.1038/srep32110] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
499 Sapmaz F, Uzman M, Basyigit S, Ozkan S, Yavuz B, Yeniova A, Kefeli A, Asilturk Z, Nazligül Y. Steatosis Grade is the Most Important Risk Factor for Development of Endothelial Dysfunction in NAFLD. Medicine (Baltimore). 2016;95:e3280. [PMID: 27057890 DOI: 10.1097/md.0000000000003280] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
500 Yadav D, Choi E, Ahn SV, Baik SK, Cho YZ, Koh SB, Huh JH, Chang Y, Sung KC, Kim JY. Incremental Predictive Value of Serum AST-to-ALT Ratio for Incident Metabolic Syndrome: The ARIRANG Study. PLoS One 2016;11:e0161304. [PMID: 27560931 DOI: 10.1371/journal.pone.0161304] [Cited by in Crossref: 17] [Cited by in F6Publishing: 23] [Article Influence: 2.4] [Reference Citation Analysis]
501 Chen S, Guo X, Yu S, Sun G, Yang H, Li Z, Sun Y. Association between Serum Uric Acid and Elevated Alanine Aminotransferase in the General Population. Int J Environ Res Public Health 2016;13:E841. [PMID: 27563918 DOI: 10.3390/ijerph13090841] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
502 Chen G, Ni Y, Nagata N, Xu L, Ota T. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17:1379. [PMID: 27563875 DOI: 10.3390/ijms17091379] [Cited by in Crossref: 33] [Cited by in F6Publishing: 40] [Article Influence: 4.7] [Reference Citation Analysis]
503 Min HK, Maruyama H, Jang BK, Shimada M, Mirshahi F, Ren S, Oh Y, Puri P, Sanyal AJ. Suppression of IGF binding protein-3 by palmitate promotes hepatic inflammatory responses. FASEB J 2016;30:4071-82. [PMID: 27553225 DOI: 10.1096/fj.201600427R] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
504 Mcavoy NC, Ferguson JW, Campbell IW, Hayes PC. Review: Non-alcoholic fatty liver disease: natural history, pathogenesis and treatment. Diabetes & Vascular Disease 2006;6:251-60. [DOI: 10.1177/14746514060060060201] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
505 Mulligan C, Kondakala S, Yang E, Stokes JV, Stewart JA, Kaplan BLF, Howell GE. Exposure to an environmentally relevant mixture of organochlorine compounds and polychlorinated biphenyls Promotes hepatic steatosis in male Ob/Ob mice: POPS-INDUCED HEPATIC STEATOSIS IN MALE OB/OB MICE. Environ Toxicol 2017;32:1399-411. [DOI: 10.1002/tox.22334] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
506 Ham H, Woo KS, Lee YY, Lee B, Kim I, Lee J. Unsaponifiable Matter from Rice Bran Attenuates High Glucose-Induced Lipid Accumulation by Activating AMPK in HepG2 Cells: HYPOLIPIDEMIC MECHANISM OF RICE BRAN. Journal of Food Biochemistry 2017;41:e12313. [DOI: 10.1111/jfbc.12313] [Reference Citation Analysis]
507 Sung KC, Chang Y, Ryu S, Chung HK. High levels of serum vitamin D are associated with a decreased risk of metabolic diseases in both men and women, but an increased risk for coronary artery calcification in Korean men. Cardiovasc Diabetol 2016;15:112. [PMID: 27519883 DOI: 10.1186/s12933-016-0432-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
508 Koronowicz AA, Banks P, Szymczyk B, Leszczyńska T, Master A, Piasna E, Szczepański W, Domagała D, Kopeć A, Piątkowska E, Laidler P. Dietary conjugated linoleic acid affects blood parameters, liver morphology and expression of selected hepatic genes in laying hens. Br Poult Sci 2016;57:663-73. [PMID: 27267260 DOI: 10.1080/00071668.2016.1192280] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
509 Flores-Toro JA, Go KL, Leeuwenburgh C, Kim JS. Autophagy in the liver: cell's cannibalism and beyond. Arch Pharm Res. 2016;39:1050-1061. [PMID: 27515049 DOI: 10.1007/s12272-016-0807-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
510 Tock L, Carneiro G, Togeiro SM, Hachul H, Pereira AZ, Tufik S, Zanella MT. Obstructive sleep apnea predisposes to nonalcoholic Fatty liver disease in patients with polycystic ovary syndrome. Endocr Pract. 2014;20:244-251. [PMID: 24246334 DOI: 10.4158/ep12366.or] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
511 Attia D, Bantel H, Lenzen H, Manns MP, Gebel MJ, Potthoff A. Liver stiffness measurement using acoustic radiation force impulse elastography in overweight and obese patients. Aliment Pharmacol Ther 2016;44:366-79. [PMID: 27363528 DOI: 10.1111/apt.13710] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
512 Bessissow T, Le NH, Rollet K, Afif W, Bitton A, Sebastiani G. Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:1937-44. [PMID: 27379445 DOI: 10.1097/MIB.0000000000000832] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 7.9] [Reference Citation Analysis]
513 Dongiovanni P, Valenti L. Genetics of nonalcoholic fatty liver disease. Metabolism 2016;65:1026-37. [DOI: 10.1016/j.metabol.2015.08.018] [Cited by in Crossref: 65] [Cited by in F6Publishing: 70] [Article Influence: 9.3] [Reference Citation Analysis]
514 Polyzos SA, Mantzoros CS. Nonalcoholic fatty future disease. Metabolism 2016;65:1007-16. [DOI: 10.1016/j.metabol.2015.12.009] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 6.7] [Reference Citation Analysis]
515 Chang B, Li B, Huang A, Sun Y, Teng G, Wang X, Liangpunsakul S, Li J, Zou Z. Changes of four common non-infectious liver diseases for the hospitalized patients in Beijing 302 hospital from 2002 to 2013. Alcohol 2016;54:61-5. [PMID: 27519542 DOI: 10.1016/j.alcohol.2016.07.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
516 Xue H, Chen D, Zhong Y, Zhou Z, Fang S, Li M, Guo C. Deferoxamine ameliorates hepatosteatosis via several mechanisms in ob/ob mice. Ann N Y Acad Sci 2016;1375:52-65. [DOI: 10.1111/nyas.13174] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
517 Windemuller F, Xu J, Rabinowitz SS, Hussain MM, Schwarz SM. Lipogenesis in Huh7 cells is promoted by increasing the fructose: Glucose molar ratio. World J Hepatol 2016; 8(20): 838-843 [PMID: 27458503 DOI: 10.4254/wjh.v8.i20.838] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
518 Betrapally NS, Gillevet PM, Bajaj JS. Gut microbiome and liver disease. Transl Res. 2017;179:49-59. [PMID: 27477080 DOI: 10.1016/j.trsl.2016.07.005] [Cited by in Crossref: 60] [Cited by in F6Publishing: 64] [Article Influence: 8.6] [Reference Citation Analysis]
519 Nam JS, Jo S, Kang S, Ahn CW, Kim KR, Park JS. Association between lipoprotein(a) and nonalcoholic fatty liver disease among Korean adults. Clin Chim Acta 2016;461:14-8. [PMID: 27394182 DOI: 10.1016/j.cca.2016.07.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
520 Larner DP, Morgan SA, Gathercole LL, Doig CL, Guest P, Weston C, Hazeldine J, Tomlinson JW, Stewart PM, Lavery GG. Male 11β-HSD1 Knockout Mice Fed Trans-Fats and Fructose Are Not Protected From Metabolic Syndrome or Nonalcoholic Fatty Liver Disease. Endocrinology 2016;157:3493-504. [PMID: 27384305 DOI: 10.1210/en.2016-1357] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
521 Song H, Lai J, Tang Q, Zheng X. Mulberry ethanol extract attenuates hepatic steatosis and insulin resistance in high-fat diet–fed mice. Nutrition Research 2016;36:710-8. [DOI: 10.1016/j.nutres.2016.01.011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
522 Lee K, Song J, Jeong B, Jeong J, Huh T, Park K. Anti-Lipogenic Effect of Functional Cereal Samples on High Sucrose Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. Journal of the Korean Society of Food Science and Nutrition 2016;45:789-796. [DOI: 10.3746/jkfn.2016.45.6.789] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
523 Baars T, Neumann U, Jinawy M, Hendricks S, Sowa JP, Kälsch J, Riemenschneider M, Gerken G, Erbel R, Heider D, Canbay A. In Acute Myocardial Infarction Liver Parameters Are Associated With Stenosis Diameter. Medicine (Baltimore) 2016;95:e2807. [PMID: 26871849 DOI: 10.1097/MD.0000000000002807] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
524 Morita S, Neto Dde S, Morita FH, Morita NK, Lobo SM. Prevalence of Non-alcoholic Fatty Liver Disease and Steatohepatitis Risk Factors in Patients Undergoing Bariatric Surgery. Obes Surg 2015;25:2335-43. [PMID: 25920616 DOI: 10.1007/s11695-015-1696-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
525 Ni Y, Zhuge F, Nagashimada M, Ota T. Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis. Nutrients. 2016;8:pii: E391. [PMID: 27347998 DOI: 10.3390/nu8070391] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 7.4] [Reference Citation Analysis]
526 Suzuki-Kemuriyama N, Matsuzaka T, Kuba M, Ohno H, Han SI, Takeuchi Y, Isaka M, Kobayashi K, Iwasaki H, Yatoh S, Suzuki H, Miyajima K, Nakae D, Yahagi N, Nakagawa Y, Sone H, Yamada N, Shimano H. Different Effects of Eicosapentaenoic and Docosahexaenoic Acids on Atherogenic High-Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice. PLoS One 2016;11:e0157580. [PMID: 27333187 DOI: 10.1371/journal.pone.0157580] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 6.1] [Reference Citation Analysis]
527 Schoeman JC, Hou J, Harms AC, Vreeken RJ, Berger R, Hankemeier T, Boonstra A. Metabolic characterization of the natural progression of chronic hepatitis B. Genome Med. 2016;8:64. [PMID: 27286979 DOI: 10.1186/s13073-016-0318-8] [Cited by in Crossref: 48] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
528 Sunbul M, Kivrak T, Durmus E, Akin H, Aydin Y, Ergelen R, Yilmaz Y, Agirbasli M. Nonalcoholic Steatohepatitis Score is an Independent Predictor of Right Ventricular Dysfunction in Patients with Nonalcoholic Fatty Liver Disease. Cardiovasc Ther 2015;33:294-9. [PMID: 26202098 DOI: 10.1111/1755-5922.12145] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
529 Fattahi MR, Niknam R, Safarpour A, Sepehrimanesh M, Lotfi M. The Prevalence of Metabolic Syndrome In Non-alcoholic Fatty Liver Disease; A Population-Based Study. Middle East J Dig Dis 2016;8:131-7. [PMID: 27252820 DOI: 10.15171/mejdd.2016.18] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.7] [Reference Citation Analysis]
530 Andrade GCD, Fujise LH, Santana Filho JED, Oliveira F, Silva RDCMAD. Non-alcoholic fatty liver disease (NAFLD) in different populations: A clinical and epidemiological study – sample of São José do Rio Preto. Rev Assoc Med Bras 2016;62:218-26. [DOI: 10.1590/1806-9282.62.03.218] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
531 Gong M, Cao C, Chen F, Li Q, Bi X, Sun Y, Zhan Z. Electroacupuncture Attenuates Hepatic Lipid Accumulation via Amp-Activated Protein Kinase (Ampk) Activation in Obese Rats. Acupunct Med 2016;34:209-14. [DOI: 10.1136/acupmed-2015-010798] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
532 Maithilikarpagaselvi N, Sridhar MG, Swaminathan RP, Sripradha R, Badhe B. Curcumin inhibits hyperlipidemia and hepatic fat accumulation in high-fructose-fed male Wistar rats. Pharm Biol 2016;54:2857-63. [PMID: 27241764 DOI: 10.1080/13880209.2016.1187179] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 6.6] [Reference Citation Analysis]
533 Filozof C, Goldstein BJ, Williams RN, Sanyal A. Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs 2015;75:1373-92. [PMID: 26201461 DOI: 10.1007/s40265-015-0437-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 47] [Article Influence: 7.1] [Reference Citation Analysis]
534 Voican CS, Martin S, Verstuyft C, Corruble E, Perlemuter G, Colle R. Liver Function Test Abnormalities in Depressed Patients Treated with Antidepressants: A Real-World Systematic Observational Study in Psychiatric Settings. PLoS One 2016;11:e0155234. [PMID: 27171561 DOI: 10.1371/journal.pone.0155234] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
535 Ayonrinde OT, Adams LA, Doherty DA, Mori TA, Beilin LJ, Oddy WH, Hickey M, Sloboda DM, Olynyk JK, Hart R. Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys. J Gastroenterol Hepatol 2016;31:980-7. [PMID: 26589977 DOI: 10.1111/jgh.13241] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
536 Beaton MD, Al-Judaibi B. Is vitamin e or ursodeoxycholic acid a valid treatment option for nonalcoholic fatty liver disease in 2016? Saudi J Gastroenterol 2016;22:169-70. [PMID: 27184632 DOI: 10.4103/1319-3767.182462] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
537 Kanwar P, Kowdley KV. The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. Clin Liver Dis 2016;20:225-43. [PMID: 27063266 DOI: 10.1016/j.cld.2015.10.002] [Cited by in Crossref: 68] [Cited by in F6Publishing: 66] [Article Influence: 9.7] [Reference Citation Analysis]
538 Uhanova J, Minuk G, Lopez Ficher F, Chandok N. Nonalcoholic Fatty Liver Disease in Canadian First Nations and Non-First Nations Patients. Can J Gastroenterol Hepatol 2016;2016:6420408. [PMID: 27446857 DOI: 10.1155/2016/6420408] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
539 Lazo M, Bilal U, Perez-Escamilla R. Epidemiology of NAFLD and Type 2 Diabetes: Health Disparities Among Persons of Hispanic Origin. Curr Diab Rep 2015;15:116. [PMID: 26468154 DOI: 10.1007/s11892-015-0674-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
540 Shih KL, Su WW, Chang CC, Kor CT, Chou CT, Chen TY, Wu HM. Comparisons of parallel potential biomarkers of 1H-MRS-measured hepatic lipid content in patients with non-alcoholic fatty liver disease. Sci Rep 2016;6:24031. [PMID: 27079922 DOI: 10.1038/srep24031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
541 Bozzetto L, Annuzzi G, Ragucci M, Di Donato O, Della Pepa G, Della Corte G, Griffo E, Anniballi G, Giacco A, Mancini M, Rivellese AA. Insulin resistance, postprandial GLP-1 and adaptive immunity are the main predictors of NAFLD in a homogeneous population at high cardiovascular risk. Nutr Metab Cardiovasc Dis 2016;26:623-9. [PMID: 27134062 DOI: 10.1016/j.numecd.2016.01.011] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
542 Yu JH, Kim JS, Lee MR, Yoon SY, Cho SY, Yoo SH, Kim BI. Risks of borderline liver enzyme abnormalities to the incidence of impaired fasting glucose and diabetes mellitus: a 7 year follow up study of workers. Ann Occup Environ Med 2016;28:18. [PMID: 27057316 DOI: 10.1186/s40557-016-0105-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
543 Yamamoto H, Kanno K, Ikuta T, Arihiro K, Sugiyama A, Kishikawa N, Tazuma S. Enhancing hepatic fibrosis in spontaneously hypertensive rats fed a choline-deficient diet: a follow-up report on long-term effects of oxidative stress in non-alcoholic fatty liver disease. J Hepatobiliary Pancreat Sci 2016;23:260-9. [DOI: 10.1002/jhbp.333] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
544 Junker AE, Gluud LL, van Hall G, Holst JJ, Knop FK, Vilsbøll T. Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease. J Hepatol 2016;64:908-15. [PMID: 26626496 DOI: 10.1016/j.jhep.2015.11.014] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
545 Howell Iii GE, Mulligan C, Young D, Kondakala S. Exposure to chlorpyrifos increases neutral lipid accumulation with accompanying increased de novo lipogenesis and decreased triglyceride secretion in McArdle-RH7777 hepatoma cells. Toxicology in Vitro 2016;32:181-9. [DOI: 10.1016/j.tiv.2016.01.002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
546 Lim H, Seo M, Lee H, Shim J, Kang H, Lee Y. Waist-to-Height Ratio as a Simple and Useful Indicator for Non-alcoholic Fatty Liver Disease in Korean Women. KJO 2016;25:19-23. [DOI: 10.7570/kjo.2016.25.1.19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
547 Forlani G, Giorda C, Manti R, Mazzella N, De Cosmo S, Rossi MC, Nicolucci A, Di Bartolo P, Ceriello A, Guida P; AMD-Annals Study Group. The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes. J Diabetes Res 2016;2016:2931985. [PMID: 27123461 DOI: 10.1155/2016/2931985] [Cited by in Crossref: 41] [Cited by in F6Publishing: 47] [Article Influence: 5.9] [Reference Citation Analysis]
548 Perticone M, Cimellaro A, Maio R, Caroleo B, Sciacqua A, Sesti G, Perticone F. Additive Effect of Non-Alcoholic Fatty Liver Disease on Metabolic Syndrome-Related Endothelial Dysfunction in Hypertensive Patients. Int J Mol Sci 2016;17:456. [PMID: 27023537 DOI: 10.3390/ijms17040456] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
549 Siow W, van der Poorten D, George J. Epidemiological Trends in NASH as a Cause for Liver Transplant. Curr Hepatology Rep 2016;15:67-74. [DOI: 10.1007/s11901-016-0294-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
550 Feng L, Luo H, Xu Z, Yang Z, Du G, Zhang Y, Yu L, Hu K, Zhu W, Tong Q, Chen K, Guo F, Huang C, Li Y. Bavachinin, as a novel natural pan-PPAR agonist, exhibits unique synergistic effects with synthetic PPAR-γ and PPAR-α agonists on carbohydrate and lipid metabolism in db/db and diet-induced obese mice. Diabetologia 2016;59:1276-86. [PMID: 26983922 DOI: 10.1007/s00125-016-3912-9] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
551 Matsuda M, Kawamoto T, Tamura R. Predictive value of serum dihomo-γ-linolenic acid level and estimated Δ-5 desaturase activity in patients with hepatic steatosis. Obes Res Clin Pract 2017;11:34-43. [PMID: 26964726 DOI: 10.1016/j.orcp.2016.02.004] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
552 Dongiovanni P, Lanti C, Riso P, Valenti L. Nutritional therapy for nonalcoholic fatty liver disease. The Journal of Nutritional Biochemistry 2016;29:1-11. [DOI: 10.1016/j.jnutbio.2015.08.024] [Cited by in Crossref: 75] [Cited by in F6Publishing: 80] [Article Influence: 10.7] [Reference Citation Analysis]
553 Kan H, Hyogo H, Ochi H, Hotta K, Fukuhara T, Kobayashi T, Naeshiro N, Honda Y, Kawaoka T, Tsuge M, Hiramatsu A, Imamura M, Kawakami Y, Aikata H, Chayama K. Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res 2016;46:E146-53. [PMID: 26147768 DOI: 10.1111/hepr.12552] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
554 Donati B, Motta BM, Pingitore P, Meroni M, Pietrelli A, Alisi A, Petta S, Xing C, Dongiovanni P, del Menico B, Rametta R, Mancina RM, Badiali S, Fracanzani AL, Craxì A, Fargion S, Nobili V, Romeo S, Valenti L. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage. Hepatology 2016;63:787-98. [PMID: 26605757 DOI: 10.1002/hep.28370] [Cited by in Crossref: 77] [Cited by in F6Publishing: 76] [Article Influence: 11.0] [Reference Citation Analysis]
555 Hossain N, Kanwar P, Mohanty SR. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract 2016;2016:7109270. [PMID: 27006654 DOI: 10.1155/2016/7109270] [Cited by in Crossref: 37] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
556 Yadav C, Dhruw S, Shekhawatia P, Gupta A. SONOGRAPHICALLY DIAGNOSED NON-ALCOHOLIC FATTY LIVER AS A PREDICTOR OF METABOLIC SYNDROME. jemds 2016;5. [DOI: 10.14260/jemds/2016/166] [Reference Citation Analysis]
557 Lim S. Is there a mechanistic link between hepatic steatosis and cardiac rather than liver events? Clinical Dilemmas in Non-Alcoholic Fatty Liver Disease 2016. [DOI: 10.1002/9781118924938.ch12] [Reference Citation Analysis]
558 Sogabe M, Okahisa T, Nakagawa T, Fukuno H, Nakasono M, Tomonari T, Tanaka T, Tanaka H, Taniguchi T, Muguruma N, Takayama T. Influence of light alcohol consumption on lifestyle-related diseases: a predictor of fatty liver with liver enzyme elevation in Japanese females with metabolic syndrome. BMC Gastroenterol 2016;16:17. [PMID: 26892109 DOI: 10.1186/s12876-016-0431-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
559 Chen S, Guo X, Yu S, Zhou Y, Li Z, Sun Y. Metabolic Syndrome and Serum Liver Enzymes in the General Chinese Population. Int J Environ Res Public Health 2016;13:223. [PMID: 26901209 DOI: 10.3390/ijerph13020223] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
560 Sodhi K, Bracero L, Feyh A, Nichols A, Srikanthan K, Latif T, Preston D, Shapiro JI, Elitsur Y. Role of Serum Biomarkers in Early Detection of Non-Alcoholic Steatohepatitis and Fibrosis in West Virginian Children. J Clin Cell Immunol 2016;7:393. [PMID: 27182456 DOI: 10.4172/2155-9899.1000393] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
561 Perera N, Indrakumar J, Abeysinghe WV, Fernando V, Samaraweera WM, Lawrence JS. Non alcoholic fatty liver disease increases the mortality from acute coronary syndrome: an observational study from Sri Lanka. BMC Cardiovasc Disord. 2016;16:37. [PMID: 26869052 DOI: 10.1186/s12872-016-0212-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
562 Qureshi K, Abrams GA. Prevalence of biopsy-proven non-alcoholic fatty liver disease in severely obese subjects without metabolic syndrome. Clin Obes 2016;6:117-23. [PMID: 26856683 DOI: 10.1111/cob.12132] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
563 Lu ZY, Cen C, Shao Z, Chen XH, Xu CF, Li YM. Association between serum α-L-fucosidase and non-alcoholic fatty liver disease: Cross-sectional study. World J Gastroenterol 2016; 22(5): 1884-1890 [PMID: 26855548 DOI: 10.3748/wjg.v22.i5.1884] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
564 Kavey RW. Management of Moderate Hypertriglyceridemia in Childhood and Adolescence. Curr Cardiovasc Risk Rep 2016;10. [DOI: 10.1007/s12170-016-0484-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
565 Xian L, Hou S, Huang Z, Tang A, Shi P, Wang Q, Song A, Jiang S, Lin Z, Guo S, Gao X. Liver-specific deletion of Ppp2cα enhances glucose metabolism and insulin sensitivity. Aging (Albany NY) 2015;7:223-32. [PMID: 25888638 DOI: 10.18632/aging.100725] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
566 Armstrong MJ, Hull D, Guo K, Barton D, Hazlehurst JM, Gathercole LL, Nasiri M, Yu J, Gough SC, Newsome PN, Tomlinson JW. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J Hepatol 2016;64:399-408. [PMID: 26394161 DOI: 10.1016/j.jhep.2015.08.038] [Cited by in Crossref: 230] [Cited by in F6Publishing: 230] [Article Influence: 32.9] [Reference Citation Analysis]
567 Wong VW, Wong GL. A LEAN treatment for non-alcoholic steatohepatitis. The Lancet 2016;387:628-30. [DOI: 10.1016/s0140-6736(15)00982-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
568 Jegatheesan P, Beutheu S, Ventura G, Sarfati G, Nubret E, Kapel N, Waligora-dupriet A, Bergheim I, Cynober L, De-bandt J. Effect of specific amino acids on hepatic lipid metabolism in fructose-induced non-alcoholic fatty liver disease. Clinical Nutrition 2016;35:175-82. [DOI: 10.1016/j.clnu.2015.01.021] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 8.3] [Reference Citation Analysis]
569 Azarkar G, Zeinali T, Sharifzadeh G, Abedi F, Hajihosseini M, Ziaee M. Prevalence of Non-Alcoholic Fatty Liver and its Related Factors in Birjand, During Year 2015. Mod Care J 2016;13. [DOI: 10.5812/modernc.58829] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
570 Robberecht H, Hermans N. Biomarkers of Metabolic Syndrome: Biochemical Background and Clinical Significance. Metab Syndr Relat Disord 2016;14:47-93. [PMID: 26808223 DOI: 10.1089/met.2015.0113] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
571 Celebi G, Genc H, Gurel H, Sertoglu E, Kara M, Tapan S, Acikel C, Karslioglu Y, Ercin CN, Dogru T. The relationship of circulating fetuin-a with liver histology and biomarkers of systemic inflammation in nondiabetic subjects with nonalcoholic fatty liver disease. Saudi J Gastroenterol 2015;21:139-45. [PMID: 26021772 DOI: 10.4103/1319-3767.157556] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
572 Shen H, Rodriguez AC, Shiani A, Lipka S, Shahzad G, Kumar A, Mustacchia P. Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis. Therap Adv Gastroenterol 2016;9:113-20. [PMID: 26770272 DOI: 10.1177/1756283X15593700] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 8.0] [Reference Citation Analysis]
573 Esposito E, Campolo M, Cordaro M, Casili G, Cuzzocrea S. Autophagy and Liver Diseases. Autophagy Networks in Inflammation 2016. [DOI: 10.1007/978-3-319-30079-5_17] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
574 Derosa G, Maffioli P. Histological Biomarkers of Nonalcoholic Fatty Liver Disease. Biomarkers in Disease: Methods, Discoveries and Applications 2016. [DOI: 10.1007/978-94-007-7742-2_23-1] [Reference Citation Analysis]
575 Gawrieh S, Chalasani N. Current and Emerging Therapies for Nonalcoholic Fatty Liver Disease. Alcoholic and Non-Alcoholic Fatty Liver Disease 2016. [DOI: 10.1007/978-3-319-20538-0_16] [Reference Citation Analysis]
576 Nicholas LM, Mcmillen IC. The Impact of Maternal Obesity and Weight Loss During the Periconceptional Period on Offspring Metabolism. Parental Obesity: Intergenerational Programming and Consequences 2016. [DOI: 10.1007/978-1-4939-6386-7_7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
577 Sabet EA, Mohammad AN, Yousef LM, Ahmed ARH, Sheneef A. Insulin Resistance, Visceral Adiposity Index and TyG Index in Genotype-4 Chronic HCV Patients and Their Relation to Hepatic Histopathology. OJGas 2016;06:249-264. [DOI: 10.4236/ojgas.2016.610030] [Reference Citation Analysis]
578 Chowdhury A, Younossi ZM. Global Epidemiology and Risk Factors for Nonalcoholic Fatty Liver Disease. Alcoholic and Non-Alcoholic Fatty Liver Disease 2016. [DOI: 10.1007/978-3-319-20538-0_2] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
579 Ruderman NB, Shulman GI. Metabolic Syndrome. Endocrinology: Adult and Pediatric 2016. [DOI: 10.1016/b978-0-323-18907-1.00043-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
580 Anderson JP, Parikh JR, Shenfeld DK, Ivanov V, Marks C, Church BW, Laramie JM, Mardekian J, Piper BA, Willke RJ, Rublee DA. Reverse Engineering and Evaluation of Prediction Models for Progression to Type 2 Diabetes: An Application of Machine Learning Using Electronic Health Records. J Diabetes Sci Technol 2015;10:6-18. [PMID: 26685993 DOI: 10.1177/1932296815620200] [Cited by in Crossref: 53] [Cited by in F6Publishing: 56] [Article Influence: 6.6] [Reference Citation Analysis]
581 Slocum SL, Skoko JJ, Wakabayashi N, Aja S, Yamamoto M, Kensler TW, Chartoumpekis DV. Keap1/Nrf2 pathway activation leads to a repressed hepatic gluconeogenic and lipogenic program in mice on a high-fat diet. Arch Biochem Biophys 2016;591:57-65. [PMID: 26701603 DOI: 10.1016/j.abb.2015.11.040] [Cited by in Crossref: 59] [Cited by in F6Publishing: 66] [Article Influence: 7.4] [Reference Citation Analysis]
582 Wan Y, Garner J, Wu N, Phillip L, Han Y, McDaniel K, Annable T, Zhou T, Francis H, Glaser S, Huang Q, Alpini G, Meng F. Role of stem cells during diabetic liver injury. J Cell Mol Med 2016;20:195-203. [PMID: 26645107 DOI: 10.1111/jcmm.12723] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
583 Sorrentino G, Crispino P, Coppola D, De Stefano G. Efficacy of lifestyle changes in subjects with non-alcoholic liver steatosis and metabolic syndrome may be improved with an antioxidant nutraceutical: a controlled clinical study. Drugs R D. 2015;15:21-25. [PMID: 25732561 DOI: 10.1007/s40268-015-0084-x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 3.6] [Reference Citation Analysis]
584 Erukainure OL, Ebuehi OA, Adeboyejo FO, Oladunmoye OO, Aliyu M, Obode OC, Olasehinde T, Elemo GN. Short-Term Feeding of Fibre-Enriched Biscuits: Protective Effect against Hepatotoxicity in Diabetic Rats. Biochem Res Int 2015;2015:868937. [PMID: 26713163 DOI: 10.1155/2015/868937] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
585 Bekaert M, Verhelst X, Geerts A, Lapauw B, Calders P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev. 2016;17:68-80. [PMID: 26597657 DOI: 10.1111/obr.12333] [Cited by in Crossref: 35] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
586 Miele L, Gasbarrini G, Giorgio V, Gasbarrini A, Grieco A. Nonalcoholic fatty liver disease as trigger of cardiovascular and metabolic complication in metabolic syndrome. Intern Emerg Med 2016;11:3-10. [PMID: 26602387 DOI: 10.1007/s11739-015-1346-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
587 Carr RM, Reid AE. FXR agonists as therapeutic agents for non-alcoholic fatty liver disease. Curr Atheroscler Rep. 2015;17:500. [PMID: 25690590 DOI: 10.1007/s11883-015-0500-2] [Cited by in Crossref: 65] [Cited by in F6Publishing: 75] [Article Influence: 8.1] [Reference Citation Analysis]
588 Hossain IA, Akter S, Rahman MK, Ali L. Gender Specific Association of Serum Leptin and Insulinemic Indices with Nonalcoholic Fatty Liver Disease in Prediabetic Subjects. PLoS One. 2015;10:e0142165. [PMID: 26569494 DOI: 10.1371/journal.pone.0142165] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
589 Vu KN, Gilbert G, Chalut M, Chagnon M, Chartrand G, Tang A. MRI-determined liver proton density fat fraction, with MRS validation: Comparison of regions of interest sampling methods in patients with type 2 diabetes. J Magn Reson Imaging 2016;43:1090-9. [PMID: 26536609 DOI: 10.1002/jmri.25083] [Cited by in Crossref: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
590 Zhang L, Zhang Z, Li Y, Liao S, Wu X, Chang Q, Liang B. Cholesterol induces lipoprotein lipase expression in a tree shrew (Tupaia belangeri chinensis) model of non-alcoholic fatty liver disease. Sci Rep 2015;5:15970. [PMID: 26522240 DOI: 10.1038/srep15970] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 3.3] [Reference Citation Analysis]
591 Zelber-Sagi S, Ben-Assuli O, Rabinowich L, Goldstein A, Magid A, Shalev V, Shibolet O, Chodick G. The association between the serum levels of uric acid and alanine aminotransferase in a population-based cohort. Liver Int 2015;35:2408-15. [PMID: 25845417 DOI: 10.1111/liv.12842] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
592 Karavia EA, Hatziri A, Kalogeropoulou C, Papachristou NI, Xepapadaki E, Constantinou C, Natsos A, Petropoulou P, Sasson S, Papachristou DJ, Kypreos KE. Deficiency in apolipoprotein A-I ablates the pharmacological effects of metformin on plasma glucose homeostasis and hepatic lipid deposition. European Journal of Pharmacology 2015;766:76-85. [DOI: 10.1016/j.ejphar.2015.09.040] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
593 Wieland A, Frank DN, Harnke B, Bambha K. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2015;42:1051-63. [PMID: 26304302 DOI: 10.1111/apt.13376] [Cited by in Crossref: 135] [Cited by in F6Publishing: 133] [Article Influence: 16.9] [Reference Citation Analysis]
594 Kim M, Lim SJ, Lee HJ, Kim SY, Nho CW. Gomisin J Inhibits Oleic Acid-Induced Hepatic Lipogenesis by Activation of the AMPK-Dependent Pathway and Inhibition of the Hepatokine Fetuin-A in HepG2 Cells. J Agric Food Chem 2015;63:9729-39. [PMID: 26455261 DOI: 10.1021/acs.jafc.5b04089] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
595 Sagawa H, Naiki-Ito A, Kato H, Naiki T, Yamashita Y, Suzuki S, Sato S, Shiomi K, Kato A, Kuno T, Matsuo Y, Kimura M, Takeyama H, Takahashi S. Connexin 32 and luteolin play protective roles in non-alcoholic steatohepatitis development and its related hepatocarcinogenesis in rats. Carcinogenesis 2015;36:1539-49. [PMID: 26494227 DOI: 10.1093/carcin/bgv143] [Cited by in Crossref: 8] [Cited by in F6Publishing: 22] [Article Influence: 1.0] [Reference Citation Analysis]
596 Takino JI, Nagamine K, Hori T, Sakasai-Sakai A, Takeuchi M. Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma. World J Hepatol 2015; 7(23): 2459-2469 [PMID: 26483867 DOI: 10.4254/wjh.v7.i23.2459] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
597 Downing LE, Heidker RM, Caiozzi GC, Wong BS, Rodriguez K, Del Rey F, Ricketts ML. A Grape Seed Procyanidin Extract Ameliorates Fructose-Induced Hypertriglyceridemia in Rats via Enhanced Fecal Bile Acid and Cholesterol Excretion and Inhibition of Hepatic Lipogenesis. PLoS One 2015;10:e0140267. [PMID: 26458107 DOI: 10.1371/journal.pone.0140267] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
598 Lee SM, Cho YH, Lee SY, Jeong DW, Cho AR, Jeon JS, Park EJ, Kim YJ, Lee JG, Yi YH, Tak YJ, Hwang HR, Lee SH, Han J. Urinary Malondialdehyde Is Associated with Visceral Abdominal Obesity in Middle-Aged Men. Mediators Inflamm 2015;2015:524291. [PMID: 26538829 DOI: 10.1155/2015/524291] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
599 Deng JN, Li J, Mu HN, Liu YY, Wang MX, Pan CS, Fan JY, Ye F, Han JY. Deepure Tea Improves High Fat Diet-Induced Insulin Resistance and Nonalcoholic Fatty Liver Disease. Evid Based Complement Alternat Med. 2015;2015:980345. [PMID: 26504484 DOI: 10.1155/2015/980345] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
600 Tanoglu A, Kara M. Nonalcoholic fatty liver disease-related cardiovascular risk: Is there an association with blood hemoglobin levels? Eur J Gastroenterol Hepatol 2015;27:1126-9. [PMID: 26193051 DOI: 10.1097/MEG.0000000000000434] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
601 Junker AE, Gluud LL, Holst JJ, Knop FK, Vilsbøll T. Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis. J Gastroenterol Hepatol 2015;30:1522-8. [PMID: 25867498 DOI: 10.1111/jgh.12981] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
602 Cuthbertson DJ, Shojaee-Moradie F, Sprung VS, Jones H, Pugh CJ, Richardson P, Kemp GJ, Barrett M, Jackson NC, Thomas EL, Bell JD, Umpleby AM. Dissociation between exercise-induced reduction in liver fat and changes in hepatic and peripheral glucose homoeostasis in obese patients with non-alcoholic fatty liver disease. Clin Sci (Lond). 2016;130:93-104. [PMID: 26424731 DOI: 10.1042/cs20150447] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 8.3] [Reference Citation Analysis]
603 Ren J, Sun J, Ning F, Pang Z, Qie L, Qiao Q; Qingdao Diabetes Survey Group in 2006 and 2009. Gender differences in the association of hypertension with gamma-glutamyltransferase and alanine aminotransferase levels in Chinese adults in Qingdao, China. J Am Soc Hypertens 2015;9:951-8. [PMID: 26542414 DOI: 10.1016/j.jash.2015.09.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
604 Tabbaa A, Shaker M, Lopez R, Hoshemand K, Nobili V, Alkhouri N. Low Serum Potassium Levels Associated with Disease Severity in Children with Nonalcoholic Fatty Liver Disease. Pediatr Gastroenterol Hepatol Nutr. 2015;18:168-174. [PMID: 26473136 DOI: 10.5223/pghn.2015.18.3.168] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
605 Liu Z, Que S, Zhou L, Zheng S. Dose-response Relationship of Serum Uric Acid with Metabolic Syndrome and Non-alcoholic Fatty Liver Disease Incidence: A Meta-analysis of Prospective Studies. Sci Rep. 2015;5:14325. [PMID: 26395162 DOI: 10.1038/srep14325] [Cited by in Crossref: 64] [Cited by in F6Publishing: 70] [Article Influence: 8.0] [Reference Citation Analysis]
606 Sinasac DS, Riordan JD, Spiezio SH, Yandell BS, Croniger CM, Nadeau JH. Genetic control of obesity, glucose homeostasis, dyslipidemia and fatty liver in a mouse model of diet-induced metabolic syndrome. Int J Obes (Lond) 2016;40:346-55. [PMID: 26381349 DOI: 10.1038/ijo.2015.184] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
607 Nicholas LM, Morrison JL, Rattanatray L, Zhang S, Ozanne SE, Mcmillen IC. The early origins of obesity and insulin resistance: timing, programming and mechanisms. Int J Obes 2016;40:229-38. [DOI: 10.1038/ijo.2015.178] [Cited by in Crossref: 83] [Cited by in F6Publishing: 93] [Article Influence: 10.4] [Reference Citation Analysis]
608 Vassilatou E, Vassiliadi DA, Salambasis K, Lazaridou H, Koutsomitopoulos N, Kelekis N, Kassanos D, Hadjidakis D, Dimitriadis G. Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease. Eur J Endocrinol 2015;173:739-47. [PMID: 26340970 DOI: 10.1530/EJE-15-0567] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
609 Karavia EA, Papachristou NI, Sakellaropoulos GC, Xepapadaki E, Papamichail E, Petropoulou P, Papakosta EP, Constantinou C, Habeos I, Papachristou DJ, Kypreos KE. Scavenger Receptor Class B Type I Regulates Plasma Apolipoprotein E Levels and Dietary Lipid Deposition to the Liver. Biochemistry 2015;54:5605-16. [DOI: 10.1021/acs.biochem.5b00700] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
610 Park JS, Kang DH, Lee DH, Bae SH. Concerted action of p62 and Nrf2 protects cells from palmitic acid-induced lipotoxicity. Biochem Biophys Res Commun 2015;466:131-7. [PMID: 26325428 DOI: 10.1016/j.bbrc.2015.08.120] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
611 Kim KH, Sung HJ, Lee WR, An HJ, Kim JY, Pak SC, Han SM, Park KK. Effects of Melittin Treatment in Cholangitis and Biliary Fibrosis in a Model of Xenobiotic-Induced Cholestasis in Mice. Toxins (Basel) 2015;7:3372-87. [PMID: 26308055 DOI: 10.3390/toxins7093372] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
612 Seale LA, Gilman CL, Hashimoto AC, Ogawa-Wong AN, Berry MJ. Diet-induced obesity in the selenocysteine lyase knockout mouse. Antioxid Redox Signal 2015;23:761-74. [PMID: 26192035 DOI: 10.1089/ars.2015.6277] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
613 Katoh S, Peltonen M, Zeniya M, Kaji M, Sakamoto Y, Utsunomiya K, Tuomilehto J. Analysis of the Japanese Diabetes Risk Score and fatty liver markers for incident diabetes in a Japanese cohort. Prim Care Diabetes 2016;10:19-26. [PMID: 26303223 DOI: 10.1016/j.pcd.2015.07.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
614 Beigi T, Shafaei A, Khoshnia M, Marjani A. Serum Fetuin A Level, Liver Enzymes Activities and Insulin Resistance in Patients with Type 2 Diabetes. J of Medical Sciences 2015;15:229-234. [DOI: 10.3923/jms.2015.229.234] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
615 Dobson R, Burgess MI, Sprung VS, Irwin A, Hamer M, Jones J, Daousi C, Adams V, Kemp GJ, Shojaee-Moradie F, Umpleby M, Cuthbertson DJ. Metabolically healthy and unhealthy obesity: differential effects on myocardial function according to metabolic syndrome, rather than obesity. Int J Obes (Lond) 2016;40:153-61. [PMID: 26271188 DOI: 10.1038/ijo.2015.151] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 7.1] [Reference Citation Analysis]
616 Schierwagen R, Maybüchen L, Zimmer S, Hittatiya K, Bäck C, Klein S, Uschner FE, Reul W, Boor P, Nickenig G, Strassburg CP, Trautwein C, Plat J, Lütjohann D, Sauerbruch T, Tacke F, Trebicka J. Seven weeks of Western diet in apolipoprotein-E-deficient mice induce metabolic syndrome and non-alcoholic steatohepatitis with liver fibrosis. Sci Rep 2015;5:12931. [PMID: 26263022 DOI: 10.1038/srep12931] [Cited by in Crossref: 100] [Cited by in F6Publishing: 102] [Article Influence: 12.5] [Reference Citation Analysis]
617 Lim S, Oh TJ, Koh KK. Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders. Int J Cardiol 2015;201:408-14. [PMID: 26310987 DOI: 10.1016/j.ijcard.2015.08.107] [Cited by in Crossref: 42] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
618 Jegatheesan P, Beutheu S, Ventura G, Nubret E, Sarfati G, Bergheim I, De Bandt J. Citrulline and Nonessential Amino Acids Prevent Fructose-Induced Nonalcoholic Fatty Liver Disease in Rats. The Journal of Nutrition 2015;145:2273-9. [DOI: 10.3945/jn.115.218982] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
619 Hamza N, Berke B, Cheze C, Marais S, Lorrain S, Abdouelfath A, Lassalle R, Carles D, Gin H, Moore N. Effect of Centaurium erythraea Rafn, Artemisia herba-alba Asso and Trigonella foenum-graecum L. on liver fat accumulation in C57BL/6J mice with high-fat diet-induced type 2 diabetes. Journal of Ethnopharmacology 2015;171:4-11. [DOI: 10.1016/j.jep.2015.05.027] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
620 Dongiovanni P, Romeo S, Valenti L. Genetic Factors in the Pathogenesis of Nonalcoholic Fatty Liver and Steatohepatitis. Biomed Res Int 2015;2015:460190. [PMID: 26273621 DOI: 10.1155/2015/460190] [Cited by in Crossref: 91] [Cited by in F6Publishing: 97] [Article Influence: 11.4] [Reference Citation Analysis]
621 Wu SJ, Zhu GQ, Ye BZ, Kong FQ, Zheng ZX, Zou H, Shi KQ, Lin L, Braddock M, Huang WJ, Chen YP, Zheng MH. Association between sex-specific serum uric acid and non-alcoholic fatty liver disease in Chinese adults: a large population-based study. Medicine (Baltimore). 2015;94:e802. [PMID: 25929934 DOI: 10.1097/md.0000000000000802] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
622 Lee MK, Park HJ, Jeon WS, Park SE, Park CY, Lee WY, Oh KW, Park SW, Rhee EJ. Higher association of coronary artery calcification with non-alcoholic fatty liver disease than with abdominal obesity in middle-aged Korean men: the Kangbuk Samsung Health Study. Cardiovasc Diabetol 2015;14:88. [PMID: 26169265 DOI: 10.1186/s12933-015-0253-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 3.5] [Reference Citation Analysis]
623 Chen S, Guo X, Zhang X, Yu S, Yang H, Jiang M, Sun G, Sun Y. Association between elevated serum alanine aminotransferase and cardiometabolic risk factors in rural Chinese population: a cross-sectional study. BMC Cardiovasc Disord 2015;15:65. [PMID: 26160405 DOI: 10.1186/s12872-015-0060-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
624 Strange RC, Shipman KE, Ramachandran S. Metabolic syndrome: A review of the role of vitamin D in mediating susceptibility and outcome. World J Diabetes 2015; 6(7): 896-911 [PMID: 26185598 DOI: 10.4239/wjd.v6.i7.896] [Cited by in CrossRef: 85] [Cited by in F6Publishing: 89] [Article Influence: 10.6] [Reference Citation Analysis]
625 Liang J, Gong Y, Wang Y, Qiu Q, Zou C, Dou L, Liu X, Song H. Serum gamma-glutamyltransferase is associated with impaired fasting glucose in Chinese adults: the Cardiometabolic Risk in Chinese (CRC) study. Cell Biochem Biophys 2014;70:1823-8. [PMID: 25030409 DOI: 10.1007/s12013-014-0136-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
626 Ashtari S, Pourhoseingholi MA, Zali MR. Non-alcohol fatty liver disease in Asia: Prevention and planning. World J Hepatol 2015; 7(13): 1788-1796 [PMID: 26167252 DOI: 10.4254/wjh.v7.i13.1788] [Cited by in Crossref: 45] [Cited by in F6Publishing: 53] [Article Influence: 5.6] [Reference Citation Analysis]
627 He KP, Zhao C, Qiang Y, Liu HR, Chen N, Tao XJ, Chen LL, Song H. Impact of elevated aspartate and alanine aminotransferase on metabolic syndrome and its components among adult people living in Ningxia, China. Chronic Dis Transl Med 2015;1:124-32. [PMID: 29062997 DOI: 10.1016/j.cdtm.2015.06.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
628 Bower G, Athanasiou T, Isla AM, Harling L, Li JV, Holmes E, Efthimiou E, Darzi A, Ashrafian H. Bariatric surgery and nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2015;27:755-68. [PMID: 25919774 DOI: 10.1097/MEG.0000000000000375] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
629 Ko SH, Baeg MK, Han KD, Ko SH, Ahn YB. Increased liver markers are associated with higher risk of type 2 diabetes. World J Gastroenterol 2015; 21(24): 7478-7487 [PMID: 26139993 DOI: 10.3748/wjg.v21.i24.7478] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 37] [Article Influence: 4.6] [Reference Citation Analysis]
630 Fabbrini E, Magkos F. Hepatic Steatosis as a Marker of Metabolic Dysfunction. Nutrients 2015;7:4995-5019. [PMID: 26102213 DOI: 10.3390/nu7064995] [Cited by in Crossref: 107] [Cited by in F6Publishing: 111] [Article Influence: 13.4] [Reference Citation Analysis]
631 Fakhoury-Sayegh N, Trak-Smayra V, Khazzaka A, Esseily F, Obeid O, Lahoud-Zouein M, Younes H. Characteristics of nonalcoholic fatty liver disease induced in wistar rats following four different diets. Nutr Res Pract 2015;9:350-7. [PMID: 26244072 DOI: 10.4162/nrp.2015.9.4.350] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
632 Shen Z, Munker S, Luo F, Ma H, Yu C, Li Y. Effect of Non-Alcoholic Fatty Liver Disease on Estimated Glomerular Filtration Rate Could Be Dependent on Age. PLoS One 2015;10:e0130614. [PMID: 26087253 DOI: 10.1371/journal.pone.0130614] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
633 Kavey RE. Combined dyslipidemia in childhood. J Clin Lipidol 2015;9:S41-56. [PMID: 26343211 DOI: 10.1016/j.jacl.2015.06.008] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.9] [Reference Citation Analysis]
634 van Best N, Jansen PL, Rensen SS. The gut microbiota of nonalcoholic fatty liver disease: current methods and their interpretation. Hepatol Int. 2015;9:406-415. [PMID: 26067771 DOI: 10.1007/s12072-015-9640-2] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
635 Sogabe M, Okahisa T, Taniguchi T, Tomonari T, Tanaka T, Tanaka H, Nakasono M, Takayama T. Light alcohol consumption plays a protective role against non-alcoholic fatty liver disease in Japanese men with metabolic syndrome. Liver Int 2015;35:1707-14. [PMID: 25438866 DOI: 10.1111/liv.12754] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
636 Tomeno W, Kawashima K, Yoneda M, Saito S, Ogawa Y, Honda Y, Kessoku T, Imajo K, Mawatari H, Fujita K, Saito S, Hirayasu Y, Nakajima A. Non-alcoholic fatty liver disease comorbid with major depressive disorder: The pathological features and poor therapeutic efficacy. J Gastroenterol Hepatol 2015;30:1009-14. [PMID: 25619308 DOI: 10.1111/jgh.12897] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 6.8] [Reference Citation Analysis]
637 Sanyal AJ. Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease. Dig Dis 2015;33:426-32. [PMID: 26045279 DOI: 10.1159/000371698] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
638 Buday B, Pach PF, Literati-Nagy B, Vitai M, Kovacs G, Vecsei Z, Koranyi L, Lengyel C. Sex influenced association of directly measured insulin sensitivity and serum transaminase levels: Why alanine aminotransferase only predicts cardiovascular risk in men? Cardiovasc Diabetol 2015;14:55. [PMID: 25986611 DOI: 10.1186/s12933-015-0222-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
639 Georgoulis M, Kontogianni MD, Margariti A, Tiniakos D, Fragopoulou E, Zafiropoulou R, Papatheodoridis G. Associations between dietary intake and the presence of the metabolic syndrome in patients with non-alcoholic fatty liver disease. J Hum Nutr Diet 2015;28:409-15. [PMID: 25988570 DOI: 10.1111/jhn.12323] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
640 Camer D, Yu Y, Szabo A, Dinh CH, Wang H, Cheng L, Huang XF. Bardoxolone methyl prevents insulin resistance and the development of hepatic steatosis in mice fed a high-fat diet. Mol Cell Endocrinol 2015;412:36-43. [PMID: 26001833 DOI: 10.1016/j.mce.2015.05.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.1] [Reference Citation Analysis]
641 van Beek L, van Klinken JB, Pronk AC, van Dam AD, Dirven E, Rensen PC, Koning F, Willems van Dijk K, van Harmelen V. The limited storage capacity of gonadal adipose tissue directs the development of metabolic disorders in male C57Bl/6J mice. Diabetologia 2015;58:1601-9. [PMID: 25962520 DOI: 10.1007/s00125-015-3594-8] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 6.4] [Reference Citation Analysis]
642 Vig S, Talwar P, Kaur K, Srivastava R, Srivastava AK, Datta M. Transcriptome profiling identifies p53 as a key player during calreticulin deficiency: Implications in lipid accumulation. Cell Cycle 2015;14:2274-84. [PMID: 25946468 DOI: 10.1080/15384101.2015.1046654] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
643 Kim SW, Jung HW. Which one is associated with nonalcoholic fatty liver disease? Small muscle mass or large fat mass. Hepatology 2015;61:1764. [PMID: 25125319 DOI: 10.1002/hep.27370] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
644 Fares R, Petta S, Lombardi R, Grimaudo S, Dongiovanni P, Pipitone R, Rametta R, Fracanzani AL, Mozzi E, Craxì A, Fargion S, Sesti G, Valenti L. The UCP2 -866 G>A promoter region polymorphism is associated with nonalcoholic steatohepatitis. Liver Int 2015;35:1574-80. [PMID: 25351290 DOI: 10.1111/liv.12707] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
645 Kumar VH, Im NN, Huilgol SV, Yendigeri SM, K N, Ch R. Dose Dependent Hepatic and Endothelial Changes in Rats Treated with Dexamethasone. J Clin Diagn Res 2015;9:FF08-10. [PMID: 26155494 DOI: 10.7860/JCDR/2015/12810.5930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
646 Ouchfoun M, Eid HM, Musallam L, Brault A, Li S, Vallerand D, Arnason JT, Haddad PS. Labrador tea (Rhododendron groenlandicum) attenuates insulin resistance in a diet-induced obesity mouse model. Eur J Nutr 2016;55:941-54. [PMID: 25916863 DOI: 10.1007/s00394-015-0908-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
647 Takahashi Y, Sugimoto K, Soejima Y, Kumagai A, Koeda T, Shojo A, Nakagawa K, Harada N, Yamaji R, Inui H, Yamanouchi T, Fukusato T. Inhibitory effects of eucalyptus and banaba leaf extracts on nonalcoholic steatohepatitis induced by a high-fructose/high-glucose diet in rats. Biomed Res Int 2015;2015:296207. [PMID: 26000287 DOI: 10.1155/2015/296207] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
648 Meloni A, Tyszka JM, Pepe A, Wood JC. Effect of inversion recovery fat suppression on hepatic R2* quantitation in transfusional siderosis. AJR Am J Roentgenol 2015;204:625-9. [PMID: 25714295 DOI: 10.2214/AJR.14.12786] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
649 Zheng T, Yang X, Wu D, Xing S, Bian F, Li W, Chi J, Bai X, Wu G, Chen X, Zhang Y, Jin S. Salidroside ameliorates insulin resistance through activation of a mitochondria-associated AMPK/PI3K/Akt/GSK3β pathway. Br J Pharmacol 2015;172:3284-301. [PMID: 25754463 DOI: 10.1111/bph.13120] [Cited by in Crossref: 139] [Cited by in F6Publishing: 146] [Article Influence: 17.4] [Reference Citation Analysis]
650 Li GQ, Kim M, Jin F, Cho J. PHYTOMEDICINES FOR FATTY LIVER DISEASE AND FUNCTIONAL GASTROINTESTINAL CONDITIONS. Phytotherapies 2015. [DOI: 10.1002/9781119006039.ch17] [Reference Citation Analysis]
651 Chung GE, Yim JY, Kim D, Lim SH, Yang JI, Kim YS, Yang SY, Kwak MS, Kim JS, Cho SH. The influence of metabolic factors for nonalcoholic Fatty liver disease in women. Biomed Res Int 2015;2015:131528. [PMID: 25973422 DOI: 10.1155/2015/131528] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
652 Streba LA, Vere CC, Rogoveanu I, Streba CT. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question. World J Gastroenterol 2015;21:4103-10. [PMID: 25892859 DOI: 10.3748/wjg.v21.i14.4103] [Cited by in CrossRef: 106] [Cited by in F6Publishing: 114] [Article Influence: 13.3] [Reference Citation Analysis]
653 Ebertz CE, Bonfleur ML, Bertasso IM, Mendes MC, Lubaczeuski C, Araujo AC, Paes AM, de Amorim EM, Balbo SL. Duodenal jejunal bypass attenuates non-alcoholic fatty liver disease in western diet-obese rats. Acta Cir Bras 2014;29:609-14. [PMID: 25252208 DOI: 10.1590/s0102-8650201400150009] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
654 Chang PF, Lin YC, Liu K, Yeh SJ, Ni YH. Heme oxygenase-1 gene promoter polymorphism and the risk of pediatric nonalcoholic fatty liver disease. Int J Obes (Lond). 2015;39:1236-1240. [PMID: 25835554 DOI: 10.1038/ijo.2015.46] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
655 Stanimirovic J, Obradovic M, Zafirovic S, Resanovic I, Bogdanovic N, Gluvic Z, Mousa SA, Isenovic ER. Effects of altered hepatic lipid metabolism on regulation of hepatic iNOS. Clinical Lipidology 2015;10:167-75. [DOI: 10.2217/clp.15.8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
656 Guerra JFDC, Maciel PS, de Abreu ICME, Pereira RR, Silva M, Cardoso LDM, Pinheiro-sant'ana HM, Lima WGD, Silva ME, Pedrosa ML. Dietary açai attenuates hepatic steatosis via adiponectin-mediated effects on lipid metabolism in high-fat diet mice. Journal of Functional Foods 2015;14:192-202. [DOI: 10.1016/j.jff.2015.01.025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
657 Lim SH, Kim D, Kang JH, Song JH, Yang SY, Yim JY, Chung SJ, Kim JS, Cho SH. Hepatic fat, not visceral fat, is associated with gallbladder polyps: a study of 2643 healthy subjects. J Gastroenterol Hepatol 2015;30:767-74. [PMID: 25376159 DOI: 10.1111/jgh.12841] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
658 Bang KB, Cho YK. Comorbidities and Metabolic Derangement of NAFLD. J Lifestyle Med. 2015;5:7-13. [PMID: 26528424 DOI: 10.15280/jlm.2015.5.1.7] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 4.6] [Reference Citation Analysis]
659 Tan S, Vollmar N, Benson S, Sowa JP, Bechmann LP, Gerken G, Fuhrer D, Canbay A. Liver Injury Indicating Fatty Liver but Not Serologic NASH Marker Improves under Metformin Treatment in Polycystic Ovary Syndrome. Int J Endocrinol 2015;2015:254169. [PMID: 25873949 DOI: 10.1155/2015/254169] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
660 Lee MS, Kim CT, Kim IH, Kim Y. Effects of Korean Red Ginseng extract on hepatic lipid accumulation in HepG2 cells. Biosci Biotechnol Biochem 2015;79:816-9. [PMID: 25774635 DOI: 10.1080/09168451.2014.997186] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
661 Bak EJ, Choi KC, Jang S, Woo GH, Yoon HG, Na Y, Yoo YJ, Lee Y, Jeong Y, Cha JH. Licochalcone F alleviates glucose tolerance and chronic inflammation in diet-induced obese mice through Akt and p38 MAPK. Clin Nutr 2016;35:414-21. [PMID: 25823386 DOI: 10.1016/j.clnu.2015.03.005] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
662 AlKhater SA. Paediatric non-alcoholic fatty liver disease: an overview. Obes Rev 2015;16:393-405. [PMID: 25753407 DOI: 10.1111/obr.12271] [Cited by in Crossref: 38] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
663 Smith A, Elnahas A, Okrainec A, Quereshy FA, Jackson TD. Is Bariatric Surgery Safe in Patients with Cirrhosis? An Analysis of Short-Term Outcomes. Bariatric Surgical Practice and Patient Care 2015;10:19-23. [DOI: 10.1089/bari.2014.0034] [Reference Citation Analysis]
664 Lonardo A, Ballestri S, Marchesini G, Angulo P, Loria P. Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome. Dig Liver Dis 2015;47:181-90. [PMID: 25739820 DOI: 10.1016/j.dld.2014.09.020] [Cited by in Crossref: 451] [Cited by in F6Publishing: 465] [Article Influence: 56.4] [Reference Citation Analysis]
665 Aigner E, Weiss G, Datz C. Dysregulation of iron and copper homeostasis in nonalcoholic fatty liver. World J Hepatol 2015; 7(2): 177-188 [PMID: 25729473 DOI: 10.4254/wjh.v7.i2.177] [Cited by in Crossref: 62] [Cited by in F6Publishing: 67] [Article Influence: 7.8] [Reference Citation Analysis]
666 Schneier AT, Citti CC, Dieterich DT. Management and diagnosis of fatty liver disease. Expert Rev Gastroenterol Hepatol. 2015;9:671-683. [PMID: 25716275 DOI: 10.1586/17474124.2015.1003209] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
667 Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5. [PMID: 25705637 DOI: 10.3978/j.issn.2305-5839] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
668 Ali AH, Carey EJ, Lindor KD. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3:5. [PMID: 25705637 DOI: 10.3978/j.issn.2305-5839.2014.12.06] [Cited by in F6Publishing: 91] [Reference Citation Analysis]
669 Uetake Y, Ikeda H, Irie R, Tejima K, Matsui H, Ogura S, Wang H, Mu S, Hirohama D, Ando K, Sawamura T, Yatomi Y, Fujita T, Shimosawa T. High-salt in addition to high-fat diet may enhance inflammation and fibrosis in liver steatosis induced by oxidative stress and dyslipidemia in mice. Lipids Health Dis 2015;14:6. [PMID: 25888871 DOI: 10.1186/s12944-015-0002-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.4] [Reference Citation Analysis]
670 Yamagishi S, Matsui T. Role of receptor for advanced glycation end products (RAGE) in liver disease. Eur J Med Res. 2015;20:15. [PMID: 25888859 DOI: 10.1186/s40001-015-0090-z] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 4.5] [Reference Citation Analysis]
671 Takeuchi M, Sakasai-Sakai A, Takata T, Ueda T, Takino J, Tsutsumi M, Hyogo H, Yamagishi S. Serum levels of toxic AGEs (TAGE) may be a promising novel biomarker in development and progression of NASH. Med Hypotheses. 2015;84:490-493. [PMID: 25697114 DOI: 10.1016/j.mehy.2015.02.002] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.8] [Reference Citation Analysis]
672 Dongiovanni P, Lanti C, Gatti S, Rametta R, Recalcati S, Maggioni M, Fracanzani AL, Riso P, Cairo G, Fargion S, Valenti L. High fat diet subverts hepatocellular iron uptake determining dysmetabolic iron overload. PLoS One. 2015;10:e0116855. [PMID: 25647178 DOI: 10.1371/journal.pone.0116855] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
673 Kessoku T, Yoneda M, Sumida Y, Eguchi Y, Fujii H, Hyogo H, Ono M, Kawaguchi T, Nakajima A; Japan Study Group of NAFLD. Insulin resistance correlated with the severity of liver histology in Japanese NAFLD patients: a multicenter retrospective study. J Clin Gastroenterol 2015;49:169-70. [PMID: 25014241 DOI: 10.1097/MCG.0000000000000186] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
674 Dongiovanni P, Petta S, Maglio C, Fracanzani AL, Pipitone R, Mozzi E, Motta BM, Kaminska D, Rametta R, Grimaudo S, Pelusi S, Montalcini T, Alisi A, Maggioni M, Kärjä V, Borén J, Käkelä P, Di Marco V, Xing C, Nobili V, Dallapiccola B, Craxi A, Pihlajamäki J, Fargion S, Sjöström L, Carlsson LM, Romeo S, Valenti L. Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology 2015;61:506-14. [PMID: 25251399 DOI: 10.1002/hep.27490] [Cited by in Crossref: 342] [Cited by in F6Publishing: 319] [Article Influence: 42.8] [Reference Citation Analysis]
675 Tortora R, Capone P, De Stefano G, Imperatore N, Gerbino N, Donetto S, Monaco V, Caporaso N, Rispo A. Metabolic syndrome in patients with coeliac disease on a gluten-free diet. Aliment Pharmacol Ther 2015;41:352-9. [PMID: 25581084 DOI: 10.1111/apt.13062] [Cited by in Crossref: 87] [Cited by in F6Publishing: 76] [Article Influence: 10.9] [Reference Citation Analysis]
676 Hirooka M, Koizumi Y, Miyake T, Ochi H, Tokumoto Y, Tada F, Matsuura B, Abe M, Hiasa Y. Nonalcoholic Fatty Liver Disease: Portal Hypertension Due to Outflow Block in Patients without Cirrhosis. Radiology 2015;274:597-604. [DOI: 10.1148/radiol.14132952] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.5] [Reference Citation Analysis]
677 Maslak E, Zabielski P, Kochan K, Kus K, Jasztal A, Sitek B, Proniewski B, Wojcik T, Gula K, Kij A, Walczak M, Baranska M, Chabowski A, Holland RJ, Saavedra JE, Keefer LK, Chlopicki S. The liver-selective NO donor, V-PYRRO/NO, protects against liver steatosis and improves postprandial glucose tolerance in mice fed high fat diet. Biochemical Pharmacology 2015;93:389-400. [DOI: 10.1016/j.bcp.2014.12.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 3.9] [Reference Citation Analysis]
678 Miranda-Henriques MS, Diniz Mde F, Araújo MS. Ginseng, green tea or fibrate: valid options for nonalcoholic steatohepatitis prevention? Arq Gastroenterol 2014;51:255-60. [PMID: 25296088 DOI: 10.1590/s0004-28032014000300016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
679 Chen LZ, Xin YN, Geng N, Jiang M, Zhang DD, Xuan SY. PNPLA3 I148M variant in nonalcoholic fatty liver disease: Demographic and ethnic characteristics and the role of the variant in nonalcoholic fatty liver fibrosis. World J Gastroenterol 2015; 21(3): 794-802 [PMID: 25624712 DOI: 10.3748/wjg.v21.i3.794] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
680 Fabbrini E, Yoshino J, Yoshino M, Magkos F, Tiemann Luecking C, Samovski D, Fraterrigo G, Okunade AL, Patterson BW, Klein S. Metabolically normal obese people are protected from adverse effects following weight gain. J Clin Invest. 2015;125:787-795. [PMID: 25555214 DOI: 10.1172/jci78425] [Cited by in Crossref: 115] [Cited by in F6Publishing: 122] [Article Influence: 14.4] [Reference Citation Analysis]
681 Hirten R, Bodenheimer HC, Bernstein D. Diabetes and Liver Disease. Principles of Diabetes Mellitus 2015. [DOI: 10.1007/978-3-319-20797-1_35-1] [Reference Citation Analysis]
682 Noureddin M, Alexanian D, Kaplowitz N. Non-Alcoholic Fatty Liver Disease (NAFLD): The Lipid Disease of the Liver and the Effect of Statins. Lipid Management 2015. [DOI: 10.1007/978-3-319-11161-2_9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
683 Sharma D, Saxena NK. Mouse Models to Study the Effect of Natural Products on Obesity-Associated NAFLD/NASH. Energy Balance and Cancer 2015. [DOI: 10.1007/978-3-319-16733-6_12] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
684 Xiao J, Tipoe GL. The Antioxidant, Anti-inflammatory, and Antiapoptotic Effects of Wolfberry in Fatty Liver Disease. Lycium Barbarum and Human Health 2015. [DOI: 10.1007/978-94-017-9658-3_3] [Reference Citation Analysis]
685 Mohamed RA, Nabih MI, Elshobaky MB, Khattab HM. The value of noninvasive scoring systems for the diagnosis of advanced fibrosis in Egyptian patients with nonalcoholic fatty liver disease. Egypt J Intern Med 2014;26:162-9. [DOI: 10.4103/1110-7782.148151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
686 Takeuchi M, Takino J, Sakasai-Sakai A, Takata T, Ueda T, Tsutsumi M, Hyogo H, Yamagishi S. Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies. World J Hepatol. 2014;6:880-893. [PMID: 25544875 DOI: 10.4254/wjh.6.i12.880] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
687 Takeuchi M, Takino JI, Sakasai-Sakai A, Takata T, Ueda T, Tsutsumi M, Hyogo H, Yamagishi SI. Involvement of the TAGE-RAGE system in non-alcoholic steatohepatitis: Novel treatment strategies. World J Hepatol 2014; 6(12): 880-893 [PMID: 25544875 DOI: 10.4254/wjh.v6.i12.880] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
688 Cho JH, Namgung JS, Lee J, Moon DH, Lee HK. Analysis of biochemical markers related to Fatty liver patients. J Phys Ther Sci 2014;26:1865-8. [PMID: 25540483 DOI: 10.1589/jpts.26.1865] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
689 Cho HJ, Kim SS, Ahn SJ, Park JH, Kim DJ, Kim YB, Cho SW, Cheong JY. Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B. Clin Mol Hepatol. 2014;20:347-354. [PMID: 25548740 DOI: 10.3350/cmh.2014.20.4.347] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
690 Lake AD, Novak P, Shipkova P, Aranibar N, Robertson DG, Reily MD, Lehman-McKeeman LD, Vaillancourt RR, Cherrington NJ. Branched chain amino acid metabolism profiles in progressive human nonalcoholic fatty liver disease. Amino Acids 2015;47:603-15. [PMID: 25534430 DOI: 10.1007/s00726-014-1894-9] [Cited by in Crossref: 124] [Cited by in F6Publishing: 129] [Article Influence: 13.8] [Reference Citation Analysis]
691 Jamshed H, Arslan J, Gilani AU. Cholesterol-cholate-butterfat diet offers multi-organ dysfunction in rats. Lipids Health Dis 2014;13:194. [PMID: 25515296 DOI: 10.1186/1476-511X-13-194] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
692 Zhang X, Mu Y, Yan W, Ba J, Li H. Alanine aminotransferase within reference range is associated with metabolic syndrome in middle-aged and elderly Chinese men and women. Int J Environ Res Public Health 2014;11:12767-76. [PMID: 25513998 DOI: 10.3390/ijerph111212767] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
693 Shen H, Lipka S, Kumar A, Mustacchia P. Association between nonalcoholic fatty liver disease and colorectal adenoma: a systemic review and meta-analysis. J Gastrointest Oncol. 2014;5:440-446. [PMID: 25436123 DOI: 10.3978/j.issn.2078-6891.2014.061] [Cited by in F6Publishing: 16] [Reference Citation Analysis]
694 Jung YS, Kim JH, Kim BC, Seok HJ, Yoo JS, Ku JR, Yoon KH, Jo JH, Jang DH, Yun HY, Yoon M, Shin SS. Comparison of Gangjihwan-1,2,3,4 and Combination of Gangjihwan-1 and Gamisochehwan in the Improvement Effects of Nonalcoholic Fatty Liver Disease in a High Fat Diet-Fed Obese Mouse Model. The Korea Journal of Herbology 2014;29:149-156. [DOI: 10.6116/kjh.2014.29.6.149.] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
695 Uemura H, Katsuura-Kamano S, Yamaguchi M, Arisawa K. Relationships of elevated levels of serum hepatic enzymes and alcohol intake with arterial stiffness in men. Atherosclerosis 2015;238:83-8. [PMID: 25437895 DOI: 10.1016/j.atherosclerosis.2014.11.021] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
696 Mor A, Svensson E, Rungby J, Ulrichsen SP, Berencsi K, Nielsen JS, Stidsen JV, Friborg S, Brandslund I, Christiansen JS, Beck-nielsen H, Sørensen HT, Thomsen RW. Modifiable clinical and lifestyle factors are associated with elevated alanine aminotransferase levels in newly diagnosed type 2 diabetes patients: results from the nationwide DD2 study: Markers of Elevated ALT in Type 2 Diabetes Patients. Diabetes Metab Res Rev 2014;30:707-15. [DOI: 10.1002/dmrr.2539] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
697 Cuthbertson DJ, Irwin A, Sprung VS, Jones H, Pugh CJ, Daousi C, Adams VL, Bimson WE, Shojaee-Moradie F, Richardson P, Umpleby AM, Wilding JP, Kemp GJ. Ectopic lipid storage in non-alcoholic fatty liver disease is not mediated by impaired mitochondrial oxidative capacity in skeletal muscle. Clin Sci (Lond) 2014;127:655-63. [PMID: 24738611 DOI: 10.1042/CS20130404] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
698 Wang DQ, Portincasa P, Neuschwander-Tetri BA. Steatosis in the liver. Compr Physiol 2013;3:1493-532. [PMID: 24265237 DOI: 10.1002/cphy.c130001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
699 Bi X, Liu W, Xia X, Chen L, Mu T, Liu J, Hou Y, Zhao Y. Effects of Callistephus chinensis flower polyphones on improving metabolic disorders in high-fat diet-induced mice. Food Funct 2014;5:3304-10. [PMID: 25367327 DOI: 10.1039/c4fo00637b] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
700 Ramezani-Binabaj M, Motalebi M, Karimi-Sari H, Rezaee-Zavareh MS, Alavian SM. Are women with polycystic ovarian syndrome at a high risk of non-alcoholic Fatty liver disease; a meta-analysis. Hepat Mon 2014;14:e23235. [PMID: 25598791 DOI: 10.5812/hepatmon.23235] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 6.0] [Reference Citation Analysis]
701 Puppala J, Bhrugumalla S, Kumar A, Siddapuram SP, Viswa PD, Kondawar M, Akka J, Munshi A. Apolipoprotein C3 gene polymorphisms in Southern Indian patients with nonalcoholic fatty liver disease. Indian J Gastroenterol 2014;33:524-9. [PMID: 25319715 DOI: 10.1007/s12664-014-0504-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
702 Jung KY, Cho SY, Kim HJ, Kim SB, Song IH. Nonalcoholic steatohepatitis associated with metabolic syndrome: relationship to insulin resistance and liver histology. J Clin Gastroenterol 2014;48:883-8. [PMID: 24440936 DOI: 10.1097/MCG.0000000000000065] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
703 Kunutsor SK, Apekey TA, Seddoh D. Gamma glutamyltransferase and metabolic syndrome risk: a systematic review and dose-response meta-analysis. Int J Clin Pract 2015;69:136-44. [PMID: 25363194 DOI: 10.1111/ijcp.12507] [Cited by in Crossref: 39] [Cited by in F6Publishing: 43] [Article Influence: 4.3] [Reference Citation Analysis]
704 Rothkopf M, Haverstick L, Nusbaum M. An Overview of Metabolic Medicine. Metabolic Medicine and Surgery 2014. [DOI: 10.1201/b17616-3] [Reference Citation Analysis]
705 Tao Y, Gu H, Wu J, Sui J. Thyroid function is associated with non-alcoholic fatty liver disease in euthyroid subjects. Endocr Res. 2015;40:74-78. [PMID: 25330278 DOI: 10.3109/07435800.2014.952014] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 3.7] [Reference Citation Analysis]
706 Sunbul M, Agirbasli M, Durmus E, Kivrak T, Akin H, Aydin Y, Ergelen R, Yilmaz Y. Arterial stiffness in patients with non-alcoholic fatty liver disease is related to fibrosis stage and epicardial adipose tissue thickness. Atherosclerosis. 2014;237:490-493. [PMID: 25463079 DOI: 10.1016/j.atherosclerosis.2014.10.004] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 5.8] [Reference Citation Analysis]
707 Liland N, Hatlen B, Takle H, Venegas C, Espe M, Torstensen B, Waagbø R. Including processed poultry and porcine by-products in diets high in plant ingredients reduced liver TAG in Atlantic salmon, Salmo salar L. Aquacult Nutr 2015;21:655-69. [DOI: 10.1111/anu.12190] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
708 Li Y, Zhao J, Zheng H, Zhong X, Zhou J, Hong Z. Treatment of Nonalcoholic Fatty Liver Disease with Total Alkaloids in Rubus aleaefolius Poir through Regulation of Fat Metabolism. Evid Based Complement Alternat Med. 2014;2014:768540. [PMID: 25404949 DOI: 10.1155/2014/768540] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
709 Morinaga H, Mayoral R, Heinrichsdorff J, Osborn O, Franck N, Hah N, Walenta E, Bandyopadhyay G, Pessentheiner AR, Chi TJ, Chung H, Bogner-Strauss JG, Evans RM, Olefsky JM, Oh DY. Characterization of distinct subpopulations of hepatic macrophages in HFD/obese mice. Diabetes 2015;64:1120-30. [PMID: 25315009 DOI: 10.2337/db14-1238] [Cited by in Crossref: 118] [Cited by in F6Publishing: 120] [Article Influence: 13.1] [Reference Citation Analysis]
710 Delvin E, Patey N, Dubois J, Henderson M, Lévy É. Pediatric Non-Alcoholic Fatty Liver Disease. J Med Biochem 2015;34:3-12. [PMID: 28356817 DOI: 10.2478/jomb-2014-0059] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
711 Macfarlane DP, Raubenheimer PJ, Preston T, Gray CD, Bastin ME, Marshall I, Iredale JP, Andrew R, Walker BR. Effects of acute glucocorticoid blockade on metabolic dysfunction in patients with Type 2 diabetes with and without fatty liver. Am J Physiol Gastrointest Liver Physiol 2014;307:G760-8. [PMID: 25104497 DOI: 10.1152/ajpgi.00030.2014] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
712 Dongiovanni P, Romeo S, Valenti L. Hepatocellular carcinoma in nonalcoholic fatty liver: Role of environmental and genetic factors. World J Gastroenterol 2014; 20(36): 12945-12955 [PMID: 25278690 DOI: 10.3748/wjg.v20.i36.12945] [Cited by in CrossRef: 92] [Cited by in F6Publishing: 96] [Article Influence: 10.2] [Reference Citation Analysis]
713 Kato K, Takeshita Y, Misu H, Zen Y, Kaneko S, Takamura T. Liver steatosis is associated with insulin resistance in skeletal muscle rather than in the liver in Japanese patients with non-alcoholic fatty liver disease. J Diabetes Investig 2015;6:158-63. [PMID: 25802723 DOI: 10.1111/jdi.12271] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
714 Paniagua JA, Escandell-Morales JM, Gil-Contreras D, Berral de la Rosa FJ, Romero-Jimenez M, Gómez-Urbano A, Sanchez-Lopez A, Bellido E, Poyato A, Calatayud B. Central obesity and altered peripheral adipose tissue gene expression characterize the NAFLD patient with insulin resistance: Role of nutrition and insulin challenge. Nutrition. 2014;30:177-185. [PMID: 24377452 DOI: 10.1016/j.nut.2013.07.017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
715 Alam S, Gupta UD, Alam M, Kabir J, Chowdhury ZR, Alam AK. Clinical, anthropometric, biochemical, and histological characteristics of nonobese nonalcoholic fatty liver disease patients of Bangladesh. Indian J Gastroenterol 2014;33:452-7. [PMID: 25023045 DOI: 10.1007/s12664-014-0488-5] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 4.9] [Reference Citation Analysis]
716 Younossi ZM, Stepanova M, Saab S, Kalwaney S, Clement S, Henry L, Frost S, Hunt S. The impact of type 2 diabetes and obesity on the long-term outcomes of more than 85 000 liver transplant recipients in the US. Aliment Pharmacol Ther 2014;40:686-94. [PMID: 25040315 DOI: 10.1111/apt.12881] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 6.8] [Reference Citation Analysis]
717 Lee JH, Lee GY, Jang H, Choe SS, Koo SH, Kim JB. Ring finger protein20 regulates hepatic lipid metabolism through protein kinase A-dependent sterol regulatory element binding protein1c degradation. Hepatology 2014;60:844-57. [PMID: 24425205 DOI: 10.1002/hep.27011] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 3.3] [Reference Citation Analysis]
718 Sesti G, Sciacqua A, Fiorentino TV, Perticone M, Succurro E, Perticone F. Association between noninvasive fibrosis markers and cardio-vascular organ damage among adults with hepatic steatosis. PLoS One 2014;9:e104941. [PMID: 25111713 DOI: 10.1371/journal.pone.0104941] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
719 Sesti G, Hribal ML, Fiorentino TV, Sciacqua A, Perticone F. Elevated 1 h postload plasma glucose levels identify adults with normal glucose tolerance but increased risk of non-alcoholic fatty liver disease. BMJ Open Diabetes Res Care 2014;2:e000016. [PMID: 25452862 DOI: 10.1136/bmjdrc-2014-000016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 3.3] [Reference Citation Analysis]
720 Kanerva N, Sandboge S, Kaartinen NE, Männistö S, Eriksson JG. Higher fructose intake is inversely associated with risk of nonalcoholic fatty liver disease in older Finnish adults. Am J Clin Nutr. 2014;100:1133-1138. [PMID: 25099548 DOI: 10.3945/ajcn.114.086074] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 4.4] [Reference Citation Analysis]
721 Lu CC, Wu SK, Chen HY, Chung WS, Lee MC, Yeh CJ. Clinical characteristics of and relationship between metabolic components and renal function among patients with early-onset juvenile tophaceous gout. J Rheumatol 2014;41:1878-83. [PMID: 25086077 DOI: 10.3899/jrheum.131240] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
722 Feng S, Lai JC. Expanded criteria donors. Clin Liver Dis 2014;18:633-49. [PMID: 25017080 DOI: 10.1016/j.cld.2014.05.005] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
723 Suh JB, Kim SM, Cho GJ, Choi KM. Serum AFBP levels are elevated in patients with nonalcoholic fatty liver disease. Scand J Gastroenterol 2014;49:979-85. [PMID: 24957697 DOI: 10.3109/00365521.2013.836754] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
724 Parekh S, Spivey JR. Recurrent Disease after Liver Transplantation. Textbook of Organ Transplantation 2014. [DOI: 10.1002/9781118873434.ch78] [Reference Citation Analysis]
725 Souza-mello V. Nonalcoholic Steatohepatitis: Lessons from Different Diet-induced Animal Models. JDMDC 2014;1. [DOI: 10.15406/jdmdc.2014.01.00014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
726 Hong NS, Kim JG, Lee YM, Kim HW, Kam S, Kim KY, Kim KS, Lee DH. Different associations between obesity and impaired fasting glucose depending on serum gamma-glutamyltransferase levels within normal range: a cross-sectional study. BMC Endocr Disord. 2014;14:57. [PMID: 25015117 DOI: 10.1186/1472-6823-14-57] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
727 Ryoo JH, Ham WT, Choi JM, Kang MA, An SH, Lee JK, Shin HC, Park SK. Clinical significance of non-alcoholic fatty liver disease as a risk factor for prehypertension. J Korean Med Sci 2014;29:973-9. [PMID: 25045230 DOI: 10.3346/jkms.2014.29.7.973] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
728 Hong ES, Kim EK, Kang SM, Khang AR, Choi SH, Park KS, Jang HC, Lim S. Effect of carnitine-orotate complex on glucose metabolism and fatty liver: a double-blind, placebo-controlled study. J Gastroenterol Hepatol 2014;29:1449-57. [PMID: 24611967 DOI: 10.1111/jgh.12536] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
729 Fukuzawa Y, Kapoor MP, Yamasaki K, Okubo T, Hotta Y, Juneja LR. Effects of green tea catechins on nonalcoholic steatohepatitis (NASH) patients. Journal of Functional Foods 2014;9:48-59. [DOI: 10.1016/j.jff.2014.04.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
730 Boyraz M, Hatipoğlu N, Sarı E, Akçay A, Taşkın N, Ulucan K, Akçay T. Non-alcoholic fatty liver disease in obese children and the relationship between metabolic syndrome criteria. Obesity Research & Clinical Practice 2014;8:e356-63. [DOI: 10.1016/j.orcp.2013.08.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
731 Lee J, Kook Y. Effects of Samhwangsasim-tang on obesity-related metabolic disease in mice. Herbal Formula Science 2014;22:93-104. [DOI: 10.14374/hfs.2014.22.1.093] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
732 Jang DH, Jung YS, Kim JH, Kim BC, Seok HJ, Yoo JS, Ku JR, Yoon KH, Jo JH, Lee HR, Roh JS, Yun HY, Yoon M, Shin SS. Comparison of Gangjihwan and Combination of Gangjihwan and Gamisochehwan in the Improvement Effects of Nonalcoholic Fatty Liver Disease in a High Fat Diet-Fed NAFLD Mouse Model. Herbal Formula Science 2014;22:167-176. [DOI: 10.14374/hfs.2014.22.1.167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
733 Liu Z,